PCIDB

KNApSAcK Metabolite C00000958

Metabolite

KNApSAcK Entry

id C00000958
Name (-)-Epigallocatechin gallate / epi-Gallocatechin 3-O-gallate / (2R-cis)-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester 3,4,5-trihydroxybenzoic acid
CAS RN 989-51-5
Standard InChI InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
Standard InChI (Main Layer) InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2

Cluster

Phytochemical cluster No. 14
KCF-S cluster No. 219

Link

ChEMBL

By standard InChI CHEMBL297453
By standard InChI Main Layer CHEMBL297453 CHEMBL311663 CHEMBL126079 CHEMBL338988 CHEMBL264938

KEGG

By LinkDB C09731

CTD

By CAS RN C045651

Human Protein / Gene in interaction

49 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
Q9UIF8 Bromodomain adjacent to zinc finger domain protein 2B Unclassified protein CHEMBL297453 CHEMBL1738312 (1)
0 / 0
O95342 Bile salt export pump drug CHEMBL297453 CHEMBL2076226 (1) CHEMBL2076242 (1)
2 / 1
P14618 Pyruvate kinase PKM Enzyme CHEMBL297453 CHEMBL1613996 (1) CHEMBL1614428 (1)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL297453 CHEMBL1008507 (1)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL311663 CHEMBL1676103 (1)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL297453 CHEMBL1071298 (1) CHEMBL1071299 (1)
CHEMBL1071300 (1) CHEMBL1071301 (1)
CHEMBL1071302 (1) CHEMBL1071303 (1)
2 / 1
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL297453 CHEMBL1664298 (1)
0 / 0
P06746 DNA polymerase beta Enzyme CHEMBL297453 CHEMBL1614079 (1)
0 / 0
P10253 Lysosomal alpha-glucosidase Hydrolase CHEMBL297453 CHEMBL1614076 (1)
1 / 1
P52209 6-phosphogluconate dehydrogenase, decarboxylating Enzyme CHEMBL297453 CHEMBL264938 CHEMBL921930 (2)
0 / 0
O75604 Ubiquitin carboxyl-terminal hydrolase 2 Enzyme CHEMBL311663 CHEMBL1614331 (1)
0 / 0
P10828 Thyroid hormone receptor beta NR1A2 CHEMBL297453 CHEMBL1794399 (1)
3 / 1
P02768 Serum albumin Secreted protein CHEMBL297453 CHEMBL1177441 (1) CHEMBL2340743 (1)
CHEMBL2340744 (1)
0 / 0
P49327 Fatty acid synthase Transferase CHEMBL297453 CHEMBL1260142 (1)
0 / 0
P54132 Bloom syndrome protein Enzyme CHEMBL311663 CHEMBL1614067 (1)
1 / 2
P51570 Galactokinase Enzyme CHEMBL311663 CHEMBL1613821 (1)
1 / 1
P11473 Vitamin D3 receptor NR1I1 CHEMBL311663 CHEMBL1794311 (1)
2 / 3
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL297453 CHEMBL1008508 (1)
0 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL311663 CHEMBL1614458 (1)
0 / 0
P50281 Matrix metalloproteinase-14 M10A CHEMBL297453 CHEMBL1064084 (1)
0 / 0
Q92830 Histone acetyltransferase KAT2A Enzyme CHEMBL311663 CHEMBL1738606 (1)
0 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL311663 CHEMBL1794467 (1)
0 / 0
P37231 Peroxisome proliferator-activated receptor gamma NR1C3 CHEMBL297453 CHEMBL1794510 (1)
5 / 3
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL297453 CHEMBL2090538 (1)
5 / 10
P08581 Hepatocyte growth factor receptor TK tyrosine-protein kinase MET subfamily CHEMBL297453 CHEMBL264938 CHEMBL1056838 (2) CHEMBL1056839 (2)
CHEMBL1056840 (1)
2 / 3
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL311663 CHEMBL1613808 (1)
0 / 0
P56817 Beta-secretase 1 A1A CHEMBL297453 CHEMBL126079 CHEMBL338988 CHEMBL653507 (2) CHEMBL653508 (2)
CHEMBL1954848 (1) CHEMBL1954849 (1)
CHEMBL1954850 (1) CHEMBL1954851 (1)
CHEMBL1954852 (1) CHEMBL1954997 (1)
CHEMBL1955004 (1) CHEMBL1955005 (1)
CHEMBL1955006 (1) CHEMBL1955007 (1)
CHEMBL1955014 (1) CHEMBL1955015 (1)
CHEMBL1955016 (1) CHEMBL1955017 (1)
CHEMBL1955020 (1) CHEMBL1955021 (1)
CHEMBL1955023 (1) CHEMBL1955024 (1)
CHEMBL1953025 (1) CHEMBL1953026 (1)
CHEMBL1953027 (1) CHEMBL1953030 (1)
CHEMBL1953031 (1)
0 / 0
P09237 Matrilysin M10A CHEMBL297453 CHEMBL1064085 (1)
0 / 0
P08253 72 kDa type IV collagenase M10A CHEMBL297453 CHEMBL1064086 (1)
1 / 3
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 Enzyme CHEMBL311663 CHEMBL1613910 (1)
3 / 3
P15428 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Enzyme CHEMBL311663 CHEMBL1614038 (1)
2 / 2
P00374 Dihydrofolate reductase Oxidoreductase CHEMBL297453 CHEMBL930269 (1)
1 / 1
P26358 DNA (cytosine-5)-methyltransferase 1 Transferase CHEMBL297453 CHEMBL2066853 (1)
2 / 0
P19838 Nuclear factor NF-kappa-B p105 subunit Transcription Factor CHEMBL297453 CHEMBL2114853 (1)
0 / 0
P16050 Arachidonate 15-lipoxygenase Enzyme CHEMBL311663 CHEMBL1614240 (1)
0 / 0
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL311663 CHEMBL1614108 (1) CHEMBL1613886 (1)
0 / 1
P27695 DNA-(apurinic or apyrimidinic site) lyase Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1614466 (1) CHEMBL1614211 (2)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL297453 CHEMBL311663 CHEMBL1614250 (2) CHEMBL1614421 (2)
CHEMBL1614502 (2)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL297453 CHEMBL2114890 (1)
0 / 0
Q13627 Dual specificity tyrosine-phosphorylation-regulated kinase 1A CMGC dual-specificity kinase DYRK1 CHEMBL297453 CHEMBL1937068 (1) CHEMBL1937069 (1)
CHEMBL1937071 (1) CHEMBL1937072 (1)
1 / 0
O14746 Telomerase reverse transcriptase Enzyme CHEMBL297453 CHEMBL2175294 (1) CHEMBL2175297 (1)
CHEMBL2175302 (1) CHEMBL2175304 (1)
CHEMBL2175309 (1) CHEMBL2175310 (1)
5 / 5
P10415 Apoptosis regulator Bcl-2 Other cytosolic protein CHEMBL297453 CHEMBL937576 (1)
0 / 7
Q9UBT6 DNA polymerase kappa Enzyme CHEMBL311663 CHEMBL1794536 (1)
0 / 0
B2RXH2 Lysine-specific demethylase 4E Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1613914 (2)
0 / 0
P46063 ATP-dependent DNA helicase Q1 Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1613829 (2)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL297453 CHEMBL1738442 (1)
0 / 0
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1614364 (2)
1 / 1
O00255 Menin Unclassified protein CHEMBL297453 CHEMBL311663 CHEMBL1614257 (2)
2 / 5
Q03164 Histone-lysine N-methyltransferase 2A Enzyme CHEMBL297453 CHEMBL311663 CHEMBL1614257 (2)
1 / 3

CTD interaction (2358)

compound gene gene name gene description interaction interaction type form reference
pmid
C045651 195827 AAED1
C9orf21
AhpC/TSA antioxidant enzyme domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AAED1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28971 AAMDC
C11orf67
CK067
adipogenesis associated, Mth938 domain containing [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AAMDC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25980 AAR2
C20orf4
AAR2 splicing factor homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AAR2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 132949 AASDH
ACSF4
LYS2
NRPS1098
NRPS998
aminoadipate-semialdehyde dehydrogenase (EC:6.2.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AASDH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) epigallocatechin gallate results in decreased expression of ABCB1 mRNA decreases expression
mRNA 18851785
C045651 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) epigallocatechin gallate results in decreased expression of ABCB1 protein decreases expression
protein 20149610
C045651 23456 ABCB10
EST20237
M-ABC2
MTABC2
ATP-binding cassette, sub-family B (MDR/TAP), member 10 epigallocatechin gallate results in increased expression of ABCB10 mRNA increases expression
mRNA 18851785
C045651 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of ABCB11 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 epigallocatechin gallate results in increased expression of ABCB11 mRNA increases expression
mRNA 22178739
C045651 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCC10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10057 ABCC5
ABC33
EST277145
MOAT-C
MOATC
MRP5
SMRP
pABC11
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5825 ABCD3
ABC43
PMP70
PXMP1
ZWS2
ATP-binding cassette, sub-family D (ALD), member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6059 ABCE1
ABC38
OABP
RLI
RNASEL1
RNASELI
RNS4I
ATP-binding cassette, sub-family E (OABP), member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABCE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9619 ABCG1
ABC8
WHITE1
ATP-binding cassette, sub-family G (WHITE), member 1 epigallocatechin gallate results in decreased expression of ABCG1 mRNA decreases expression
mRNA 16084531
C045651 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 epigallocatechin gallate results in decreased activity of ABCG2 protein decreases activity
protein 20149610
C045651 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 epigallocatechin gallate results in increased expression of ABCG2 mRNA increases expression
mRNA 18851785
C045651 57406 ABHD6
abhydrolase domain containing 6 (EC:3.1.1.23) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABHD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27 ABL2
ABLL
ARG
c-abl oncogene 2, non-receptor tyrosine kinase (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ABL2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 29 ABR
MDB
active BCR-related [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ABR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 34 ACADM
ACAD1
MCAD
MCADH
acyl-CoA dehydrogenase, C-4 to C-12 straight chain (EC:1.3.8.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACADM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23527 ACAP2
CENTB2
CNT-B2
ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACAP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 47 ACLY
ACL
ATPCL
CLATP
ATP citrate lyase (EC:2.3.3.8) epigallocatechin gallate results in increased expression of ACLY mRNA increases expression
mRNA 20706672
C045651 55860 ACTR10
ACTR11
Arp11
HARP11
actin-related protein 10 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ACTR10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8728 ADAM19
MADDAM
MLTNB
ADAM metallopeptidase domain 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAM19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8748 ADAM20
ADAM metallopeptidase domain 20 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADAM20 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81792 ADAMTS12
PRO4389
ADAM metallopeptidase with thrombospondin type 1 motif, 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 170689 ADAMTS15
ADAM metallopeptidase with thrombospondin type 1 motif, 15 epigallocatechin gallate results in increased expression of ADAMTS15 mRNA increases expression
mRNA 22079256
C045651 170689 ADAMTS15
ADAM metallopeptidase with thrombospondin type 1 motif, 15 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11096 ADAMTS5
ADAM-TS_11
ADAM-TS_5
ADAM-TS5
ADAMTS-11
ADAMTS-5
ADAMTS11
ADMP-2
ADAM metallopeptidase with thrombospondin type 1 motif, 5 epigallocatechin gallate results in increased expression of ADAMTS5 mRNA increases expression
mRNA 22079256
C045651 11096 ADAMTS5
ADAM-TS_11
ADAM-TS_5
ADAM-TS5
ADAMTS-11
ADAMTS-5
ADAMTS11
ADMP-2
ADAM metallopeptidase with thrombospondin type 1 motif, 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAMTS5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 574406 ADAMTSL4-AS1
C1orf138
ADAMTSL4 antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADAMTSL4-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 104 ADARB1
ADAR2
DRABA2
DRADA2
RED1
adenosine deaminase, RNA-specific, B1 (EC:3.5.4.37) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADARB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23536 ADAT1
HADAT1
adenosine deaminase, tRNA-specific 1 (EC:3.5.4.34) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADAT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100380740 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADFP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 133 ADM
AM
adrenomedullin epigallocatechin gallate results in decreased secretion of ADM protein decreases secretion
protein 22178239
C045651 147 ADRA1B
ADRA1
ALPHA1BAR
adrenoceptor alpha 1B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADRA1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154 ADRB2
ADRB2R
ADRBR
B2AR
BAR
BETA2AR
adrenoceptor beta 2, surface [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ADRB2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 157 ADRBK2
BARK2
GRK3
adrenergic, beta, receptor kinase 2 (EC:2.7.11.15) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADRBK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 159 ADSS
ADEH
ADSS_2
adenylosuccinate synthase (EC:6.3.4.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ADSS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4299 AFF1
AF4
MLLT2
PBM1
AF4/FMR2 family, member 1 epigallocatechin gallate results in increased expression of AFF1 mRNA increases expression
mRNA 22079256
C045651 4299 AFF1
AF4
MLLT2
PBM1
AF4/FMR2 family, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AFF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116987 AGAP1
AGAP-1
CENTG2
GGAP1
cnt-g2
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 178 AGL
GDE
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (EC:2.4.1.25 3.2.1.33) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8540 AGPS
ADAP-S
ADAS
ADHAPS
ADPS
ALDHPSY
alkylglycerone phosphate synthase (EC:2.5.1.26) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGPS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 185 AGTR1
AG2S
AGTR1A
AGTR1B
AT1
AT1AR
AT1B
AT1BR
AT1R
AT2R1
AT2R1A
AT2R1B
HAT1R
angiotensin II receptor, type 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AGTR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 191 AHCY
SAHH
adoHcyase
adenosylhomocysteinase (EC:3.3.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AHCY mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate binds to and results in decreased activity of AHR protein affects binding
/ decreases activity
protein 11064004
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 11064004
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] decreases reaction
/ increases localization
protein 20450880
C045651 196 AHR
bHLHe76
aryl hydrocarbon receptor epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AHR protein] decreases reaction
/ increases phosphorylation
protein 20450880
C045651 64853 AIDA
C1orf80
RP11-378J18.7
axin interactor, dorsalization associated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AIDA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 epigallocatechin gallate analog affects the localization of AIFM1 protein affects localization
protein 16115949
C045651 9255 AIMP1
EMAP2
EMAPII
HLD3
SCYE1
p43
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 epigallocatechin gallate results in decreased expression of AIMP1 mRNA decreases expression
mRNA 16084531
C045651 84962 AJUBA
JUB
ajuba LIM protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AJUBA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11214 AKAP13
AKAP-13
AKAP-Lbc
ARHGEF13
BRX
HA-3
Ht31
LBC
PRKA13
PROTO-LB
PROTO-LBC
c-lbc
p47
A kinase (PRKA) anchor protein 13 epigallocatechin gallate results in increased expression of AKAP13 mRNA increases expression
mRNA 22079256
C045651 11214 AKAP13
AKAP-13
AKAP-Lbc
ARHGEF13
BRX
HA-3
Ht31
LBC
PRKA13
PROTO-LB
PROTO-LBC
c-lbc
p47
A kinase (PRKA) anchor protein 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKAP13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56672 AKIP1
BCA3
C11orf17
A kinase (PRKA) interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55122 AKIRIN2
C6orf166
FBI1
dJ486L4.2
akirin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AKIRIN2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8644 AKR1C3
DD3
DDX
HA1753
HAKRB
HAKRe
HSD17B5
PGFS
hluPGFS
aldo-keto reductase family 1, member C3 (EC:1.3.1.20 1.1.1.188 1.1.1.239 1.1.1.64 1.1.1.112 1.1.1.357) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKR1C3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 10000 AKT3
MPPH
PKB-GAMMA
PKBG
PRKBG
RAC-PK-gamma
RAC-gamma
STK-2
v-akt murine thymoma viral oncogene homolog 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKT3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64400 AKTIP
FT1
FTS
AKT interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AKTIP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 224 ALDH3A2
ALDH10
FALDH
SLS
aldehyde dehydrogenase 3 family, member A2 (EC:1.2.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALDH3A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 199857 ALG14
ALG14, UDP-N-acetylglucosaminyltransferase subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29929 ALG6
CDG1C
ALG6, alpha-1,3-glucosyltransferase (EC:2.4.1.267) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79053 ALG8
CDG1H
ALG8, alpha-1,3-glucosyltransferase (EC:2.4.1.265) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALG8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115701 ALPK2
HAK
alpha-kinase 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ALPK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 268 AMH
MIF
MIS
anti-Mullerian hormone [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AMH mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9949 AMMECR1
AMMERC1
Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AMMECR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 270 AMPD1
MAD
MADA
MMDD
adenosine monophosphate deaminase 1 (EC:3.5.4.6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AMPD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10393 ANAPC10
APC10
DOC1
anaphase promoting complex subunit 10 epigallocatechin gallate results in decreased expression of ANAPC10 mRNA decreases expression
mRNA 22079256
C045651 10393 ANAPC10
APC10
DOC1
anaphase promoting complex subunit 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29945 ANAPC4
APC4
anaphase promoting complex subunit 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51434 ANAPC7
APC7
anaphase promoting complex subunit 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANAPC7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54467 ANKIB1
ankyrin repeat and IBR domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKIB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57037 ANKMY2
ZMYND20
ankyrin repeat and MYND domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKMY2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55608 ANKRD10
ankyrin repeat domain 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ANKRD10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 22852 ANKRD26
THC2
bA145E8.1
ankyrin repeat domain 26 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD26 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 375248 ANKRD36
UNQ2430
ankyrin repeat domain 36 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD36 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91526 ANKRD44
PP6-ARS-B
ankyrin repeat domain 44 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANKRD44 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 121601 ANO4
TMEM16D
anoctamin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ANO4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 130340 AP1S3
adaptor-related protein complex 1, sigma 3 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP1S3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 161 AP2A2
ADTAB
CLAPA2
HIP-9
HIP9
HYPJ
adaptor-related protein complex 2, alpha 2 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP2A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55317 AP5S1
C20orf29
adaptor-related protein complex 5, sigma 1 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AP5S1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 317 APAF1
APAF-1
CED4
apoptotic peptidase activating factor 1 epigallocatechin gallate results in increased expression of APAF1 protein increases expression
protein 15657356
C045651 323 APBB2
FE65L
FE65L1
amyloid beta (A4) precursor protein-binding, family B, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APBB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83464 APH1B
APH-1B
PRO1328
PSFL
TAAV688
APH1B gamma secretase subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APH1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23780 APOL2
APOL-II
APOL3
apolipoprotein L, 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APOL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55198 APPL2
DIP13B
adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of APPL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 358 AQP1
AQP-CHIP
CHIP28
CO
aquaporin 1 epigallocatechin gallate results in decreased expression of AQP1 mRNA decreases expression
mRNA 20706672
C045651 358 AQP1
AQP-CHIP
CHIP28
CO
aquaporin 1 epigallocatechin gallate results in increased expression of AQP1 mRNA increases expression
mRNA 20706672
C045651 360 AQP3
AQP-3
GIL
aquaporin 3 (Gill blood group) epigallocatechin gallate results in increased expression of AQP3 mRNA increases expression
mRNA 20706672
C045651 9716 AQR
IBP160
fSAP164
aquarius intron-binding spliceosomal factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AQR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor epigallocatechin gallate results in decreased expression of AR mRNA decreases expression
mRNA 20706672
C045651 64411 ARAP3
CENTD3
DRAG1
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARAP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10565 ARFGEF1
ARFGEP1
BIG1
P200
ADP-ribosylation factor guanine nucleotide-exchange factor 1 (brefeldin A-inhibited) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARFGEF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79658 ARHGAP10
GRAF2
PS-GAP
PSGAP
Rho GTPase activating protein 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9824 ARHGAP11A
GAP_(1-12)
Rho GTPase activating protein 11A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP11A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 94134 ARHGAP12
Rho GTPase activating protein 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 93663 ARHGAP18
MacGAP
SENEX
bA307O14.2
Rho GTPase activating protein 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57569 ARHGAP20
RARHOGAP
Rho GTPase activating protein 20 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP20 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57584 ARHGAP21
ARHGAP10
Rho GTPase activating protein 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP21 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83478 ARHGAP24
FILGAP
RC-GAP72
RCGAP72
p73
p73RhoGAP
Rho GTPase activating protein 24 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP24 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79822 ARHGAP28
Rho GTPase activating protein 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9411 ARHGAP29
PARG1
RP11-255E17.1
Rho GTPase activating protein 29 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGAP29 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26084 ARHGEF26
CSGEF
HMFN1864
SGEF
Rho guanine nucleotide exchange factor (GEF) 26 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF26 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64283 ARHGEF28
RGNEF
RIP2
p190RHOGEF
Rho guanine nucleotide exchange factor (GEF) 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50650 ARHGEF3
GEF3
STA3
XPLN
Rho guanine nucleotide exchange factor (GEF) 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARHGEF3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54622 ARL15
ARFRP2
ADP-ribosylation factor-like 15 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARL15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55156 ARMC1
Arcp
armadillo repeat containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55130 ARMC4
CILD23
armadillo repeat containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80210 ARMC9
ARM
KU-MEL-1
armadillo repeat containing 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARMC9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 405 ARNT
HIF-1-beta
HIF-1beta
HIF1-beta
HIF1B
HIF1BETA
TANGO
bHLHe2
aryl hydrocarbon receptor nuclear translocator epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ARNT protein] decreases reaction
/ increases phosphorylation
protein 20450880
C045651 405 ARNT
HIF-1-beta
HIF-1beta
HIF1-beta
HIF1B
HIF1BETA
TANGO
bHLHe2
aryl hydrocarbon receptor nuclear translocator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARNT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 406 ARNTL
BMAL1
BMAL1c
JAP3
MOP3
PASD3
TIC
bHLHe5
aryl hydrocarbon receptor nuclear translocator-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARNTL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81873 ARPC5L
ARC16-2
actin related protein 2/3 complex, subunit 5-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARPC5L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 408 ARRB1
ARB1
ARR1
arrestin, beta 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARRB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57561 ARRDC3
TLIMP
arrestin domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ARRDC3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 340075 ARSI
arylsulfatase family, member I [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARSI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79642 ARSJ
arylsulfatase family, member J (EC:3.1.6.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARSJ mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 420 ART4
ARTC4
CD297
DO
DOK1
ADP-ribosyltransferase 4 (EC:2.4.2.31) epigallocatechin gallate results in decreased expression of ART4 mRNA decreases expression
mRNA 16084531
C045651 64801 ARV1
ARV1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ARV1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50807 ASAP1
AMAP1
CENTB4
DDEF1
PAG2
PAP
ZG14P
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 140459 ASB6
ankyrin repeat and SOCS box containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ASB6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10973 ASCC3
ASC1p200
HELIC1
RNAH
activating signal cointegrator 1 complex subunit 3 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASCC3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25842 ASF1A
CGI-98
CIA
HSPC146
anti-silencing function 1A histone chaperone [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASF1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9070 ASH2L
ASH2
ASH2L1
ASH2L2
Bre2
ash2 (absent, small, or homeotic)-like (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASH2L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 259266 ASPM
ASP
Calmbp1
MCPH5
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ASPM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54454 ATAD2B
ATPase family, AAA domain containing 2B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATAD2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11101 ATE1
arginyltransferase 1 (EC:2.3.2.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 467 ATF3
activating transcription factor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATF3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 468 ATF4
CREB-2
CREB2
TAXREB67
TXREB
activating transcription factor 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATF4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 83734 ATG10
APG10
APG10L
pp12616
autophagy related 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115201 ATG4A
APG4A
AUTL2
autophagy related 4A, cysteine peptidase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG4A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84938 ATG4C
APG4-C
APG4C
AUTL1
AUTL3
autophagy related 4C, cysteine peptidase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG4C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84971 ATG4D
APG4-D
APG4D
AUTL4
autophagy related 4D, cysteine peptidase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATG4D mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9474 ATG5
APG5
APG5-LIKE
APG5L
ASP
hAPG5
autophagy related 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATG5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51062 ATL1
AD-FSP
FSP1
GBP3
HSN1D
SPG3
SPG3A
atlastin1
atlastin GTPase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1822 ATN1
B37
D12S755E
DRPLA
HRS
NOD
atrophin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATN1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57205 ATP10D
ATPVD
ATPase, class V, type 10D (EC:3.6.3.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP10D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 481 ATP1B1
ATP1B
ATPase, Na+/K+ transporting, beta 1 polypeptide [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP1B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 488 ATP2A2
ATP2B
DAR
DD
SERCA2
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (EC:3.6.3.8) epigallocatechin gallate results in increased expression of ATP2A2 mRNA increases expression
mRNA 16084531
C045651 490 ATP2B1
PMCA1
PMCA1kb
ATPase, Ca++ transporting, plasma membrane 1 (EC:3.6.3.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 493 ATP2B4
ATP2B2
MXRA1
PMCA4
PMCA4b
PMCA4x
ATPase, Ca++ transporting, plasma membrane 4 (EC:3.6.3.8) epigallocatechin gallate results in increased expression of ATP2B4 mRNA increases expression
mRNA 22079256
C045651 493 ATP2B4
ATP2B2
MXRA1
PMCA4
PMCA4b
PMCA4x
ATPase, Ca++ transporting, plasma membrane 4 (EC:3.6.3.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP2B4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 267020 ATP5L2
ATP5K2
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit G2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATP5L2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 527 ATP6V0C
ATP6C
ATP6L
ATPL
VATL
VPPC
Vma3
ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c (EC:3.6.3.14) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATP6V0C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 540 ATP7B
PWD
WC1
WD
WND
ATPase, Cu++ transporting, beta polypeptide (EC:3.6.3.54) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP7B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5205 ATP8B1
ATPIC
BRIC
FIC1
ICP1
PFIC
PFIC1
ATPase, aminophospholipid transporter, class I, type 8B, member 1 (EC:3.6.3.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATP8B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 545 ATR
FCTCS
FRP1
MEC1
SCKL
SCKL1
ataxia telangiectasia and Rad3 related (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6311 ATXN2
ASL13
ATX2
SCA2
TNRC13
ataxin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11273 ATXN2L
A2D
A2LG
A2LP
A2RP
ataxin 2-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ATXN2L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4287 ATXN3
AT3
ATX3
JOS
MJD
MJD1
SCA3
ataxin 3 (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 222255 ATXN7L1
ATXN7L4
ataxin 7-like 1 epigallocatechin gallate results in increased expression of ATXN7L1 mRNA increases expression
mRNA 22079256
C045651 222255 ATXN7L1
ATXN7L4
ataxin 7-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ATXN7L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6790 AURKA
AIK
ARK1
AURA
AURORA2
BTAK
PPP1R47
STK15
STK6
STK7
aurora kinase A (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of AURKA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 33419 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AXUD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51582 AZIN1
OAZI
OAZIN
ODC1L
antizyme inhibitor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of AZIN1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 145173 B3GALTL
B3GLCT
B3GTL
B3Glc-T
Gal-T
beta3Glc-T
beta 1,3-galactosyltransferase-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of B3GALTL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 146712 B3GNTL1
B3GNT8
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 (EC:2.4.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of B3GNTL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 570 BAAT
BACAT
BAT
bile acid CoA: amino acid N-acyltransferase (glycine N-choloyltransferase) (EC:2.3.1.65 3.1.2.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAAT mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23621 BACE1
ASP2
BACE
HSPC104
beta-site APP-cleaving enzyme 1 (EC:3.4.23.46) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BACE1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 573 BAG1
BAG-1
HAP
RAP46
BCL2-associated athanogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9532 BAG2
BAG-2
dJ417I1.2
BCL2-associated athanogene 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAG2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9531 BAG3
BAG-3
BIS
CAIR-1
MFM6
BCL2-associated athanogene 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9530 BAG4
BAG-4
SODD
BCL2-associated athanogene 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7917 BAG6
BAG-6
BAT3
D6S52E
G3
BCL2-associated athanogene 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BAG6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 578 BAK1
BAK
BAK-LIKE
BCL2L7
CDN1
BCL2-antagonist/killer 1 epigallocatechin gallate results in decreased expression of BAK1 mRNA decreases expression
mRNA 18851785
C045651 581 BAX
BCL2L4
BCL2-associated X protein BAX protein results in increased susceptibility to epigallocatechin gallate increases response to substance
protein 15764647
C045651 581 BAX
BCL2L4
BCL2-associated X protein [decitabine co-treated with epigallocatechin gallate] affects the expression of BAX mRNA affects cotreatment
/ affects expression
mRNA 18250043
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate affects the expression of BAX protein affects expression
protein 15975156
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate analog affects the localization of BAX protein affects localization
protein 16115949
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein] decreases reaction
/ increases expression
protein 12672908
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate promotes the reaction [BAX protein binds to BAX protein] affects binding
/ increases reaction
protein 15705601
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate results in decreased expression of BAX mRNA decreases expression
mRNA 18851785
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate results in increased activity of BAX protein increases activity
protein 15705601
C045651 581 BAX
BCL2L4
BCL2-associated X protein epigallocatechin gallate results in increased expression of BAX protein increases expression
protein 15657356
15764647
20149610
C045651 11177 BAZ1A
ACF1
WALp1
WCRF180
hACF1
bromodomain adjacent to zinc finger domain, 1A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAZ1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29994 BAZ2B
WALp4
bromodomain adjacent to zinc finger domain, 2B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BAZ2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79738 BBS10
C12orf58
Bardet-Biedl syndrome 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 583 BBS2
BBS
Bardet-Biedl syndrome 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 585 BBS4
Bardet-Biedl syndrome 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBS4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56987 BBX
ARTC1
HBP2
HSPC339
MDS001
bobby sox homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BBX mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 20950636
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 16115949
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [decitabine co-treated with epigallocatechin gallate] affects the expression of BCL2 mRNA affects cotreatment
/ affects expression
mRNA 18250043
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate affects the expression of BCL2 protein affects expression
protein 15975156
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate analog results in decreased expression of BCL2 protein decreases expression
protein 16115949
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
/ increases degradation
protein 19557821
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 12672908
C045651 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 epigallocatechin gallate results in decreased expression of BCL2 protein decreases expression
protein 15657356
20149610
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 protein affects cotreatment
/ decreases expression
protein 20950636
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form affects cotreatment
/ decreases expression
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form affects cotreatment
/ increases expression
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 18348186
C045651 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of BCL2L1 mRNA alternative form] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 18348186
C045651 602 BCL3
BCL4
D19S37
B-cell CLL/lymphoma 3 epigallocatechin gallate results in increased expression of BCL3 mRNA increases expression
mRNA 22079256
C045651 602 BCL3
BCL4
D19S37
B-cell CLL/lymphoma 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BCL3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 604 BCL6
BCL5
BCL6A
LAZ3
ZBTB27
ZNF51
B-cell CLL/lymphoma 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BCL6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 605 BCL7A
BCL7
B-cell CLL/lymphoma 7A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BCL7A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 623 BDKRB1
B1BKR
B1R
BKB1R
BKR1
BRADYB1
bradykinin receptor B1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BDKRB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23299 BICD2
SMALED2
bA526D8.1
bicaudal D homolog 2 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BICD2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55909 BIN3
bridging integrator 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BIN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 330 BIRC3
AIP1
API2
CIAP2
HAIP1
HIAP1
MALT2
MIHC
RNF49
c-IAP2
baculoviral IAP repeat containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BIRC3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 414899 BLID
BRCC2
BH3-like motif containing, cell death inducer [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BLID mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 644 BLVRA
BLVR
BVR
BVRA
biliverdin reductase A (EC:1.3.1.24) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BLVRA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55589 BMP2K
BIKE
BMP2 inducible kinase (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMP2K mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 652 BMP4
BMP2B
BMP2B1
MCOPS6
OFC11
ZYME
bone morphogenetic protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 168667 BMPER
CRIM3
CV-2
CV2
BMP binding endothelial regulator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMPER mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 657 BMPR1A
10q23del
ACVRLK3
ALK3
CD292
SKR5
bone morphogenetic protein receptor, type IA (EC:2.7.11.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BMPR1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51027 BOLA1
bolA family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BOLA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79866 BORA
C13orf34
bora, aurora kinase A activator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BORA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 669 BPGM
DPGM
2,3-bisphosphoglycerate mutase (EC:3.1.3.13 5.4.2.4 5.4.2.11) epigallocatechin gallate results in decreased expression of BPGM mRNA decreases expression
mRNA 16084531
C045651 672 BRCA1
BRCAI
BRCC1
BROVCA1
IRIS
PNCA4
PPP1R53
PSCP
RNF53
breast cancer 1, early onset [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 675 BRCA2
BRCC2
BROVCA2
FACD
FAD
FAD1
FANCB
FANCD
FANCD1
GLM3
PNCA2
breast cancer 2, early onset [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRCA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23774 BRD1
BRL
BRPF1
BRPF2
bromodomain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BRD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 83990 BRIP1
BACH1
FANCJ
OF
BRCA1 interacting protein C-terminal helicase 1 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27154 BRPF3
bromodomain and PHD finger containing, 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BRPF3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 254065 BRWD3
BRODL
MRX93
bromodomain and WD repeat domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BRWD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 689 BTF3
BETA-NAC
BTF3a
BTF3b
NACB
basic transcription factor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BTF3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 91408 BTF3L4
basic transcription factor 3-like 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTF3L4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 694 BTG1
B-cell translocation gene 1, anti-proliferative epigallocatechin gallate results in decreased expression of BTG1 mRNA decreases expression
mRNA 16084531
C045651 694 BTG1
B-cell translocation gene 1, anti-proliferative [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BTG1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11119 BTN3A1
BT3.1
BTF5
CD277
butyrophilin, subfamily 3, member A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTN3A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11118 BTN3A2
BT3.2
BTF4
CD277
butyrophilin, subfamily 3, member A2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTN3A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10384 BTN3A3
BTF3
butyrophilin, subfamily 3, member A3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTN3A3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8945 BTRC
BETA-TRCP
FBW1A
FBXW1
FBXW1A
FWD1
bTrCP
bTrCP1
betaTrCP
beta-transducin repeat containing E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BTRC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 699 BUB1
BUB1A
BUB1L
hBUB1
BUB1 mitotic checkpoint serine/threonine kinase (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of BUB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8896 BUD31
Cwc14
EDG-2
EDG2
G10
YCR063W
fSAP17
BUD31 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of BUD31 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56652 C10orf2
ATXN8
IOSCA
MTDPS7
PEO
PEO1
PEOA3
SANDO
SCA8
TWINL
chromosome 10 open reading frame 2 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C10ORF2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51501 C11orf73
HSPC179
Hikeshi
L7RN6
OPI10
chromosome 11 open reading frame 73 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C11ORF73 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55017 C14orf119
chromosome 14 open reading frame 119 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C14ORF119 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56905 C15orf39
chromosome 15 open reading frame 39 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C15ORF39 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84529 C15orf41
HH114
chromosome 15 open reading frame 41 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C15ORF41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84419 C15orf48
FOAP-11
NMES1
chromosome 15 open reading frame 48 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C15ORF48 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29035 C16orf72
PRO0149
chromosome 16 open reading frame 72 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C16ORF72 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 125144 C17orf76-AS1
C17orf45
NCRNA00188
TSAP19
FAM211A-AS1
C17orf76 antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C17ORF76-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56913 C1GALT1
C1GALT
T-synthase
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 (EC:2.4.1.122) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1GALT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55732 C1orf112
RP1-97P20.1
chromosome 1 open reading frame 112 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1ORF112 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 128346 C1orf162
chromosome 1 open reading frame 162 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF162 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81563 C1orf21
PIG13
chromosome 1 open reading frame 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C1ORF21 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 148523 C1orf51
chromosome 1 open reading frame 51 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF51 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 148423 C1orf52
RP11-234D19.1
gm117
chromosome 1 open reading frame 52 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C1ORF52 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9854 C2CD2L
TMEM24
C2CD2-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C2CD2L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26005 C2CD3
C2 calcium-dependent domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2CD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9847 C2CD5
CDP138
KIAA0528
C2 calcium-dependent domain containing 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2CD5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60526 C2orf43
chromosome 2 open reading frame 43 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C2ORF43 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57415 C3orf14
chromosome 3 open reading frame 14 epigallocatechin gallate results in decreased expression of C3ORF14 mRNA decreases expression
mRNA 22079256
C045651 57415 C3orf14
chromosome 3 open reading frame 14 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C3ORF14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 152078 C3orf55
chromosome 3 open reading frame 55 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C3ORF55 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54969 C4orf27
chromosome 4 open reading frame 27 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C4ORF27 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64417 C5orf28
chromosome 5 open reading frame 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C5ORF28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65250 C5orf42
JBTS17
chromosome 5 open reading frame 42 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C5ORF42 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100425666 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C6ORF125 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51250 C6orf203
PRED31
RP11-59I9.1
chromosome 6 open reading frame 203 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C6ORF203 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57827 C6orf47
D6S53E
G4
NG34
chromosome 6 open reading frame 47 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C6ORF47 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50854 C6orf48
D6S57
G8
chromosome 6 open reading frame 48 epigallocatechin gallate results in decreased expression of C6ORF48 mRNA decreases expression
mRNA 22079256
C045651 50854 C6orf48
D6S57
G8
chromosome 6 open reading frame 48 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C6ORF48 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 78996 C7orf49
MRI
chromosome 7 open reading frame 49 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C7ORF49 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 138724 C9orf131
chromosome 9 open reading frame 131 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C9ORF131 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84688 C9orf24
CBE1
NYD-SP22
SMRP1
bA573M23.4
chromosome 9 open reading frame 24 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of C9ORF24 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84909 C9orf3
AOPEP
AP-O
APO
C90RF3
ONPEP
chromosome 9 open reading frame 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C9ORF3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 138199 C9orf41
chromosome 9 open reading frame 41 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C9ORF41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 782 CACNB1
CAB1
CACNLB1
CCHLB1
calcium channel, voltage-dependent, beta 1 subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CACNB1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 817 CAMK2D
CAMKD
calcium/calmodulin-dependent protein kinase II delta (EC:2.7.11.17) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAMK2D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79823 CAMKMT
C2orf34
CLNMT
CaM_KMT
Cam
KMT
calmodulin-lysine N-methyltransferase (EC:2.1.1.60) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAMKMT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 819 CAMLG
CAML
calcium modulating ligand [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CAMLG mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 65981 CAPRIN2
C1QDC1
EEG-1
EEG1
RNG140
caprin family member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAPRIN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22794 CASC3
BTZ
MLN51
cancer susceptibility candidate 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CASC3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64921 CASD1
C7orf12
NBLA04196
CAS1 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 834 CASP1
ICE
IL1BC
P45
caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [arsenic trioxide co-treated with epigallocatechin gallate] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 20950636
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate affects the cleavage of CASP3 protein affects cleavage
protein 15975156
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate analog results in increased cleavage of CASP3 protein increases cleavage
protein 16115949
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased cleavage of and results in increased activity of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 12672908
15795422
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased cleavage of and results in increased activity of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 22079256
C045651 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) epigallocatechin gallate results in increased activity of CASP3 protein increases activity
protein 15657356
15705601
15764647
C045651 839 CASP6
MCH2
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CASP8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) epigallocatechin gallate analog results in increased cleavage of CASP9 protein increases cleavage
protein 16115949
C045651 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) epigallocatechin gallate results in increased activity of CASP9 protein increases activity
protein 15764647
C045651 847 CAT
catalase (EC:1.11.1.6) CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 16115949
C045651 847 CAT
catalase (EC:1.11.1.6) CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of MCL1 protein] decreases expression
/ decreases reaction
protein 16115949
C045651 847 CAT
catalase (EC:1.11.1.6) CAT protein inhibits the reaction [epigallocatechin gallate analog results in increased abundance of Reactive Oxygen Species] decreases reaction
/ increases abundance
protein 16115949
C045651 858 CAV2
CAV
caveolin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CAV2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 868 CBLB
Cbl-b
RNF56
Cbl proto-oncogene B, E3 ubiquitin protein ligase epigallocatechin gallate results in increased expression of CBLB mRNA increases expression
mRNA 22079256
C045651 868 CBLB
Cbl-b
RNF56
Cbl proto-oncogene B, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CBLB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79872 CBLL1
HAKAI
RNF188
Cbl proto-oncogene-like 1, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CBLL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8535 CBX4
NBP16
PC2
chromobox homolog 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CBX4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25776 CBY1
C22orf2
CBY
HS508I15A
PGEA1
PIGEA-14
PIGEA14
arb1
chibby homolog 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CBY1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 200014 CC2D1B
coiled-coil and C2 domain containing 1B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CC2D1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57545 CC2D2A
JBTS9
MKS6
coiled-coil and C2 domain containing 2A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CC2D2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 388389 CCDC103
CILD17
PR46b
SMH
coiled-coil domain containing 103 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC103 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 202243 CCDC125
KENAE
coiled-coil domain containing 125 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC125 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90693 CCDC126
coiled-coil domain containing 126 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC126 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55610 CCDC132
coiled-coil domain containing 132 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC132 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 165055 CCDC138
coiled-coil domain containing 138 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC138 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154467 CCDC167
C6orf129
HSPC265
coiled-coil domain containing 167 epigallocatechin gallate results in decreased expression of CCDC167 mRNA decreases expression
mRNA 22079256
C045651 154467 CCDC167
C6orf129
HSPC265
coiled-coil domain containing 167 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC167 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 343099 CCDC18
NY-SAR-41
dJ717I23.1
coiled-coil domain containing 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 374969 CCDC23
coiled-coil domain containing 23 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC23 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51134 CCDC41
Cep83
NY-REN-58
coiled-coil domain containing 41 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100286684 epigallocatechin gallate results in decreased expression of CCDC5 mRNA decreases expression
mRNA 22079256
C045651 100286684 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84660 CCDC62
CT109
ERAP75
TSP-NY
coiled-coil domain containing 62 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCDC62 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64925 CCDC71
coiled-coil domain containing 71 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC71 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84318 CCDC77
coiled-coil domain containing 77 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC77 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79080 CCDC86
coiled-coil domain containing 86 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCDC86 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55297 CCDC91
p56
coiled-coil domain containing 91 epigallocatechin gallate results in decreased expression of CCDC91 mRNA decreases expression
mRNA 22079256
C045651 55297 CCDC91
p56
coiled-coil domain containing 91 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCDC91 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54535 CCHCR1
C6orf18
HCR
SBP
coiled-coil alpha-helical rod protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCHCR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 epigallocatechin gallate results in decreased secretion of CCL2 protein decreases secretion
protein 20816778
C045651 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 891 CCNB1
CCNB
cyclin B1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57820 CCNB1IP1
C14orf18
HEI10
cyclin B1 interacting protein 1, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNB1IP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 epigallocatechin gallate results in decreased expression of CCND1 protein decreases expression
protein 15142168
C045651 899 CCNF
FBX1
FBXO1
cyclin F [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 900 CCNG1
CCNG
cyclin G1 epigallocatechin gallate results in increased expression of CCNG1 mRNA increases expression
mRNA 18851785
C045651 900 CCNG1
CCNG
cyclin G1 epigallocatechin gallate results in increased expression of CCNG1 protein increases expression
protein 18851785
C045651 901 CCNG2
cyclin G2 epigallocatechin gallate results in increased expression of CCNG2 mRNA increases expression
mRNA 18851785
C045651 57018 CCNL1
ANIA6A
PRO1073
ania-6a
cyclin L1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 905 CCNT2
CYCT2
cyclin T2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCNT2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 219771 CCNY
C10orf9
CBCP1
CCNX
CFP1
cyclin Y [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCNY mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25819 CCRN4L
CCR4L
NOC
CCR4 carbon catabolite repression 4-like (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CCRN4L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54462 CCSER2
FAM190B
Gcap14
KIAA1128
bA486O22.1
coiled-coil serine-rich protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CCSER2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 929 CD14
CD14 molecule [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23607 CD2AP
CMS
CD2-associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD2AP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 965 CD58
LFA-3
LFA3
ag3
CD58 molecule [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CD58 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 993 CDC25A
CDC25A2
cell division cycle 25A (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDC25A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC25C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 996 CDC27
ANAPC3
APC3
CDC27Hs
D0S1430E
D17S978E
HNUC
NUC2
cell division cycle 27 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC27 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10602 CDC42EP3
BORG2
CEP3
UB1
CDC42 effector protein (Rho GTPase binding) 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC42EP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56990 CDC42SE2
SPEC2
CDC42 small effector 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC42SE2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79577 CDC73
C1orf28
HPTJT
HRPT2
HYX
cell division cycle 73 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDC73 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83461 CDCA3
GRCC8
TOME-1
cell division cycle associated 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDCA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1012 CDH13
CDHH
P105
cadherin 13 (EC:3.6.1.3) epigallocatechin gallate results in decreased expression of CDH13 mRNA decreases expression
mRNA 16084531
C045651 1019 CDK4
CMM3
PSK-J3
cyclin-dependent kinase 4 (EC:2.7.11.22) epigallocatechin gallate results in decreased expression of CDK4 protein decreases expression
protein 15142168
C045651 8851 CDK5R1
CDK5P35
CDK5R
NCK5A
p23
p25
p35
p35nck5a
cyclin-dependent kinase 5, regulatory subunit 1 (p35) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDK5R1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55755 CDK5RAP2
C48
Cep215
MCPH3
CDK5 regulatory subunit associated protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDK5RAP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1021 CDK6
PLSTIRE
cyclin-dependent kinase 6 (EC:2.7.11.22) epigallocatechin gallate results in decreased expression of CDK6 protein decreases expression
protein 15142168
C045651 1021 CDK6
PLSTIRE
cyclin-dependent kinase 6 (EC:2.7.11.22) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDK6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6792 CDKL5
EIEE2
ISSX
STK9
cyclin-dependent kinase-like 5 (EC:2.7.11.22) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDKL5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A protein results in increased susceptibility to epigallocatechin gallate increases response to substance
protein 15764647
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) epigallocatechin gallate results in decreased expression of CDKN1A mRNA decreases expression
mRNA 18851785
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) epigallocatechin gallate results in increased expression of CDKN1A protein increases expression
protein 15764647
C045651 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Sulindac co-treated with epigallocatechin gallate] results in increased expression of CDKN1A mRNA affects cotreatment
/ increases expression
mRNA 12628509
C045651 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDKN1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in decreased metabolism of CDKN2A promoter decreases metabolic processing
promoter 16037419
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in decreased methylation of CDKN2A gene decreases methylation
gene 17683969
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in decreased methylation of CDKN2A promoter decreases methylation
promoter 14633667
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in increased expression of CDKN2A mRNA increases expression
mRNA 14633667
C045651 1029 CDKN2A
ARF
CDK4I
CDKN2
CMM2
INK4
INK4A
MLM
MTS-1
MTS1
P14
P14ARF
P16
P16-INK4A
P16INK4
P16INK4A
P19
P19ARF
TP16
cyclin-dependent kinase inhibitor 2A epigallocatechin gallate results in increased expression of CDKN2A protein increases expression
protein 17683969
C045651 55602 CDKN2AIP
CARF
CDKN2A interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CDKN2AIP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 50937 CDON
CDO
CDON1
HPE11
ORCAM
cell adhesion associated, oncogene regulated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CDON mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1052 CEBPD
C/EBP-delta
CELF
CRP3
NF-IL6-beta
CCAAT/enhancer binding protein (C/EBP), delta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEBPD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1057 CELP
CELL
cell1
cell2
cell3
carboxyl ester lipase pseudogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CELP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1058 CENPA
CENP-A
CenH3
centromere protein A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1062 CENPE
CENP-E
KIF10
PPP1R61
centromere protein E, 312kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2491 CENPI
CENP-I
FSHPRH1
LRPR1
Mis6
centromere protein I [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 401541 CENPP
CENP-P
centromere protein P [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CENPP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 201134 CEP112
CCDC46
MACOCO
centrosomal protein 112kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP112 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 145508 CEP128
C14orf145
C14orf61
LEDP/132
centrosomal protein 128kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP128 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9859 CEP170
FAM68A
KAB
KIAA0470
centrosomal protein 170kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP170 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80184 CEP290
3H11Ag
BBS14
CT87
JBTS5
LCA10
MKS4
NPHP6
POC3
SLSN6
rd16
centrosomal protein 290kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP290 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 95681 CEP41
JBTS15
TSGA14
centrosomal protein 41kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP41 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80321 CEP70
BITE
centrosomal protein 70kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEP70 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10390 CEPT1
choline/ethanolamine phosphotransferase 1 (EC:2.7.8.2 2.7.8.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CEPT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1070 CETN3
CDC31
CEN3
centrin, EF-hand protein, 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CETN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 629 CFB
AHUS4
BF
BFD
CFAB
FB
FBI12
GBG
H2-Bf
PBF2
complement factor B (EC:3.4.21.47) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CFB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8837 CFLAR
CASH
CASP8AP1
CLARP
Casper
FLAME
FLAME-1
FLAME1
FLIP
I-FLICE
MRIT
c-FLIP
c-FLIPL
c-FLIPR
c-FLIPS
CASP8 and FADD-like apoptosis regulator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CFLAR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79094 CHAC1
ChaC, cation transport regulator homolog 1 (E. coli) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHAC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 494143 CHAC2
ChaC, cation transport regulator homolog 2 (E. coli) epigallocatechin gallate results in decreased expression of CHAC2 mRNA decreases expression
mRNA 22079256
C045651 494143 CHAC2
ChaC, cation transport regulator homolog 2 (E. coli) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHAC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 118487 CHCHD1
C10orf34
C2360
MRP-S37
coiled-coil-helix-coiled-coil-helix domain containing 1 epigallocatechin gallate results in decreased expression of CHCHD1 mRNA decreases expression
mRNA 22079256
C045651 118487 CHCHD1
C10orf34
C2360
MRP-S37
coiled-coil-helix-coiled-coil-helix domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHCHD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84181 CHD6
CHD-6
CHD5
RIGB
chromodomain helicase DNA binding protein 6 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55636 CHD7
HH5
IS3
KAL5
chromodomain helicase DNA binding protein 7 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80205 CHD9
AD013
CReMM
KISH2
PRIC320
chromodomain helicase DNA binding protein 9 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHD9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79643 CHMP6
VPS20
charged multivesicular body protein 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHMP6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50515 CHST11
C4ST
C4ST-1
C4ST1
HSA269537
carbohydrate (chondroitin 4) sulfotransferase 11 (EC:2.8.2.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHST11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51363 CHST15
BRAG
GALNAC4S-6ST
RP11-47G11.1
carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 (EC:2.8.2.33) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CHST15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55847 CISD1
C10orf70
ZCD1
mitoNEET
CDGSH iron sulfur domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CISD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25792 CIZ1
LSFR1
NP94
ZNF356
CDKN1A interacting zinc finger protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CIZ1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9793 CKAP5
CHTOG
MSPS
TOG
TOGp
ch-TOG
cytoskeleton associated protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CKAP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1164 CKS2
CKSHS2
CDC28 protein kinase regulatory subunit 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CKS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23332 CLASP1
MAST1
cytoplasmic linker associated protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLASP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1366 CLDN7
CEPTRL2
CLDN-7
CPETRL2
Hs.84359
claudin-1
claudin 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLDN7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1195 CLK1
CLK
CLK/STY
STY
CDC-like kinase 1 (EC:2.7.12.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLK1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1198 CLK3
PHCLK3
PHCLK3/152
CDC-like kinase 3 (EC:2.7.12.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLK3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79789 CLMN
calmin (calponin-like, transmembrane) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLMN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79827 CLMP
ACAM
ASAM
CSBM
CSBS
CXADR-like membrane protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLMP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9575 CLOCK
KAT13D
bHLHe8
clock circadian regulator (EC:2.3.1.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLOCK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10978 CLP1
HEAB
hClp1
cleavage and polyadenylation factor I subunit 1 (EC:2.7.1.78) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CLP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81570 CLPB
HSP78
SKD3
ClpB caseinolytic peptidase B homolog (E. coli) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLPB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8218 CLTCL1
CHC22
CLH22
CLTCL
CLTD
clathrin, heavy chain-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CLTCL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55907 CMAS
CSS
cytidine monophosphate N-acetylneuraminic acid synthetase (EC:2.7.7.43) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CMAS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80790 CMIP
TCMIP
c-Maf inducing protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CMIP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22866 CNKSR2
CNK2
KSR2
MAGUIN
connector enhancer of kinase suppressor of Ras 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNKSR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154043 CNKSR3
MAGI1
CNKSR family member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNKSR3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26507 CNNM1
ACDP1
CLP-1
cyclin M1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNNM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55571 CNOT11
C2orf29
CCR4-NOT transcription complex, subunit 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4848 CNOT2
CDC36
NOT2
NOT2H
CCR4-NOT transcription complex, subunit 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 246175 CNOT6L
CCR4b
CCR4-NOT transcription complex, subunit 6-like (EC:3.1.13.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT6L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54875 CNTLN
C9orf101
C9orf39
RP11-340N12.1
bA340N12.1
centlein, centrosomal protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNTLN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28958 COA3
CCDC56
MITRAC12
cytochrome c oxidase assembly factor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 388753 COA6
C1orf31
cytochrome c oxidase assembly factor 6 homolog (S. cerevisiae) epigallocatechin gallate results in decreased expression of COA6 mRNA decreases expression
mRNA 22079256
C045651 388753 COA6
C1orf31
cytochrome c oxidase assembly factor 6 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COA6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22796 COG2
LDLC
component of oligomeric golgi complex 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57511 COG6
CDG2L
COD2
SHNS
component of oligomeric golgi complex 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91949 COG7
CDG2E
component of oligomeric golgi complex 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COG7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1277 COL1A1
OI4
collagen, type I, alpha 1 epigallocatechin gallate results in increased expression of COL1A1 mRNA increases expression
mRNA 20706672
C045651 1282 COL4A1
HANAC
ICH
POREN1
arresten
collagen, type IV, alpha 1 epigallocatechin gallate results in decreased expression of COL4A1 mRNA decreases expression
mRNA 16084531
C045651 1291 COL6A1
OPLL
collagen, type VI, alpha 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of COL6A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27235 COQ2
CL640
COQ10D1
MSA1
coenzyme Q2 4-hydroxybenzoate polyprenyltransferase (EC:2.5.1.39) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84274 COQ5
coenzyme Q5 homolog, methyltransferase (S. cerevisiae) (EC:2.1.1.201) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57017 COQ9
C16orf49
COQ10D5
coenzyme Q9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COQ9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23406 COTL1
CLP
coactosin-like 1 (Dictyostelium) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of COTL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4512 COX1
COI
MTCO1
MT-CO1
cytochrome c oxidase subunit I epigallocatechin gallate results in increased expression of COX1 mRNA increases expression
mRNA 20706672
C045651 10063 COX17
COX17 cytochrome c oxidase copper chaperone epigallocatechin gallate results in decreased expression of COX17 mRNA decreases expression
mRNA 22079256
C045651 10063 COX17
COX17 cytochrome c oxidase copper chaperone [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of COX17 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1359 CPA3
MC-CPA
carboxypeptidase A3 (mast cell) (EC:3.4.17.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1363 CPE
carboxypeptidase E (EC:3.4.17.10) epigallocatechin gallate results in decreased expression of CPE mRNA decreases expression
mRNA 16084531
C045651 132864 CPEB2
CPE-BP2
CPEB-2
hCPEB-2
cytoplasmic polyadenylation element binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPEB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144402 CPNE8
copine VIII [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPNE8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51692 CPSF3
CPSF-73
CPSF73
cleavage and polyadenylation specific factor 3, 73kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CPSF3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8738 CRADD
MRT34
RAIDD
CASP2 and RIPK1 domain containing adaptor with death domain epigallocatechin gallate results in decreased expression of CRADD mRNA decreases expression
mRNA 16084531
C045651 8738 CRADD
MRT34
RAIDD
CASP2 and RIPK1 domain containing adaptor with death domain [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRADD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1385 CREB1
CREB
cAMP responsive element binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CREB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90993 CREB3L1
OASIS
cAMP responsive element binding protein 3-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CREB3L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 153222 CREBRF
C5orf41
LRF
CREB3 regulatory factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CREBRF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 58487 CREBZF
SMILE
ZF
CREB/ATF bZIP transcription factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CREBZF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 147081 CRHR1-IT1
C17orf69
CRHR1 intronic transcript 1 (non-protein coding) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CRHR1-IT1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54677 CROT
COT
carnitine O-octanoyltransferase (EC:2.3.1.137) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CROT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1410 CRYAB
CMD1II
CRYA2
CTPP2
CTRCT16
HSPB5
MFM2
crystallin, alpha B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRYAB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1415 CRYBB2
CCA2
CRYB2
CRYB2A
CTRCT3
D22S665
crystallin, beta B2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CRYBB2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9946 CRYZL1
4P11
QOH-1
crystallin, zeta (quinone reductase)-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CRYZL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1459 CSNK2A2
CK2A2
CSNK2A1
casein kinase 2, alpha prime polypeptide (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CSNK2A2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1464 CSPG4
HMW-MAA
MCSP
MCSPG
MEL-CSPG
MSK16
NG2
chondroitin sulfate proteoglycan 4 epigallocatechin gallate results in increased expression of CSPG4 mRNA increases expression
mRNA 22079256
C045651 1464 CSPG4
HMW-MAA
MCSP
MCSPG
MEL-CSPG
MSK16
NG2
chondroitin sulfate proteoglycan 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CSPG4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57325 CSRP2BP
ATAC2
CRP2BP
KAT14
PRO1194
dJ717M23.1
CSRP2 binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CSRP2BP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9811 CTIF
Gm672
KIAA0427
CBP80/20-dependent translation initiation factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTIF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased expression of CTNNB1 mRNA decreases expression
mRNA 16968065
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased expression of CTNNB1 protein decreases expression
protein 16968065
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased localization of CTNNB1 protein decreases localization
protein 16968065
C045651 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa epigallocatechin gallate results in decreased phosphorylation of CTNNB1 protein decreases phosphorylation
protein 16968065
C045651 1497 CTNS
CTNS-LSB
PQLC4
cystinosin, lysosomal cystine transporter [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTNS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51797 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTPS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56474 CTPS2
CTP synthase 2 (EC:6.3.4.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CTPS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2919 CXCL1
FSP
GRO1
GROa
MGSA
MGSA-a
NAP-3
SCYB1
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXCL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3627 CXCL10
C7
IFI10
INP10
IP-10
SCYB10
crg-2
gIP-10
mob-1
chemokine (C-X-C motif) ligand 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXCL10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51523 CXXC5
CF5
RINF
WID
CXXC finger protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CXXC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11068 CYB561D2
101F6
TSP10
cytochrome b561 family, member D2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYB561D2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 124637 CYB5D1
cytochrome b5 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CYB5D1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic epigallocatechin gallate affects the localization of CYCS protein affects localization
protein 15657356
C045651 114757 CYGB
HGB
STAP
cytoglobin epigallocatechin gallate results in decreased expression of CYGB mRNA decreases expression
mRNA 20706672
C045651 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) epigallocatechin gallate inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA] affects binding
/ decreases reaction
/ increases activity
/ increases expression
mRNA 11064004
C045651 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) epigallocatechin gallate inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] decreases reaction
/ increases expression
mRNA 14558788
C045651 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) epigallocatechin gallate results in decreased expression of CYP1A1 mRNA decreases expression
mRNA 20816778
C045651 1545 CYP1B1
CP1B
CYPIB1
GLC3A
P4501B1
cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYP1B1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1594 CYP27B1
CP2B
CYP1
CYP1alpha
CYP27B
P450c1
PDDR
VDD1
VDDR
VDDRI
VDR
cytochrome P450, family 27, subfamily B, polypeptide 1 (EC:1.14.13.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of CYP27B1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9265 CYTH3
ARNO3
GRP1
PSCD3
cytohesin 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CYTH3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23002 DAAM1
dishevelled associated activator of morphogenesis 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAAM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1601 DAB2
DOC-2
DOC2
Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1612 DAPK1
DAPK
death-associated protein kinase 1 (EC:2.7.11.1) epigallocatechin gallate results in decreased expression of DAPK1 mRNA decreases expression
mRNA 12628509
C045651 1612 DAPK1
DAPK
death-associated protein kinase 1 (EC:2.7.11.1) epigallocatechin gallate results in increased expression of DAPK1 mRNA increases expression
mRNA 22079256
C045651 1612 DAPK1
DAPK
death-associated protein kinase 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAPK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1613 DAPK3
ZIP
ZIPK
death-associated protein kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DAPK3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55157 DARS2
ASPRS
LBSL
MT-ASPRS
RP3-383J4.2
aspartyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DARS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285761 DCBLD1
dJ94G16.1
discoidin, CUB and LCCL domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCBLD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 166614 DCLK2
CL2
CLICK-II
CLICK2
CLIK2
DCAMKL2
DCDC3
DCDC3B
DCK2
doublecortin-like kinase 2 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCLK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9937 DCLRE1A
PSO2
SNM1
SNM1A
DNA cross-link repair 1A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCLRE1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23142 DCUN1D4
DCN1, defective in cullin neddylation 1, domain containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DCUN1D4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100286728 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDEF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80821 DDHD1
PA-PLA1
PAPLA1
SPG28
DDHD domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDHD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 mRNA affects cotreatment
/ increases expression
mRNA 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 protein affects cotreatment
/ increases expression
protein 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 epigallocatechin gallate results in increased expression of DDIT3 mRNA increases expression
mRNA 16084531
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DDIT3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 [Sulindac co-treated with epigallocatechin gallate] results in increased expression of DDIT3 mRNA affects cotreatment
/ increases expression
mRNA 12628509
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 U 0126 inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 16463383
C045651 1649 DDIT3
CEBPZ
CHOP
CHOP-10
CHOP10
GADD153
DNA-damage-inducible transcript 3 U 0126 inhibits the reaction [[epigallocatechin gallate co-treated with celecoxib] results in increased expression of DDIT3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 16463383
C045651 1662 DDX10
HRH-J8
DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23586 DDX58
RIG-I
RIGI
RLR-1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX58 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55601 DDX60
DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DDX60 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 163259 DENND2C
dJ1156J9.1
DENN/MADD domain containing 2C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DENND2C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79961 DENND2D
DENN/MADD domain containing 2D [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND2D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22898 DENND3
DENN/MADD domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10260 DENND4A
IRLB
MYCPBP
DENN/MADD domain containing 4A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND4A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55667 DENND4C
C9orf55
C9orf55B
bA513M16.3
DENN/MADD domain containing 4C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND4C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 201627 DENND6A
AFI1A
FAM116A
DENN/MADD domain containing 6A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENND6A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8562 DENR
DRP
DRP1
SMAP-3
density-regulated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DENR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 120863 DEPDC4
DEP.4
DEP domain containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DEPDC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91614 DEPDC7
TR2
dJ85M6.4
DEP domain containing 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DEPDC7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55070 DET1
de-etiolated homolog 1 (Arabidopsis) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DET1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1687 DFNA5
ICERE-1
deafness, autosomal dominant 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DFNA5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8527 DGKD
DGKdelta
dgkd-2
diacylglycerol kinase, delta 130kDa (EC:2.7.1.107) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DGKD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 160851 DGKH
DGKeta
diacylglycerol kinase, eta (EC:2.7.1.107) epigallocatechin gallate results in increased expression of DGKH mRNA increases expression
mRNA 22079256
C045651 160851 DGKH
DGKeta
diacylglycerol kinase, eta (EC:2.7.1.107) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DGKH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1719 DHFR
DHFRP1
DYR
dihydrofolate reductase (EC:1.5.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DHFR mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55760 DHX32
DDX32
DHLP1
DEAH (Asp-Glu-Ala-His) box polypeptide 32 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX32 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60625 DHX35
C20orf15
DDX35
KAIA0875
DEAH (Asp-Glu-Ala-His) box polypeptide 35 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX35 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90957 DHX57
DDX57
DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DHX57 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein epigallocatechin gallate analog affects the localization of DIABLO protein affects localization
protein 16115949
C045651 81624 DIAPH3
AN
AUNA1
DIA2
DRF3
NSDAN
diap3
mDia2
diaphanous-related formin 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIAPH3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 445162 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIMT1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1734 DIO2
5DII
D2
DIOII
SelY
TXDI2
deiodinase, iodothyronine, type II (EC:1.97.1.10) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIO2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23181 DIP2A
C21orf106
DIP2
DIP2 disco-interacting protein 2 homolog A (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIP2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57609 DIP2B
DIP2 disco-interacting protein 2 homolog B (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIP2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115752 DIS3L
DIS3L1
DIS3 mitotic control homolog (S. cerevisiae)-like (EC:3.1.13.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIS3L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84976 DISP1
DISPA
dispatched homolog 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DISP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85458 DIXDC1
CCD1
DIX domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DIXDC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22943 DKK1
DKK-1
SK
dickkopf WNT signaling pathway inhibitor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DKK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1738 DLD
DLDD
DLDH
E3
GCSL
LAD
PHE3
dihydrolipoamide dehydrogenase (EC:1.8.1.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8847 DLEU2
1B4
BCMSUN
DLB2
LEU2
LINC00022
MIR15AHG
NCRNA00022
RFP2OS
TRIM13OS
deleted in lymphocytic leukemia 2 (non-protein coding) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLEU2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1739 DLG1
DLGH1
SAP-97
SAP97
dJ1061C18.1.1
hdlg
discs, large homolog 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9787 DLGAP5
DLG7
HURP
discs, large (Drosophila) homolog-associated protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLGAP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65989 DLK2
DLK-2
EGFL9
delta-like 2 homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DLK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54567 DLL4
hdelta2
delta-like 4 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DLL4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55929 DMAP1
DNMAP1
DNMTAP1
EAF2
MEAF2
SWC4
DNA methyltransferase 1 associated protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1657 DMXL1
Dmx-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMXL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23312 DMXL2
RC3
Dmx-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DMXL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1763 DNA2
DNA2L
PEOA6
hDNA2
DNA replication helicase/nuclease 2 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55172 DNAAF2
C14orf104
CILD10
KTU
PF13
dynein, axonemal, assembly factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAAF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11080 DNAJB4
DNAJW
DjB4
HLJ1
DnaJ (Hsp40) homolog, subfamily B, member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJB4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25822 DNAJB5
Hsc40
DnaJ (Hsp40) homolog, subfamily B, member 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJB5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4189 DNAJB9
ERdj4
MDG-1
MDG1
MST049
MSTP049
DnaJ (Hsp40) homolog, subfamily B, member 9 epigallocatechin gallate results in increased expression of DNAJB9 mRNA increases expression
mRNA 16084531
C045651 23317 DNAJC13
RME8
DnaJ (Hsp40) homolog, subfamily C, member 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85406 DNAJC14
DNAJ
DRIP78
HDJ3
LIP6
DnaJ (Hsp40) homolog, subfamily C, member 14 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 131118 DNAJC19
PAM18
TIM14
TIMM14
DnaJ (Hsp40) homolog, subfamily C, member 19 epigallocatechin gallate results in decreased expression of DNAJC19 mRNA decreases expression
mRNA 22079256
C045651 131118 DNAJC19
PAM18
TIM14
TIMM14
DnaJ (Hsp40) homolog, subfamily C, member 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54943 DNAJC28
C21orf55
C21orf78
DnaJ (Hsp40) homolog, subfamily C, member 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNAJC28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144132 DNHD1
C11orf47
CCDC35
DHCD1
DNHD1L
dynein heavy chain domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DNHD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26052 DNM3
Dyna_III
dynamin 3 (EC:3.6.5.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNM3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1786 DNMT1
ADCADN
AIM
CXXC9
DNMT
HSN1E
MCMT
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) epigallocatechin gallate binds to and results in decreased activity of DNMT1 protein affects binding
/ decreases activity
protein 14633667
C045651 1786 DNMT1
ADCADN
AIM
CXXC9
DNMT
HSN1E
MCMT
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) epigallocatechin gallate results in decreased activity of DNMT1 protein decreases activity
protein 16037419
C045651 1786 DNMT1
ADCADN
AIM
CXXC9
DNMT
HSN1E
MCMT
DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37) Magnesium promotes the reaction [epigallocatechin gallate results in decreased activity of DNMT1 protein] decreases activity
/ increases reaction
protein 16037419
C045651 1789 DNMT3B
ICF
ICF1
M.HsaIIIB
DNA (cytosine-5-)-methyltransferase 3 beta (EC:2.1.1.37) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNMT3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23549 DNPEP
ASPEP
DAP
aspartyl aminopeptidase (EC:3.4.11.21) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNPEP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116092 DNTTIP1
C20orf167
Tdif1
dJ447F3.4
deoxynucleotidyltransferase, terminal, interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DNTTIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 30836 DNTTIP2
ERBP
FCF2
HSU15552
LPTS-RP2
TdIF2
deoxynucleotidyltransferase, terminal, interacting protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DNTTIP2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55619 DOCK10
DRIP2
Nbla10300
ZIZ3
dedicator of cytokinesis 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 139818 DOCK11
ACG
ZIZ2
bB128O4.1
dedicator of cytokinesis 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85440 DOCK7
ZIR2
dedicator of cytokinesis 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23348 DOCK9
ZIZ1
ZIZIMIN1
dedicator of cytokinesis 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOCK9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1796 DOK1
P62DOK
docking protein 1, 62kDa (downstream of tyrosine kinase 1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9980 DOPEY2
21orf5
C21orf5
dopey family member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DOPEY2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 89978 DPH6
ATPBD4
diphthamine biosynthesis 6 (EC:6.3.1.14) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DPH6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1803 DPP4
ADABP
ADCP2
CD26
DPPIV
TP103
dipeptidyl-peptidase 4 (EC:3.4.14.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DPP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55332 DRAM1
DRAM
DNA-damage regulated autophagy modulator 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DRAM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1813 DRD2
D2DR
D2R
dopamine receptor D2 epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] affects binding
/ decreases reaction
/ increases abundance
/ increases activity
protein 17958328
C045651 79075 DSCC1
DCC1
DNA replication and sister chromatid cohesion 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DSCC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29940 DSE
DSEP
DSEPI
SART-2
SART2
dermatan sulfate epimerase (EC:5.1.3.19) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DSE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1830 DSG3
CDHF6
PVA
desmoglein 3 epigallocatechin gallate results in decreased expression of DSG3 mRNA decreases expression
mRNA 20706672
C045651 667 DST
BP240
BPA
BPAG1
CATX-15
CATX15
D6S1101
DMH
DT
EBSB2
HSAN6
MACF2
dystonin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DST mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 112487 DTD2
C14orf126
D-tyrosyl-tRNA deacylase 2 (putative) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84062 DTNBP1
BLOC1S8
DBND
HPS7
My031
SDY
dystrobrevin binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTNBP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285605 DTWD2
DTW domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DTWD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1841 DTYMK
CDC8
PP3731
TMPK
TYMK
deoxythymidylate kinase (thymidylate kinase) (EC:2.7.4.9) epigallocatechin gallate results in decreased expression of DTYMK mRNA decreases expression
mRNA 18851785
C045651 54920 DUS2
DUS2L
SMM1
URLC8
dihydrouridine synthase 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DUS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1846 DUSP4
HVH2
MKP-2
MKP2
TYP
dual specificity phosphatase 4 (EC:3.1.3.16 3.1.3.48) epigallocatechin gallate results in increased expression of DUSP4 mRNA increases expression
mRNA 16084531
C045651 1847 DUSP5
DUSP
HVH3
dual specificity phosphatase 5 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1848 DUSP6
HH19
MKP3
PYST1
dual specificity phosphatase 6 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1849 DUSP7
MKPX
PYST2
dual specificity phosphatase 7 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP7 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1850 DUSP8
C11orf81
HB5
HVH-5
HVH8
dual specificity phosphatase 8 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of DUSP8 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6993 DYNLT1
CW-1
TCTEL1
tctex-1
dynein, light chain, Tctex-type 1 epigallocatechin gallate results in decreased expression of DYNLT1 mRNA decreases expression
mRNA 22079256
C045651 6993 DYNLT1
CW-1
TCTEL1
tctex-1
dynein, light chain, Tctex-type 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DYNLT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1859 DYRK1A
DYRK
DYRK1
HP86
MNB
MNBH
MRD7
dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (EC:2.7.12.1) epigallocatechin gallate results in decreased activity of DYRK1A protein decreases activity
protein 12534346
C045651 9666 DZIP3
PPP1R66
UURF2
hRUL138
DAZ interacting zinc finger protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of DZIP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85403 EAF1
ELL associated factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EAF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9166 EBAG9
EB9
PDAF
estrogen receptor binding site associated, antigen, 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EBAG9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1889 ECE1
ECE
endothelin converting enzyme 1 (EC:3.4.24.71) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ECE1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1893 ECM1
URBWD
extracellular matrix protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ECM1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1894 ECT2
ARHGEF31
epithelial cell transforming sequence 2 oncogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ECT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80267 EDEM3
C1orf22
ER degradation enhancer, mannosidase alpha-like 3 (EC:3.2.1.113) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDEM3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1906 EDN1
ET1
HDLCQ7
PPET1
endothelin 1 epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased expression of EDN1 mRNA] decreases reaction
/ increases expression
mRNA 20021702
C045651 1906 EDN1
ET1
HDLCQ7
PPET1
endothelin 1 epigallocatechin gallate results in decreased expression of EDN1 mRNA decreases expression
mRNA 20021702
C045651 1910 EDNRB
ABCDS
ET-B
ET-BR
ETB
ETBR
ETRB
HSCR
HSCR2
WS4A
endothelin receptor type B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDNRB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8411 EEA1
MST105
MSTP105
ZFYVE2
early endosome antigen 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EEA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1915 EEF1A1
CCS-3
CCS3
EE1A1
EEF-1
EEF1A
EF-Tu
EF1A
GRAF-1EF
HNGC:16303
LENG7
PTI1
eEF1A-1
eukaryotic translation elongation factor 1 alpha 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EEF1A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 29904 EEF2K
HSU93850
eEF-2K
eukaryotic elongation factor-2 kinase (EC:2.7.11.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EEF2K mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114327 EFHC1
dJ304B14.2
EF-hand domain (C-terminal) containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFHC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1942 EFNA1
B61
ECKLG
EFL1
EPLG1
LERK-1
LERK1
TNFAIP4
ephrin-A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1945 EFNA4
EFL4
EPLG4
LERK4
ephrin-A4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1946 EFNA5
AF1
EFL5
EPLG7
GLC1M
LERK7
RAGS
ephrin-A5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFNA5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1948 EFNB2
EPLG5
HTKL
Htk-L
LERK5
ephrin-B2 epigallocatechin gallate results in decreased expression of EFNB2 mRNA decreases expression
mRNA 16084531
C045651 1948 EFNB2
EPLG5
HTKL
Htk-L
LERK5
ephrin-B2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EFNB2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23167 EFR3A
EFR3 homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22979 EFR3B
KIAA0953
EFR3 homolog B (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFR3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79631 EFTUD1
FAM42A
HsT19294
RIA1
elongation factor Tu GTP binding domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EFTUD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein] affects binding
/ decreases reaction
protein 17616711
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] affects binding
/ decreases reaction
/ increases reaction
protein 17616711
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] decreases reaction
/ increases phosphorylation
protein 17616711
C045651 1950 EGF
HOMG4
URG
epidermal growth factor epigallocatechin gallate results in decreased expression of EGF mRNA decreases expression
mRNA 20346928
20706672
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate inhibits the reaction [EGF protein binds to EGFR protein] affects binding
/ decreases reaction
protein 17616711
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] affects binding
/ decreases reaction
/ increases reaction
protein 17616711
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] decreases reaction
/ increases phosphorylation
protein 17616711
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) epigallocatechin gallate results in increased expression of EGFR mRNA increases expression
mRNA 22079256
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EGFR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) [Raloxifene co-treated with epigallocatechin gallate] results in decreased phosphorylation of EGFR protein affects cotreatment
/ decreases phosphorylation
protein 18371987
C045651 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased expression of EGR1 mRNA] decreases reaction
/ increases expression
mRNA 22079256
C045651 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 epigallocatechin gallate results in increased expression of EGR1 mRNA increases expression
mRNA 22079256
C045651 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EGR1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23301 EHBP1
HPC12
NACSIN
EH domain binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHBP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1962 EHHADH
ECHD
L-PBE
LBFP
LBP
PBFE
enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase (EC:1.1.1.35 5.3.3.8 4.2.1.17) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHHADH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79813 EHMT1
EUHMTASE1
Eu-HMTase1
FP13812
GLP
GLP1
KMT1D
bA188C12.1
euchromatic histone-lysine N-methyltransferase 1 (EC:2.1.1.43) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EHMT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 440275 EIF2AK4
GCN2
eukaryotic translation initiation factor 2 alpha kinase 4 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EIF2AK4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1968 EIF2S3
EIF2
EIF2G
EIF2gamma
eIF-2gA
eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF2S3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1974 EIF4A2
BM-010
DDX2B
EIF4A
EIF4F
eIF-4A-II
eIF4A-II
eukaryotic translation initiation factor 4A2 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF4A2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 1975 EIF4B
EIF-4B
PRO1843
eukaryotic translation initiation factor 4B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EIF4B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55520 ELAC1
D29
elaC ribonuclease Z 1 (EC:3.1.26.11) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELAC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1993 ELAVL2
HEL-N1
HELN1
HUB
ELAV like neuron-specific RNA binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELAVL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1997 ELF1
E74-like factor 1 (ets domain transcription factor) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2002 ELK1
ELK1, member of ETS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ELK1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 22936 ELL2
elongation factor, RNA polymerase II, 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84337 ELOF1
ELF1
elongation factor 1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ELOF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64834 ELOVL1
Ssc1
ELOVL fatty acid elongase 1 (EC:2.3.1.199) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELOVL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54898 ELOVL2
SSC2
ELOVL fatty acid elongase 2 (EC:2.3.1.199) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELOVL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26610 ELP4
C11orf19
PAX6NEB
PAXNEB
dJ68P15A.1
elongator acetyltransferase complex subunit 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ELP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9694 EMC2
KIAA0103
TTC35
ER membrane protein complex subunit 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EMC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2010 EMD
EDMD
LEMD5
STA
emerin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EMD mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10436 EMG1
C2F
Grcc2f
NEP1
EMG1 N1-specific pseudouridine methyltransferase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EMG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27436 EML4
C2orf2
ELP120
EMAP-4
EMAPL4
ROPP120
echinoderm microtubule associated protein like 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EML4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10495 ENOX2
APK1
COVA1
tNOX
ecto-NOX disulfide-thiol exchanger 2 ENOX2 results in increased susceptibility to epigallocatechin gallate increases response to substance
15706060
C045651 10495 ENOX2
APK1
COVA1
tNOX
ecto-NOX disulfide-thiol exchanger 2 epigallocatechin gallate results in decreased activity of ENOX2 protein decreases activity
protein 20518072
C045651 10495 ENOX2
APK1
COVA1
tNOX
ecto-NOX disulfide-thiol exchanger 2 [epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD decreases activity
/ increases abundance
protein 20518072
C045651 114915 EPB41L4A-AS1
C5orf26
NCRNA00219
TIGA1
EPB41L4A antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EPB41L4A-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54566 EPB41L4B
CG1
EHM2
erythrocyte membrane protein band 4.1 like 4B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPB41L4B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57724 EPG5
HEEW1
KIAA1632
VICIS
hEPG5
ectopic P-granules autophagy protein 5 homolog (C. elegans) epigallocatechin gallate results in increased expression of EPG5 mRNA increases expression
mRNA 22079256
C045651 57724 EPG5
HEEW1
KIAA1632
VICIS
hEPG5
ectopic P-granules autophagy protein 5 homolog (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPG5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2043 EPHA4
HEK8
SEK
TYRO1
EPH receptor A4 (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPHA4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9852 EPM2AIP1
EPM2A (laforin) interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of EPM2AIP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 22905 EPN2
EHB21
epsin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2059 EPS8
epidermal growth factor receptor pathway substrate 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPS8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 94240 EPSTI1
BRESI1
epithelial stromal interaction 1 (breast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EPSTI1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23085 ERC1
Cast2
ELKS
RAB6IP2
ELKS/RAB6-interacting/CAST family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2072 ERCC4
ERCC11
FANCQ
RAD1
XPF
excision repair cross-complementing rodent repair deficiency, complementation group 4 epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of ERCC4 mRNA] decreases expression
/ decreases reaction
mRNA 22079256
C045651 2072 ERCC4
ERCC11
FANCQ
RAD1
XPF
excision repair cross-complementing rodent repair deficiency, complementation group 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 375748 ERCC6L2
C9orf102
RAD26L
SR278
excision repair cross-complementing rodent repair deficiency, complementation group 6-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC6L2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51290 ERGIC2
Erv41
PTX1
cd002
ERGIC and golgi 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERGIC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 157697 ERICH1
glutamate-rich 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERICH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27248 ERLEC1
C2orf30
CIM
CL24936
CL25084
XTP3-B
XTP3TPB
endoplasmic reticulum lectin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERLEC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55780 ERMARD
C6orf70
dJ266L20.3
ER membrane-associated RNA degradation [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERMARD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10961 ERP29
C12orf8
ERp28
ERp31
PDI-DB
PDIA9
endoplasmic reticulum protein 29 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ERP29 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54206 ERRFI1
GENE-33
MIG-6
MIG6
RALT
ERBB receptor feedback inhibitor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ERRFI1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2098 ESD
FGH
esterase D (EC:3.1.2.12 3.1.1.56) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ESD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 284729 ESPNP
RP1-163M9.1
dJ1182A14.1
espin pseudogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ESPNP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) epigallocatechin gallate results in decreased expression of ESR2 mRNA decreases expression
mRNA 20706672
C045651 54465 ETAA1
ETAA16
Ewing tumor-associated antigen 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ETAA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2117 ETV3
METS
PE-1
PE1
bA110J1.4
ets variant 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ETV3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2119 ETV5
ERM
ets variant 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ETV5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2120 ETV6
TEL
TEL/ABL
ets variant 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ETV6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55763 EXOC1
BM-102
SEC3
SEC3L1
SEC3P
exocyst complex component 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55770 EXOC2
SEC5
SEC5L1
Sec5p
exocyst complex component 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60412 EXOC4
SEC8
SEC8L1
Sec8p
exocyst complex component 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54536 EXOC6
EXOC6A
SEC15
SEC15L
SEC15L1
SEC15L3
Sec15p
exocyst complex component 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXOC6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23086 EXPH5
SLAC2-B
SLAC2B
exophilin 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EXPH5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2139 EYA2
EAB1
eyes absent homolog 2 (Drosophila) (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EYA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [F2 protein results in increased activity of F3 protein] decreases reaction
/ increases activity
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 mRNA] decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 protein] decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
C045651 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [F2 protein results in increased activity of F3 protein] decreases reaction
/ increases activity
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 mRNA] decreases reaction
/ increases expression
mRNA 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [F2 protein results in increased expression of F3 protein] decreases reaction
/ increases expression
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 19944065
C045651 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
C045651 8772 FADD
MORT1
Fas (TNFRSF6)-associated via death domain [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FADD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3995 FADS3
CYB5RP
LLCDL3
fatty acid desaturase 3 (EC:1.14.19.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FADS3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55179 FAIM
FAIM1
Fas apoptotic inhibitory molecule [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAIM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144347 FAM101A
family with sequence similarity 101, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM101A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 284611 FAM102B
SYM-3B
family with sequence similarity 102, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM102B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90362 FAM110B
C8orf72
family with sequence similarity 110, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM110B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 92689 FAM114A1
Noxp20
family with sequence similarity 114, member A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM114A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285966 FAM115C
FAM139A
family with sequence similarity 115, member C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM115C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79607 FAM118B
family with sequence similarity 118, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM118B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26355 FAM162A
C3orf28
E2IG5
HGTD-P
family with sequence similarity 162, member A epigallocatechin gallate results in decreased expression of FAM162A mRNA decreases expression
mRNA 22079256
C045651 26355 FAM162A
C3orf28
E2IG5
HGTD-P
family with sequence similarity 162, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM162A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 400823 FAM177B
family with sequence similarity 177, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM177B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51313 FAM198B
AD036
C4orf18
family with sequence similarity 198, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM198B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85395 FAM207A
C21orf70
family with sequence similarity 207, member A epigallocatechin gallate results in decreased expression of FAM207A mRNA decreases expression
mRNA 22079256
C045651 85395 FAM207A
C21orf70
family with sequence similarity 207, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM207A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23272 FAM208A
C3orf63
RAP140
se89-1
family with sequence similarity 208, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM208A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54537 FAM35A
FAM35A1
bA163M19.1
family with sequence similarity 35, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM35A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10447 FAM3C
ILEI
family with sequence similarity 3, member C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM3C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51571 FAM49B
L1
family with sequence similarity 49, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM49B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26240 FAM50B
D6S2654E
X5L
family with sequence similarity 50, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM50B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 199870 FAM76A
family with sequence similarity 76, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAM76A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22909 FAN1
KIAA1018
KMIN
MTMR15
FANCD2/FANCI-associated nuclease 1 (EC:3.1.4.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2176 FANCC
FA3
FAC
FACC
Fanconi anemia, complementation group C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FANCC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57697 FANCM
FAAP250
KIAA1596
Fanconi anemia, complementation group M (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FANCM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55711 FAR2
MLSTD1
SDR10E2
fatty acyl CoA reductase 2 (EC:1.2.1.n2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10667 FARS2
COXPD14
FARS1
HSPC320
PheRS
dJ520B18.2
phenylalanyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FARS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2194 FASN
FAS
OA-519
SDR27X1
fatty acid synthase (EC:2.3.1.85 2.3.1.38 2.3.1.39 2.3.1.41 3.1.2.14 4.2.1.59 1.1.1.100 1.3.1.39) epigallocatechin gallate results in decreased expression of FASN mRNA decreases expression
mRNA 20816778
C045651 79675 FASTKD1
FAST kinase domains 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FASTKD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22868 FASTKD2
KIAA0971
FAST kinase domains 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FASTKD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2195 FAT1
CDHF7
CDHR8
FAT
ME5
hFat1
FAT atypical cadherin 1 epigallocatechin gallate results in increased expression of FAT1 mRNA increases expression
mRNA 22079256
C045651 2195 FAT1
CDHF7
CDHR8
FAT
ME5
hFat1
FAT atypical cadherin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79633 FAT4
CDHF14
CDHR11
FAT-J
FATJ
NBLA00548
FAT atypical cadherin 4 epigallocatechin gallate results in increased expression of FAT4 mRNA increases expression
mRNA 22079256
C045651 79633 FAT4
CDHF14
CDHR11
FAT-J
FATJ
NBLA00548
FAT atypical cadherin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FAT4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2200 FBN1
ACMICD
ECTOL1
FBN
GPHYSD2
MASS
MFS1
OCTD
SGS
SSKS
WMS
WMS2
fibrillin 1 epigallocatechin gallate results in decreased expression of FBN1 mRNA decreases expression
mRNA 20706672
C045651 2200 FBN1
ACMICD
ECTOL1
FBN
GPHYSD2
MASS
MFS1
OCTD
SGS
SSKS
WMS
WMS2
fibrillin 1 epigallocatechin gallate results in increased expression of FBN1 mRNA increases expression
mRNA 22079256
C045651 2200 FBN1
ACMICD
ECTOL1
FBN
GPHYSD2
MASS
MFS1
OCTD
SGS
SSKS
WMS
WMS2
fibrillin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2201 FBN2
CCA
DA9
fibrillin 2 epigallocatechin gallate results in decreased expression of FBN2 mRNA decreases expression
mRNA 20706672
C045651 54850 FBXL12
Fbl12
F-box and leucine-rich repeat protein 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FBXL12 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25827 FBXL2
FBL2
FBL3
F-box and leucine-rich repeat protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26235 FBXL4
FBL4
FBL5
MTDPS13
F-box and leucine-rich repeat protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26234 FBXL5
FBL4
FBL5
FLR1
F-box and leucine-rich repeat protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23194 FBXL7
FBL6
FBL7
F-box and leucine-rich repeat protein 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXL7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84893 FBXO18
FBH1
Fbx18
F-box protein, helicase, 18 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXO18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 554251 FBXO48
F-box protein 48 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FBXO48 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115548 FCHO2
FCH domain only 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FCHO2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9873 FCHSD2
NWK
SH3MD3
FCH and double SH3 domains 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FCHSD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55527 FEM1A
EPRAP
fem-1 homolog a (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FEM1A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56929 FEM1C
EUROIMAGE686608
EUROIMAGE783647
FEM1A
fem-1 homolog c (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FEM1C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2241 FER
FerT
PPP1R74
TYK3
fer (fps/fes related) tyrosine kinase (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FER mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10979 FERMT2
KIND2
MIG2
PLEKHC1
UNC112
UNC112B
mig-2
fermitin family member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FERMT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55785 FGD6
ZFYVE24
FYVE, RhoGEF and PH domain containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2246 FGF1
AFGF
ECGF
ECGF-beta
ECGFA
ECGFB
FGF-1
FGF-alpha
FGFA
GLIO703
HBGF-1
HBGF1
fibroblast growth factor 1 (acidic) epigallocatechin gallate results in decreased expression of FGF1 mRNA decreases expression
mRNA 20706672
C045651 2257 FGF12
FGF12B
FHF1
fibroblast growth factor 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8817 FGF18
FGF-18
ZFGF5
fibroblast growth factor 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FGF18 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2247 FGF2
BFGF
FGF-2
FGFB
HBGF-2
fibroblast growth factor 2 (basic) epigallocatechin gallate results in decreased expression of FGF2 mRNA decreases expression
mRNA 16084531
C045651 2247 FGF2
BFGF
FGF-2
FGFB
HBGF-2
fibroblast growth factor 2 (basic) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11259 FILIP1L
DOC-1
DOC1
GIP130
GIP90
filamin A interacting protein 1-like epigallocatechin gallate results in decreased expression of FILIP1L mRNA decreases expression
mRNA 16084531
C045651 60681 FKBP10
FKBP65
OI11
OI6
PPIASE
hFKBP65
FK506 binding protein 10, 65 kDa (EC:5.2.1.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FKBP10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11328 FKBP9
FKBP60
FKBP63
PPIase
FK506 binding protein 9, 63 kDa (EC:5.2.1.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FKBP9 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23768 FLRT2
fibronectin leucine rich transmembrane protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FLRT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114793 FMNL2
FHOD2
formin-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FMNL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54874 FNBP1L
C1orf39
TOCA1
formin binding protein 1-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNBP1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22862 FNDC3A
FNDC3
HUGO
bA203I16.1
bA203I16.5
fibronectin type III domain containing 3A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNDC3A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64778 FNDC3B
FAD104
PRO4979
YVTM2421
fibronectin type III domain containing 3B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FNDC3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 163479 FNDC7
RP11-293A10.2
fibronectin type III domain containing 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FNDC7 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54914 FOCAD
KIAA1797
focadhesin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FOCAD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog epigallocatechin gallate results in decreased activity of FOS protein decreases activity
protein 12663506
C045651 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FOS mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2354 FOSB
AP-1
G0S3
GOS3
GOSB
FBJ murine osteosarcoma viral oncogene homolog B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FOSB mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27086 FOXP1
12CC4
QRF1
hFKH1B
forkhead box P1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FOXP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 122786 FRMD6
C14orf31
EX1
Willin
c14_5320
FERM domain containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRMD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10818 FRS2
FRS2A
FRS2alpha
SNT
SNT-1
SNT1
fibroblast growth factor receptor substrate 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FRS2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10129 FRY
13CDNA73
214K23.2
C13orf14
CG003
bA207N4.2
bA37E23.1
furry homolog (Drosophila) epigallocatechin gallate results in increased expression of FRY mRNA increases expression
mRNA 22079256
C045651 10129 FRY
13CDNA73
214K23.2
C13orf14
CG003
bA207N4.2
bA37E23.1
furry homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRY mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285527 FRYL
KIAA0826
FRY-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FRYL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2519 FUCA2
dJ20N2.5
fucosidase, alpha-L- 2, plasma (EC:3.2.1.51) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FUCA2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2530 FUT8
fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (EC:2.4.1.68) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FUT8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2395 FXN
CyaY
FA
FARR
FRDA
X25
frataxin (EC:1.16.3.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FXN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 53827 FXYD5
DYSAD
IWU1
KCT1
OIT2
PRO6241
RIC
FXYD domain containing ion transport regulator 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FXYD5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2534 FYN
SLK
SYN
p59-FYN
FYN oncogene related to SRC, FGR, YES (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FYN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8321 FZD1
frizzled family receptor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FZD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2535 FZD2
Fz2
fz-2
fzE2
hFz2
frizzled family receptor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FZD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55632 G2E3
KIAA1333
PHF7B
G2/M-phase specific E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of G2E3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2548 GAA
LYAG
glucosidase, alpha; acid (EC:3.2.1.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GAA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2549 GAB1
GRB2-associated binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GAB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9846 GAB2
GRB2-associated binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GAB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2564 GABRE
gamma-aminobutyric acid (GABA) A receptor, epsilon [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GABRE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1647 GADD45A
DDIT1
GADD45
growth arrest and DNA-damage-inducible, alpha epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased expression of GADD45A mRNA] decreases reaction
/ increases expression
mRNA 22079256
C045651 1647 GADD45A
DDIT1
GADD45
growth arrest and DNA-damage-inducible, alpha [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GADD45A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51083 GAL
GAL-GMAP
GALN
GLNN
GMAP
galanin/GMAP prepropeptide [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GAL mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 130589 GALM
IBD1
galactose mutarotase (aldose 1-epimerase) (EC:5.1.3.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GALM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2589 GALNT1
GALNAC-T1
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) (EC:2.4.1.41) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GALNT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2632 GBE1
APBD
GBE
GSD4
glucan (1,4-alpha-), branching enzyme 1 (EC:2.4.1.18) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2633 GBP1
guanylate binding protein 1, interferon-inducible epigallocatechin gallate results in decreased expression of GBP1 mRNA decreases expression
mRNA 16084531
C045651 2634 GBP2
guanylate binding protein 2, interferon-inducible [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2635 GBP3
guanylate binding protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115361 GBP4
Mpa2
guanylate binding protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GBP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25801 GCA
GCL
grancalcin, EF-hand calcium binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GCA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79571 GCC1
GCC1P
GCC88
GRIP and coiled-coil domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GCC1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2650 GCNT1
C2GNT
C2GNT-L
C2GNT1
G6NT
NACGT2
NAGCT2
glucosaminyl (N-acetyl) transferase 1, core 2 (EC:2.4.1.102) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GCNT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2651 GCNT2
CCAT
CTRCT13
GCNT2C
GCNT5
IGNT
II
NACGT1
NAGCT1
ULG3
bA360O19.2
bA421M1.1
glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) (EC:2.4.1.150) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GCNT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2661 GDF9
growth differentiation factor 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GDF9 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 284161 GDPD1
GDE4
glycerophosphodiester phosphodiesterase domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GDPD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79833 GEMIN6
gem (nuclear organelle) associated protein 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GEMIN6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9945 GFPT2
GFAT2
glutamine-fructose-6-phosphate transaminase 2 (EC:2.6.1.16) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GFPT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26058 GIGYF2
GYF2
PARK11
PERQ2
PERQ3
TNRC15
GRB10 interacting GYF protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GIGYF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54826 GIN1
GIN-1
TGIN1
ZH2C2
gypsy retrotransposon integrase 1 epigallocatechin gallate results in decreased expression of GIN1 mRNA decreases expression
mRNA 22079256
C045651 54826 GIN1
GIN-1
TGIN1
ZH2C2
gypsy retrotransposon integrase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GIN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9837 GINS1
PSF1
GINS complex subunit 1 (Psf1 homolog) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GINS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9815 GIT2
CAT-2
CAT2
G protein-coupled receptor kinase interacting ArfGAP 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GIT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2701 GJA4
CX37
gap junction protein, alpha 4, 37kDa epigallocatechin gallate results in decreased expression of GJA4 mRNA decreases expression
mRNA 16084531
C045651 113263 GLCCI1
FAM117C
GCTR
GIG18
TSSN1
glucocorticoid induced transcript 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLCCI1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2736 GLI2
HPE9
THP1
THP2
GLI family zinc finger 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLI2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2737 GLI3
ACLS
GCPS
GLI3-190
GLI3FL
PAP-A
PAPA
PAPA1
PAPB
PHS
PPDIV
GLI family zinc finger 3 epigallocatechin gallate results in increased expression of GLI3 mRNA increases expression
mRNA 22079256
C045651 2737 GLI3
ACLS
GCPS
GLI3-190
GLI3FL
PAP-A
PAPA
PAPA1
PAPB
PHS
PPDIV
GLI family zinc finger 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLI3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 169792 GLIS3
ZNF515
GLIS family zinc finger 3 epigallocatechin gallate results in increased expression of GLIS3 mRNA increases expression
mRNA 22079256
C045651 169792 GLIS3
ZNF515
GLIS family zinc finger 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLIS3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11146 GLMN
FAP
FAP48
FAP68
FKBPAP
GLML
GVM
VMGLOM
glomulin, FKBP associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLMN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51022 GLRX2
CGI-133
GRX2
glutaredoxin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLRX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2744 GLS
AAD20
GAC
GAM
GLS1
KGA
glutaminase (EC:3.5.1.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55830 GLT8D1
MSTP139
glycosyltransferase 8 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLT8D1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80772 GLTPD1
CPTP
glycolipid transfer protein domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GLTPD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29997 GLTSCR2
PICT-1
PICT1
glioma tumor suppressor candidate region gene 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GLTSCR2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2766 GMPR
GMPR1
guanosine monophosphate reductase (EC:1.7.1.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GMPR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2770 GNAI1
Gi
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNAI1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2776 GNAQ
CMC1
G-ALPHA-q
GAQ
SWS
guanine nucleotide binding protein (G protein), q polypeptide [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNAQ mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10020 GNE
DMRV
GLCNE
IBM2
NM
Uae1
glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (EC:2.7.1.60 3.2.1.183) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26354 GNL3
C77032
E2IG3
NNP47
NS
guanine nucleotide binding protein-like 3 (nucleolar) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GNL3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79158 GNPTAB
GNPTA
ICD
N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits (EC:2.7.8.17) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GNPTAB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2796 GNRH1
GNRH
GRH
HH12
LHRH
LNRH
gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GNRH1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2800 GOLGA1
golgin-97
golgin A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GOLGA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27333 GOLIM4
GIMPC
GOLPH4
GPP130
P138
golgi integral membrane protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GOLIM4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54865 GPATCH4
GPATC4
G patch domain containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GPATCH4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10243 GPHN
GEPH
GPH
GPHRYN
HKPX1
MOCODC
gephyrin (EC:2.10.1.1 2.7.7.75) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPHN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26996 GPR160
GPCR1
GPCR150
G protein-coupled receptor 160 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR160 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 160897 GPR180
ITR
G protein-coupled receptor 180 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR180 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2844 GPR21
G protein-coupled receptor 21 epigallocatechin gallate results in increased expression of GPR21 mRNA increases expression
mRNA 22079256
C045651 2844 GPR21
G protein-coupled receptor 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GPR21 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2863 GPR39
G protein-coupled receptor 39 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR39 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 53836 GPR87
GPR95
KPG_002
G protein-coupled receptor 87 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPR87 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51704 GPRC5B
RAIG-2
RAIG2
G protein-coupled receptor, family C, group 5, member B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPRC5B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29899 GPSM2
CMCS
DFNB82
LGN
PINS
G-protein signaling modulator 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GPSM2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2876 GPX1
GPXD
GSHPX1
glutathione peroxidase 1 (EC:1.11.1.9) epigallocatechin gallate results in decreased expression of GPX1 mRNA decreases expression
mRNA 18851785
C045651 57476 GRAMD1B
GRAM domain containing 1B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GRAMD1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65983 GRAMD3
NS3TP2
GRAM domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GRAMD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80000 GREB1L
C18orf6
KIAA1772
growth regulation by estrogen in breast cancer-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GREB1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2896 GRN
CLN11
GEP
GP88
PCDGF
PEPI
PGRN
granulin epigallocatechin gallate results in increased expression of GRN mRNA increases expression
mRNA 20706672
C045651 54103 GSAP
PION
gamma-secretase activating protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GSAP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2931 GSK3A
glycogen synthase kinase 3 alpha (EC:2.7.11.1 2.7.11.26) epigallocatechin gallate results in increased phosphorylation of GSK3A protein increases phosphorylation
protein 16968065
C045651 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) epigallocatechin gallate results in increased phosphorylation of GSK3B protein increases phosphorylation
protein 16968065
C045651 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GSK3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2937 GSS
GSHS
glutathione synthetase (EC:6.3.2.3) epigallocatechin gallate results in decreased expression of GSS mRNA decreases expression
mRNA 18851785
C045651 2941 GSTA4
GSTA4-4
GTA4
glutathione S-transferase alpha 4 (EC:2.5.1.18) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GSTA4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) epigallocatechin gallate results in decreased expression of GSTP1 mRNA decreases expression
mRNA 18851785
C045651 404672 GTF2H5
C6orf175
TFB5
TFIIH
TGF2H5
TTD
TTD-A
TTDA
bA120J8.2
general transcription factor IIH, polypeptide 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTF2H5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9569 GTF2IRD1
BEN
CREAM1
GTF3
MUSTRD1
RBAP2
WBS
WBSCR11
WBSCR12
hMusTRD1alpha1
GTF2I repeat domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTF2IRD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2976 GTF3C2
TFIIIC-BETA
TFIIIC110
general transcription factor IIIC, polypeptide 2, beta 110kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTF3C2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9329 GTF3C4
KAT12
TFIII90
TFIIIC290
TFIIIC90
TFIIICDELTA
general transcription factor IIIC, polypeptide 4, 90kDa (EC:2.3.1.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GTF3C4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54676 GTPBP2
GTP binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GTPBP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51454 GULP1
CED-6
CED6
GULP
GULP, engulfment adaptor PTB domain containing 1 epigallocatechin gallate results in decreased expression of GULP1 mRNA decreases expression
mRNA 16084531
C045651 2990 GUSB
BG
MPS7
glucuronidase, beta (EC:3.2.1.31) epigallocatechin gallate inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of GUSB protein] decreases reaction
/ increases secretion
protein 11944907
C045651 2990 GUSB
BG
MPS7
glucuronidase, beta (EC:3.2.1.31) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of GUSB mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3005 H1F0
H10
H1FV
H1 histone family, member 0 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H1F0 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55506 H2AFY2
macroH2A2
H2A histone family, member Y2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of H2AFY2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 145864 HAPLN3
EXLD1
HsT19883
hyaluronan and proteoglycan link protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HAPLN3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3036 HAS1
HAS
hyaluronan synthase 1 (EC:2.4.1.212) epigallocatechin gallate results in decreased expression of HAS1 mRNA decreases expression
mRNA 20706672
C045651 1839 HBEGF
DTR
DTS
DTSF
HEGFL
heparin-binding EGF-like growth factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HBEGF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10014 HDAC5
HD5
NY-CO-9
histone deacetylase 5 (EC:3.5.1.98) epigallocatechin gallate results in decreased expression of HDAC5 mRNA decreases expression
mRNA 18851785
C045651 55869 HDAC8
CDLS5
HD8
HDACL1
MRXS6
RPD3
WTS
histone deacetylase 8 (EC:3.5.1.98) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HDAC8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 67365 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HDHD1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55027 HEATR3
SYO1
HEAT repeat containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25938 HEATR5A
C14orf125
HEAT repeat containing 5A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR5A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54497 HEATR5B
HEAT repeat containing 5B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR5B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 63897 HEATR6
ABC1
HEAT repeat containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEATR6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51696 HECA
HDC
HDCL
HHDC
dJ225E12.1
headcase homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HECA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57493 HEG1
HEG
MST112
MSTP112
heart development protein with EGF-like domains 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51409 HEMK1
HEMK
MTQ1
HemK methyltransferase family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HEMK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8925 HERC1
p532
p619
HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 epigallocatechin gallate results in increased expression of HERC1 mRNA increases expression
mRNA 22079256
C045651 8925 HERC1
p532
p619
HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26091 HERC4
HECT and RLD domain containing E3 ubiquitin protein ligase 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55008 HERC6
HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERC6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9709 HERPUD1
HERP
Mif1
SUP
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 epigallocatechin gallate results in increased expression of HERPUD1 mRNA increases expression
mRNA 16084531
C045651 64224 HERPUD2
HERPUD family member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HERPUD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3280 HES1
HES-1
HHL
HRY
bHLHb39
hes family bHLH transcription factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HES1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10614 HEXIM1
CLP1
EDG1
HIS1
MAQ1
hexamethylene bis-acetamide inducible 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HEXIM1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3082 HGF
DFNB39
F-TCF
HGFB
HPTA
SF
hepatocyte growth factor (hepapoietin A; scatter factor) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 3082 HGF
DFNB39
F-TCF
HGFB
HPTA
SF
hepatocyte growth factor (hepapoietin A; scatter factor) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 3082 HGF
DFNB39
F-TCF
HGFB
HPTA
SF
hepatocyte growth factor (hepapoietin A; scatter factor) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 3082 HGF
DFNB39
F-TCF
HGFB
HPTA
SF
hepatocyte growth factor (hepapoietin A; scatter factor) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 138050 HGSNAT
HGNAT
MPS3C
TMEM76
heparan-alpha-glucosaminide N-acetyltransferase (EC:2.3.1.78) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HGSNAT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3087 HHEX
HEX
HMPH
HOX11L-PEN
PRH
PRHX
hematopoietically expressed homeobox [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HHEX mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26275 HIBCH
HIBYLCOAH
3-hydroxyisobutyryl-CoA hydrolase (EC:3.1.2.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIBCH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) epigallocatechin gallate results in decreased expression of HIF1A mRNA decreases expression
mRNA 20346928
C045651 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) epigallocatechin gallate results in decreased expression of HIF1A protein decreases expression
protein 20346928
C045651 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) epigallocatechin gallate results in decreased hydroxylation of and results in decreased degradation of HIF1A protein decreases degradation
/ decreases hydroxylation
protein 16005427
C045651 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) epigallocatechin gallate results in increased expression of and results in increased activity of HIF1A protein increases activity
/ increases expression
protein 16005427
C045651 55662 HIF1AN
FIH1
hypoxia inducible factor 1, alpha subunit inhibitor (EC:1.14.11.30 1.14.11.n4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIF1AN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3092 HIP1
HIP-I
ILWEQ
huntingtin interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3024 HIST1H1A
H1.1
H1A
H1F1
HIST1
histone cluster 1, H1a [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST1H1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3009 HIST1H1B
H1
H1.5
H1B
H1F5
H1s-3
histone cluster 1, H1b epigallocatechin gallate results in decreased expression of HIST1H1B mRNA decreases expression
mRNA 22079256
C045651 3009 HIST1H1B
H1
H1.5
H1B
H1F5
H1s-3
histone cluster 1, H1b [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST1H1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3006 HIST1H1C
H1.2
H1C
H1F2
H1s-1
histone cluster 1, H1c [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST1H1C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3007 HIST1H1D
H1.3
H1D
H1F3
H1s-2
histone cluster 1, H1d [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST1H1D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8334 HIST1H2AC
H2A/l
H2AFL
dJ221C16.4
histone cluster 1, H2ac [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST1H2AC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8345 HIST1H2BH
H2B/j
H2BFJ
histone cluster 1, H2bh [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST1H2BH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8342 HIST1H2BM
H2B/e
H2BFE
dJ160A22.3
histone cluster 1, H2bm [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST1H2BM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 317772 HIST2H2AB
H2AB
histone cluster 2, H2ab [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIST2H2AB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3096 HIVEP1
CIRIP
CRYBP1
MBP-1
PRDII-BF1
Schnurri-1
ZAS1
ZNF40
ZNF40A
human immunodeficiency virus type I enhancer binding protein 1 epigallocatechin gallate results in increased expression of HIVEP1 mRNA increases expression
mRNA 22079256
C045651 3096 HIVEP1
CIRIP
CRYBP1
MBP-1
PRDII-BF1
Schnurri-1
ZAS1
ZNF40
ZNF40A
human immunodeficiency virus type I enhancer binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIVEP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3097 HIVEP2
HIV-EP2
MBP-2
MIBP1
SHN2
ZAS2
ZNF40B
human immunodeficiency virus type I enhancer binding protein 2 epigallocatechin gallate results in increased expression of HIVEP2 mRNA increases expression
mRNA 22079256
C045651 3097 HIVEP2
HIV-EP2
MBP-2
MIBP1
SHN2
ZAS2
ZNF40B
human immunodeficiency virus type I enhancer binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HIVEP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3099 HK2
HKII
HXK2
hexokinase 2 (EC:2.7.1.1) epigallocatechin gallate results in increased expression of HK2 mRNA increases expression
mRNA 16084531
C045651 3099 HK2
HKII
HXK2
hexokinase 2 (EC:2.7.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HK2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3141 HLCS
HCS
holocarboxylase synthetase (biotin-(proprionyl-CoA-carboxylase (ATP-hydrolysing)) ligase) (EC:6.3.4.10 6.3.4.11 6.3.4.15 6.3.4.9) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HLCS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6596 HLTF
HIP116
HIP116A
HLTF1
RNF80
SMARCA3
SNF2L3
ZBU1
helicase-like transcription factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HLTF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3159 HMGA1
HMG-R
HMGA1A
HMGIY
high mobility group AT-hook 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HMGA1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3146 HMGB1
HMG1
HMG3
SBP-1
high mobility group box 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HMGB1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3157 HMGCS1
HMGCS
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) (EC:2.3.3.10) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMGCS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9324 HMGN3
PNAS-25
TRIP7
high mobility group nucleosomal binding domain 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMGN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3161 HMMR
CD168
IHABP
RHAMM
hyaluronan-mediated motility receptor (RHAMM) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMMR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) epigallocatechin gallate results in increased expression of HMOX1 protein increases expression
protein 16799064
C045651 3163 HMOX2
HO-2
heme oxygenase (decycling) 2 (EC:1.14.99.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HMOX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 340784 HMX3
NKX-5.1
NKX5.1
Nkx5-1
H6 family homeobox 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HMX3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3187 HNRNPH1
HNRPH
HNRPH1
hnRNPH
heterogeneous nuclear ribonucleoprotein H1 (H) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HNRNPH1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9456 HOMER1
HOMER
HOMER1A
HOMER1B
HOMER1C
SYN47
Ves-1
homer homolog 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HOMER1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3219 HOXB9
HOX-2.5
HOX2
HOX2E
homeobox B9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of HOXB9 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84343 HPS3
SUTAL
Hermansky-Pudlak syndrome 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HPS3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11234 HPS5
AIBP63
Hermansky-Pudlak syndrome 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HPS5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10247 HRSP12
P14.5
PSP
UK114
heat-responsive protein 12 epigallocatechin gallate results in decreased expression of HRSP12 mRNA decreases expression
mRNA 22079256
C045651 10247 HRSP12
P14.5
PSP
UK114
heat-responsive protein 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HRSP12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 158160 HSD17B7P2
HSD17B7
Hsd17b_2
bA291L22.1
hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSD17B7P2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84263 HSDL2
C9orf99
SDR13C1
hydroxysteroid dehydrogenase like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSDL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3304 HSPA1B
HSP70-1B
HSP70-2
heat shock 70kDa protein 1B epigallocatechin gallate results in decreased expression of HSPA1B mRNA decreases expression
mRNA 18851785
C045651 3305 HSPA1L
HSP70-1L
HSP70-HOM
HSP70T
hum70t
heat shock 70kDa protein 1-like epigallocatechin gallate results in decreased expression of HSPA1L mRNA decreases expression
mRNA 18851785
C045651 22824 HSPA4L
APG-1
HSPH3
Osp94
heat shock 70kDa protein 4-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSPA4L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27129 HSPB7
cvHSP
heat shock 27kDa protein family, member 7 (cardiovascular) epigallocatechin gallate results in decreased expression of HSPB7 mRNA decreases expression
mRNA 18851785
C045651 503731 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HTATIP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10553 HTATIP2
CC3
SDR44U1
TIP30
HIV-1 Tat interactive protein 2, 30kDa (EC:1.1.1.-) epigallocatechin gallate results in decreased expression of HTATIP2 mRNA decreases expression
mRNA 16084531
C045651 10553 HTATIP2
CC3
SDR44U1
TIP30
HIV-1 Tat interactive protein 2, 30kDa (EC:1.1.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HTATIP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3352 HTR1D
5-HT1D
HT1DA
HTR1DA
HTRL
RDC4
5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HTR1D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27429 HTRA2
OMI
PARK13
PRSS25
HtrA serine peptidase 2 (EC:3.4.21.108) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HTRA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 219844 HYLS1
HLS
hydrolethalus syndrome 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HYLS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25998 IBTK
BTBD26
BTKI
RP1-93K22.1
inhibitor of Bruton agammaglobulinemia tyrosine kinase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IBTK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23308 ICOSLG
B7-H2
B7H2
B7RP-1
B7RP1
CD275
GL50
ICOS-L
ICOSL
LICOS
inducible T-cell co-stimulator ligand [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ICOSLG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3398 ID2
GIG8
ID2A
ID2H
bHLHb26
inhibitor of DNA binding 2, dominant negative helix-loop-helix protein epigallocatechin gallate results in decreased expression of ID2 mRNA decreases expression
mRNA 16084531
C045651 3416 IDE
INSULYSIN
insulin-degrading enzyme (EC:3.4.24.56) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IDE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55853 IDI2-AS1
C10orf110
IDI2-AS
IDI2 antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IDI2-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9592 IER2
ETR101
immediate early response 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IER2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64135 IFIH1
Hlcd
IDDM19
MDA-5
MDA5
RLR-2
interferon induced with helicase C domain 1 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFIH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3434 IFIT1
C56
G10P1
IFI-56
IFI-56K
IFI56
IFIT-1
IFNAI1
ISG56
P56
RNM561
interferon-induced protein with tetratricopeptide repeats 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFIT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3437 IFIT3
CIG-49
GARG-49
IFI60
IFIT4
IRG2
ISG60
P60
RIG-G
interferon-induced protein with tetratricopeptide repeats 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFIT3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 24138 IFIT5
P58
RI58
interferon-induced protein with tetratricopeptide repeats 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFIT5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 163702 IFNLR1
CRF2/12
IFNLR
IL-28R1
IL28RA
LICR2
interferon, lambda receptor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IFNLR1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56912 IFT46
C11orf2
C11orf60
intraflagellar transport 46 homolog (Chlamydomonas) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT46 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80173 IFT74
CCDC2
CMG-1
CMG1
intraflagellar transport 74 homolog (Chlamydomonas) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT74 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57560 IFT80
ATD2
WDR56
intraflagellar transport 80 homolog (Chlamydomonas) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT80 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28981 IFT81
CDV-1
CDV-1R
CDV1
CDV1R
intraflagellar transport 81 homolog (Chlamydomonas) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT81 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8100 IFT88
D13S1056E
DAF19
TG737
TTC10
hTg737
intraflagellar transport 88 homolog (Chlamydomonas) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IFT88 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3479 IGF1
IGF-I
IGF1A
IGFI
insulin-like growth factor 1 (somatomedin C) epigallocatechin gallate results in decreased expression of IGF1 mRNA decreases expression
mRNA 20346928
20706672
C045651 3480 IGF1R
CD221
IGFIR
IGFR
JTK13
insulin-like growth factor 1 receptor (EC:2.7.10.1) epigallocatechin gallate results in decreased expression of IGF1R protein modified form decreases expression
protein 20346928
C045651 3480 IGF1R
CD221
IGFIR
IGFR
JTK13
insulin-like growth factor 1 receptor (EC:2.7.10.1) epigallocatechin gallate results in increased expression of IGF1R mRNA increases expression
mRNA 22079256
C045651 3480 IGF1R
CD221
IGFIR
IGFR
JTK13
insulin-like growth factor 1 receptor (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IGF1R mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3481 IGF2
C11orf43
IGF-II
PP9974
insulin-like growth factor 2 (somatomedin A) epigallocatechin gallate results in decreased expression of IGF2 mRNA decreases expression
mRNA 20346928
C045651 10643 IGF2BP3
CT98
IMP-3
IMP3
KOC1
VICKZ3
insulin-like growth factor 2 mRNA binding protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IGF2BP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3551 IKBKB
IKK-beta
IKK2
IKKB
NFKBIKB
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IKBKB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8517 IKBKG
AMCBX1
FIP-3
FIP3
Fip3p
IKK-gamma
IP
IP1
IP2
IPD2
NEMO
ZC2HC9
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IKBKG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22807 IKZF2
ANF1A2
HELIOS
ZNF1A2
ZNFN1A2
IKAROS family zinc finger 2 (Helios) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IKZF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3588 IL10RB
CDW210B
CRF2-4
CRFB4
D21S58
D21S66
IL-10R2
interleukin 10 receptor, beta epigallocatechin gallate results in decreased expression of IL10RB mRNA decreases expression
mRNA 16084531
C045651 3588 IL10RB
CDW210B
CRF2-4
CRFB4
D21S58
D21S66
IL-10R2
interleukin 10 receptor, beta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL10RB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3589 IL11
AGIF
IL-11
interleukin 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IL11 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3552 IL1A
IL-1A
IL1
IL1-ALPHA
IL1F1
interleukin 1, alpha epigallocatechin gallate results in decreased expression of IL1A mRNA decreases expression
mRNA 20706672
C045651 3552 IL1A
IL-1A
IL1
IL1-ALPHA
IL1F1
interleukin 1, alpha [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of IL1B mRNA] decreases reaction
/ increases expression
mRNA 19557821
C045651 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of IL1B protein] decreases reaction
/ increases expression
protein 19557821
C045651 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta epigallocatechin gallate inhibits the reaction [IL1B protein results in increased secretion of IL8 protein] decreases reaction
/ increases secretion
protein 18377686
C045651 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta epigallocatechin gallate results in decreased expression of IL1B mRNA decreases expression
mRNA 20816778
C045651 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta [Sulindac co-treated with epigallocatechin gallate] results in decreased expression of IL1B mRNA affects cotreatment
/ decreases expression
mRNA 12628509
C045651 3554 IL1R1
CD121A
D2S1473
IL-1R-alpha
IL1R
IL1RA
P80
interleukin 1 receptor, type I [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL1R1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 epigallocatechin gallate results in decreased expression of and results in decreased secretion of IL2 protein decreases expression
/ decreases secretion
protein 19761891
C045651 9466 IL27RA
CRL1
IL-27RA
IL27R
TCCR
WSX1
zcytor1
interleukin 27 receptor, alpha epigallocatechin gallate results in decreased expression of IL27RA mRNA decreases expression
mRNA 16084531
C045651 9466 IL27RA
CRL1
IL-27RA
IL27R
TCCR
WSX1
zcytor1
interleukin 27 receptor, alpha [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IL27RA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of MT1X mRNA] decreases reaction
/ increases expression
protein 20471814
C045651 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of MT2A mRNA] decreases reaction
/ increases expression
protein 20471814
C045651 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of SLC39A14 mRNA] decreases reaction
/ increases expression
protein 20471814
C045651 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) epigallocatechin gallate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] decreases reaction
/ increases expression
mRNA 18209571
C045651 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) epigallocatechin gallate results in decreased secretion of IL6 protein decreases secretion
protein 20816778
C045651 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) epigallocatechin gallate results in increased expression of IL6 mRNA increases expression
mRNA 18025290
C045651 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3574 IL7
IL-7
interleukin 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3575 IL7R
CD127
CDW127
IL-7R-alpha
IL7RA
ILRA
interleukin 7 receptor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IL7R mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 epigallocatechin gallate inhibits the reaction [Acetylmuramyl-Alanyl-Isoglutamine results in increased expression of and results in increased secretion of IL8 protein] decreases reaction
/ increases expression
/ increases secretion
protein 18413660
C045651 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 epigallocatechin gallate inhibits the reaction [IL1B protein results in increased secretion of IL8 protein] decreases reaction
/ increases secretion
protein 18377686
C045651 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 epigallocatechin gallate results in decreased secretion of IL8 protein decreases secretion
protein 20816778
C045651 196294 IMMP1L
IMP1
IMP1-LIKE
IMP1 inner mitochondrial membrane peptidase-like (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IMMP1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54928 IMPAD1
GPAPP
IMP_3
IMP-3
IMPA3
inositol monophosphatase domain containing 1 (EC:3.1.3.7 3.1.3.25) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IMPAD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 50939 IMPG2
IPM200
RP56
SPACRCAN
interphotoreceptor matrix proteoglycan 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IMPG2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3632 INPP5A
5PTASE
inositol polyphosphate-5-phosphatase, 40kDa (EC:3.1.3.56) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INPP5A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3638 INSIG1
CL-6
CL6
insulin induced gene 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INSIG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55174 INTS10
C8orf35
INT10
integrator complex subunit 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTS10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55656 INTS8
C8orf52
INT8
integrator complex subunit 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTS8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55756 INTS9
CPSF2L
INT9
RC74
integrator complex subunit 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTS9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27152 INTU
INT
PDZD6
PDZK6
inturned planar cell polarity protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INTU mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27130 INVS
INV
NPH2
NPHP2
inversin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of INVS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51447 IP6K2
IHPK2
PIUS
inositol hexakisphosphate kinase 2 (EC:2.7.4.21) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IP6K2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51194 IPO11
RanBP11
importin 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IPO11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 134728 IRAK1BP1
AIP70
SIMPL
interleukin-1 receptor-associated kinase 1 binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IRAK1BP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11213 IRAK3
ASRT5
IRAKM
interleukin-1 receptor-associated kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IRAK3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3658 IREB2
ACO3
IRP2
IRP2AD
iron-responsive element binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IREB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3660 IRF2
IRF-2
interferon regulatory factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IRF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8660 IRS2
IRS-2
insulin receptor substrate 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of IRS2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 122961 ISCA2
HBLD1
ISA2
c14_5557
iron-sulfur cluster assembly 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ISCA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64843 ISL2
ISL LIM homeobox 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ISL2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 83737 ITCH
AIF4
AIP4
NAPP1
dJ468O1.1
itchy E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITCH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3676 ITGA4
CD49D
IA4
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITGA4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3655 ITGA6
CD49f
ITGA6B
VLA-6
integrin, alpha 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITGA6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3685 ITGAV
CD51
MSK8
VNRA
VTNR
integrin, alpha V epigallocatechin gallate results in decreased expression of ITGAV mRNA decreases expression
mRNA 16084531
C045651 26548 ITGB1BP2
CHORDC3
ITGB1BP
MELUSIN
integrin beta 1 binding protein (melusin) 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ITGB1BP2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23421 ITGB3BP
CENP-R
CENPR
HSU37139
NRIF3
TAP20
integrin beta 3 binding protein (beta3-endonexin) epigallocatechin gallate results in decreased expression of ITGB3BP mRNA decreases expression
mRNA 22079256
C045651 23421 ITGB3BP
CENP-R
CENPR
HSU37139
NRIF3
TAP20
integrin beta 3 binding protein (beta3-endonexin) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITGB3BP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3691 ITGB4
CD104
integrin, beta 4 [Sulindac co-treated with epigallocatechin gallate] results in decreased expression of ITGB4 mRNA affects cotreatment
/ decreases expression
mRNA 12628509
C045651 3709 ITPR2
IP3R2
inositol 1,4,5-trisphosphate receptor, type 2 epigallocatechin gallate results in increased expression of ITPR2 mRNA increases expression
mRNA 22079256
C045651 3709 ITPR2
IP3R2
inositol 1,4,5-trisphosphate receptor, type 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITPR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85450 ITPRIP
DANGER
KIAA1754
bA127L20
bA127L20.2
inositol 1,4,5-trisphosphate receptor interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ITPRIP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6453 ITSN1
ITSN
SH3D1A
SH3P17
intersectin 1 (SH3 domain protein) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ITSN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55677 IWS1
IWS1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of IWS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 182 JAG1
AGS
AHD
AWS
CD339
HJ1
JAGL1
jagged 1 epigallocatechin gallate results in decreased expression of JAG1 mRNA decreases expression
mRNA 16084531
C045651 3717 JAK2
JTK10
THCYT3
Janus kinase 2 (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of JAK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3720 JARID2
JMJ
jumonji, AT rich interactive domain 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of JARID2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene epigallocatechin gallate results in increased expression of JUN protein increases expression
protein 12663506
C045651 23189 KANK1
ANKRD15
CPSQ2
KANK
KN motif and ankyrin repeat domains 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KANK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54934 KANSL2
C12orf41
NSL2
KAT8 regulatory NSL complex subunit 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KANSL2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23522 KAT6B
GTPTS
MORF
MOZ2
MYST4
ZC2HC6B
qkf
querkopf
K(lysine) acetyltransferase 6B (EC:2.3.1.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT6B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84056 KATNAL1
katanin p60 subunit A-like 1 (EC:3.6.4.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KATNAL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79768 KATNBL1
C15orf29
katanin p80 subunit B-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KATNBL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23254 KAZN
KAZ
kazrin, periplakin interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAZN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25948 KBTBD2
BKLHD1
kelch repeat and BTB (POZ) domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KBTBD2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27345 KCNMB4
potassium large conductance calcium-activated channel, subfamily M, beta member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KCNMB4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83892 KCTD10
BTBD28
ULRO61
hBACURD3
potassium channel tetramerization domain containing 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KCTD10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57528 KCTD16
potassium channel tetramerization domain containing 16 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KCTD16 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11015 KDELR3
ERD2L3
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KDELR3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23081 KDM4C
GASC1
JHDM3C
JMJD2C
TDRD14C
bA146B14.1
lysine (K)-specific demethylase 4C (EC:1.14.11.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KDM4C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3791 KDR
CD309
FLK1
VEGFR
VEGFR2
kinase insert domain receptor (a type III receptor tyrosine kinase) (EC:2.7.10.1) epigallocatechin gallate results in decreased expression of KDR protein decreases expression
protein 17992120
20346928
C045651 3791 KDR
CD309
FLK1
VEGFR
VEGFR2
kinase insert domain receptor (a type III receptor tyrosine kinase) (EC:2.7.10.1) epigallocatechin gallate results in decreased expression of KDR protein modified form decreases expression
protein 20346928
C045651 3795 KHK
ketohexokinase (fructokinase) (EC:2.7.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KHK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9897 SPG8
KIAA0196 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA0196 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9692 MRPP3
PRORP
KIAA0391 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA0391 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23247 KIAA0556 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA0556 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9786 Talpid3
KIAA0586 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA0586 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22889 BLOM7
RP11-336K24.1
KIAA0907 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KIAA0907 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23240 TMEM131L
KIAA0922 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA0922 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23325 SWIP
KIAA1033 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1033 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23285 KIAA1107 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1107 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84162 FSA
Tweek
KIAA1109 epigallocatechin gallate results in increased expression of KIAA1109 mRNA increases expression
mRNA 22079256
C045651 84162 FSA
Tweek
KIAA1109 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1109 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57536 KIAA1328 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1328 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57589 CIP150
bA207C16.1
KIAA1432 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1432 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57698 KIAA1598 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1598 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84542 KIAA1841 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA1841 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 158358 KIAA2026 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIAA2026 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 63971 KIF13A
RBKIN
bA500C11.2
kinesin family member 13A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF13A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9928 KIF14
kinesin family member 14 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56992 KIF15
HKLP2
KNSL7
NY-BR-62
kinesin family member 15 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55614 KIF16B
C20orf23
KISC20ORF
SNX23
kinesin family member 16B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF16B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81930 KIF18A
MS-KIF18A
kinesin family member 18A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF18A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9585 KIF20B
CT90
KRMP1
MPHOSPH1
MPP-1
MPP1
kinesin family member 20B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF20B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 24137 KIF4A
KIF4
KIF4G1
kinesin family member 4A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIF4A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22920 KIFAP3
FLA3
KAP-1
KAP-3
KAP3
SMAP
Smg-GDS
dJ190I16.1
kinesin-associated protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIFAP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3815 KIT
C-Kit
CD117
PBT
SCFR
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KIT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9365 KL
klotho (EC:3.2.1.31) epigallocatechin gallate results in decreased expression of KL mRNA decreases expression
mRNA 20706672
C045651 7071 KLF10
EGR-alpha
EGRA
TIEG
TIEG1
Kruppel-like factor 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLF10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9314 KLF4
EZF
GKLF
Kruppel-like factor 4 (gut) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLF4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8609 KLF7
UKLF
Kruppel-like factor 7 (ubiquitous) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLF7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23588 KLHDC2
HCLP-1
HCLP1
LCP
kelch domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHDC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116138 KLHDC3
PEAS
RP1-20C7.3
dJ20C7.3
kelch domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHDC3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 59349 KLHL12
C3IP1
DKIR
hDKIR
kelch-like family member 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHL12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80311 KLHL15
kelch-like family member 15 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL15 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23276 KLHL18
kelch-like family member 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL18 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27252 KLHL20
KHLHX
KLEIP
KLHLX
RP3-383J4.3
kelch-like family member 20 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHL20 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9903 KLHL21
kelch-like family member 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL21 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55295 KLHL26
kelch-like family member 26 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLHL26 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55958 KLHL9
kelch-like family member 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KLHL9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 16627 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of KLRA1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 58508 KMT2C
HALR
MLL3
lysine (K)-specific methyltransferase 2C (EC:2.1.1.43) epigallocatechin gallate results in increased expression of KMT2C mRNA increases expression
mRNA 22079256
C045651 58508 KMT2C
HALR
MLL3
lysine (K)-specific methyltransferase 2C (EC:2.1.1.43) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KMT2C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90417 KNSTRN
C15orf23
SKAP
TRAF4AF1
kinetochore-localized astrin/SPAG5 binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KNSTRN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9735 KNTC1
ROD
kinetochore associated 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KNTC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 889 KRIT1
CAM
CCM1
KRIT1, ankyrin repeat containing [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KRIT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84456 L3MBTL3
MBT-1
MBT1
RP11-73O6.1
l(3)mbt-like 3 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of L3MBTL3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 246269 LACE1
AFG1
lactation elevated 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LACE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114294 LACTB
G24
MRPL56
lactamase, beta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LACTB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51110 LACTB2
lactamase, beta 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LACTB2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28956 LAMTOR2
ENDAP
HSPC003
MAPBPIP
MAPKSP1AP
ROBLD3
Ragulator2
p14
late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LAMTOR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26524 LATS2
KPM
large tumor suppressor kinase 2 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LATS2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3949 LDLR
FH
FHC
LDLCQ2
low density lipoprotein receptor epigallocatechin gallate results in increased expression of LDLR mRNA increases expression
mRNA 22079256
C045651 3949 LDLR
FH
FHC
LDLCQ2
low density lipoprotein receptor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LDLR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 143458 LDLRAD3
LRAD3
low density lipoprotein receptor class A domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LDLRAD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116842 LEAP2
LEAP-2
liver expressed antimicrobial peptide 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LEAP2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 114823 LENG8
pp13842
leukocyte receptor cluster (LRC) member 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LENG8 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 3959 LGALS3BP
90K
BTBD17B
MAC-2-BP
TANGO10B
lectin, galactoside-binding, soluble, 3 binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LGALS3BP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55366 LGR4
BNMD17
GPR48
leucine-rich repeat containing G protein-coupled receptor 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LGR4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10186 LHFP
lipoma HMGIC fusion partner (EC:3.6.5.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LHFP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3980 LIG3
LIG2
ligase III, DNA, ATP-dependent (EC:6.5.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LIG3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8994 LIMD1
LIM domains containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LIMD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 286826 LIN9
BARA
BARPsv
Lin-9
TGS
TGS1
TGS2
lin-9 homolog (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LIN9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 284029 LINC00324
C17orf44
NCRNA00324
long intergenic non-protein coding RNA 324 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LINC00324 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81562 LMAN2L
VIPL
lectin, mannose-binding 2-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMAN2L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64327 LMBR1
ACHP
C7orf2
DIF14
PPD2
TPT
ZRS
limb development membrane protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMBR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55788 LMBRD1
C6orf209
LMBD1
MAHCF
NESI
LMBR1 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMBRD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4001 LMNB1
ADLD
LMN
LMN2
LMNB
lamin B1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LMNB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4012 LNPEP
CAP
IRAP
P-LAP
PLAP
leucyl/cystinyl aminopeptidase (EC:3.4.11.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LNPEP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4015 LOX
lysyl oxidase (EC:1.4.3.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LOX mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 2846 LPAR4
GPR23
LPA4
P2RY9
P2Y5-LIKE
P2Y9
lysophosphatidic acid receptor 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LPAR4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 254531 LPCAT4
AGPAT7
AYTL3
LPAAT-eta
LPEAT2
lysophosphatidylcholine acyltransferase 4 (EC:2.3.1.23 2.3.1.67 2.3.1.n6 2.3.1.n7 2.3.1.121) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LPCAT4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 987 LRBA
BGL
CDC4L
CVID8
LAB300
LBA
LPS-responsive vesicle trafficking, beach and anchor containing [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRBA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23143 LRCH1
CHDC1
NP81
leucine-rich repeats and calponin homology (CH) domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRCH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84859 LRCH3
leucine-rich repeats and calponin homology (CH) domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRCH3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84918 LRP11
MANSC3
bA350J20.3
low density lipoprotein receptor-related protein 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRP11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 122769 LRR1
4-1BBLRR
LRR-1
PPIL5
leucine rich repeat protein 1 epigallocatechin gallate results in decreased expression of LRR1 mRNA decreases expression
mRNA 22079256
C045651 122769 LRR1
4-1BBLRR
LRR-1
PPIL5
leucine rich repeat protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55604 LRRC16A
CARMIL
CARMIL1
CARMIL1a
LRRC16
dJ501N12.1
dJ501N12.5
leucine rich repeat containing 16A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC16A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 123355 LRRC28
leucine rich repeat containing 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55631 LRRC40
dJ677H15.1
leucine rich repeat containing 40 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC40 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54839 LRRC49
PGs4
leucine rich repeat containing 49 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC49 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65999 LRRC61
HSPC295
leucine rich repeat containing 61 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC61 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57554 LRRC7
DENSIN
leucine rich repeat containing 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56262 LRRC8A
AGM5
LRRC8
leucine rich repeat containing 8 family, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LRRC8A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55144 LRRC8D
LRRC5
leucine rich repeat containing 8 family, member D [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRC8D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85444 LRRCC1
CLERC
SAP2
VFL1
leucine rich repeat and coiled-coil centrosomal protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRRCC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9208 LRRFIP1
FLAP-1
FLAP1
FLIIAP1
GCF-2
GCF2
HUFI-1
TRIP
leucine rich repeat (in FLII) interacting protein 1 epigallocatechin gallate results in increased expression of LRRFIP1 mRNA increases expression
mRNA 22079256
C045651 9208 LRRFIP1
FLAP-1
FLAP1
FLIIAP1
GCF-2
GCF2
HUFI-1
TRIP
leucine rich repeat (in FLII) interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LRRFIP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 90678 LRSAM1
CMT2P
RIFLE
TAL
leucine rich repeat and sterile alpha motif containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LRSAM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84967 LSM10
MST074
MSTP074
LSM10, U7 small nuclear RNA associated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LSM10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11157 LSM6
YDR378C
LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) epigallocatechin gallate results in decreased expression of LSM6 mRNA decreases expression
mRNA 22079256
C045651 11157 LSM6
YDR378C
LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LSM6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 286006 LSMEM1
C7orf53
leucine-rich single-pass membrane protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LSMEM1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51599 LSR
ILDR3
LISCH7
lipolysis stimulated lipoprotein receptor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of LSR mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56925 LXN
ECI
TCI
latexin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LXN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 130574 LYPD6
LY6/PLAUR domain containing 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LYPD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144363 LYRM5
LYR motif containing 5 epigallocatechin gallate results in decreased expression of LYRM5 mRNA decreases expression
mRNA 22079256
C045651 144363 LYRM5
LYR motif containing 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LYRM5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1130 LYST
CHS
CHS1
lysosomal trafficking regulator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LYST mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8216 LZTR1
BTBD29
LZTR-1
leucine-zipper-like transcription regulator 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of LZTR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 130951 M1AP
C2orf65
D6Mm5e
SPATA37
meiosis 1 associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of M1AP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23499 MACF1
ABP620
ACF7
MACF
OFC4
microtubule-actin crosslinking factor 1 epigallocatechin gallate results in increased expression of MACF1 mRNA increases expression
mRNA 22079256
C045651 23499 MACF1
ABP620
ACF7
MACF
OFC4
microtubule-actin crosslinking factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MACF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23764 MAFF
U-MAF
hMafF
v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAFF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4097 MAFG
hMAF
v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog G [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAFG mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9223 MAGI1
AIP-3
AIP3
BAIAP1
BAP-1
BAP1
MAGI-1
TNRC19
WWP3
membrane associated guanylate kinase, WW and PDZ domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAGI1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114569 MAL2
mal, T-cell differentiation protein 2 (gene/pseudogene) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10892 MALT1
IMD12
MLT
MLT1
mucosa associated lymphoid tissue lymphoma translocation gene 1 (EC:3.4.22.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MALT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84441 MAML2
MAM-3
MAM2
MAM3
MLL-MAML2
mastermind-like 2 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAML2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4122 MAN2A2
MANA2X
mannosidase, alpha, class 2A, member 2 (EC:3.2.1.114) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAN2A2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79694 MANEA
ENDO
hEndo
mannosidase, endo-alpha (EC:3.2.1.130) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MANEA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81631 MAP1LC3B
ATG8F
LC3B
MAP1A/1BLC3
MAP1LC3B-a
microtubule-associated protein 1 light chain 3 beta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAP1LC3B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5608 MAP2K6
MAPKK6
MEK6
MKK6
PRKMK6
SAPKK-3
SAPKK3
mitogen-activated protein kinase kinase 6 (EC:2.7.12.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP2K6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4214 MAP3K1
MAPKKK1
MEKK
MEKK_1
MEKK1
SRXY6
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase (EC:2.7.11.25) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP3K1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9020 MAP3K14
FTDCR1B
HS
HSNIK
NIK
mitogen-activated protein kinase kinase kinase 14 (EC:2.7.11.25) epigallocatechin gallate results in decreased expression of MAP3K14 mRNA decreases expression
mRNA 12628509
C045651 1326 MAP3K8
COT
EST
ESTF
MEKK8
TPL2
Tpl-2
c-COT
mitogen-activated protein kinase kinase kinase 8 (EC:2.7.11.25) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP3K8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8491 MAP4K3
GLK
MAPKKKK3
MEKKK_3
MEKKK3
RAB8IPL1
mitogen-activated protein kinase kinase kinase kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP4K3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [epigallocatechin gallate results in increased activity of MAPK1 protein] decreases reaction
/ increases activity
protein 17931610
C045651 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [epigallocatechin gallate co-treated with celecoxib] results in increased activity of MAPK1 protein affects cotreatment
/ increases activity
protein 16463383
C045651 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 19557821
C045651 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) epigallocatechin gallate results in decreased expression of MAPK1 protein modified form decreases expression
protein 20346928
C045651 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) epigallocatechin gallate results in increased activity of MAPK1 protein increases activity
protein 17931610
C045651 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) epigallocatechin gallate results in increased phosphorylation of MAPK1 protein increases phosphorylation
protein 19720055
C045651 1432 MAPK14
CSBP
CSBP1
CSBP2
CSPB1
EXIP
Mxi2
PRKM14
PRKM15
RK
SAPK2A
p38
p38ALPHA
mitogen-activated protein kinase 14 (EC:2.7.11.24) [epigallocatechin gallate co-treated with celecoxib] results in increased activity of MAPK14 protein affects cotreatment
/ increases activity
protein 16463383
C045651 1432 MAPK14
CSBP
CSBP1
CSBP2
CSPB1
EXIP
Mxi2
PRKM14
PRKM15
RK
SAPK2A
p38
p38ALPHA
mitogen-activated protein kinase 14 (EC:2.7.11.24) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAPK14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [epigallocatechin gallate results in increased activity of MAPK3 protein] decreases reaction
/ increases activity
protein 17931610
C045651 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [epigallocatechin gallate co-treated with celecoxib] results in increased activity of MAPK3 protein affects cotreatment
/ increases activity
protein 16463383
C045651 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 19557821
C045651 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) epigallocatechin gallate results in decreased expression of MAPK3 protein modified form decreases expression
protein 20346928
C045651 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) epigallocatechin gallate results in increased activity of MAPK3 protein increases activity
protein 17931610
C045651 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) epigallocatechin gallate results in increased phosphorylation of MAPK3 protein increases phosphorylation
protein 19720055
C045651 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
C045651 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) epigallocatechin gallate results in increased activity of MAPK8 protein increases activity
protein 15705601
C045651 5601 MAPK9
JNK-55
JNK2
JNK2A
JNK2ALPHA
JNK2B
JNK2BETA
PRKM9
SAPK
SAPK1a
p54a
p54aSAPK
mitogen-activated protein kinase 9 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
C045651 8550 MAPKAPK5
MAPKAP-K5
MK-5
MK5
PRAK
mitogen-activated protein kinase-activated protein kinase 5 (EC:2.7.11.1) epigallocatechin gallate results in decreased activity of MAPKAPK5 protein decreases activity
protein 12534346
C045651 22924 MAPRE3
EB3
EBF3
EBF3-S
RP3
microtubule-associated protein, RP/EB family, member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAPRE3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 115123 MARCH3
MARCH-III
RNF173
membrane-associated ring finger (C3HC4) 3, E3 ubiquitin protein ligase (EC:6.3.2.19) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MARCH3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4144 MAT2A
MATA2
MATII
SAMS2
methionine adenosyltransferase II, alpha (EC:2.5.1.6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAT2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55777 MBD5
MRD1
methyl-CpG binding domain protein 5 epigallocatechin gallate results in increased expression of MBD5 mRNA increases expression
mRNA 22079256
C045651 55777 MBD5
MRD1
methyl-CpG binding domain protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MBD5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10150 MBNL2
MBLL
MBLL39
PRO2032
muscleblind-like splicing regulator 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MBNL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154141 MBOAT1
1
LPEAT1
LPLAT
LPLAT_1
LPSAT
OACT1
dJ434O11.1
membrane bound O-acyltransferase domain containing 1 (EC:2.3.1.n6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MBOAT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4157 MC1R
CMM5
MSH-R
SHEP2
melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor) epigallocatechin gallate results in decreased expression of MC1R mRNA decreases expression
mRNA 20706672
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of MCL1 mRNA alternative form] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 18348186
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) calyculin A inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of MCL1 mRNA alternative form] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 18348186
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of MCL1 protein] decreases expression
/ decreases reaction
protein 16115949
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) epigallocatechin gallate analog results in decreased expression of MCL1 protein decreases expression
protein 16115949
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) [Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of MCL1 mRNA alternative form affects cotreatment
/ decreases expression
mRNA 18348186
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) [Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of MCL1 mRNA alternative form affects cotreatment
/ increases expression
mRNA 18348186
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in decreased expression of MCL1 mRNA alternative form] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 18348186
C045651 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) tautomycin inhibits the reaction [[Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of MCL1 mRNA alternative form] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 18348186
C045651 255231 MCOLN2
TRP-ML2
TRPML2
mucolipin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MCOLN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28985 MCTS1
MCT-1
MCT1
malignant T cell amplified sequence 1 epigallocatechin gallate results in decreased expression of MCTS1 mRNA decreases expression
mRNA 22079256
C045651 28985 MCTS1
MCT-1
MCT1
malignant T cell amplified sequence 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MCTS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90550 MCU
C10orf42
CCDC109A
mitochondrial calcium uniporter [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MCU mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 400569 MED11
mediator complex subunit 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116931 MED12L
NOPAR
TNRC11L
TRALP
TRALPUSH
mediator complex subunit 12-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED12L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23389 MED13L
PROSIT240
THRAP2
TRAP240L
mediator complex subunit 13-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED13L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9441 MED26
CRSP7
CRSP70
mediator complex subunit 26 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MED26 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9443 MED7
ARC34
CRSP33
CRSP9
mediator complex subunit 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MED7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55090 MED9
MED25
mediator complex subunit 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MED9 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84935 MEDAG
AWMS3
C13orf33
MEDA-4
MEDA4
hAWMS3
mesenteric estrogen-dependent adipogenesis [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MEDAG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4212 MEIS2
HsT18361
MRG1
Meis homeobox 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MEIS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9833 MELK
HPK38
maternal embryonic leucine zipper kinase (EC:2.7.11.1 2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MELK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4233 MET
AUTS9
HGFR
RCCP2
c-Met
met proto-oncogene (EC:2.7.10.1) epigallocatechin gallate inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] decreases reaction
/ increases phosphorylation
protein 19244381
C045651 196074 METTL15
METT5D1
methyltransferase like 15 (EC:2.1.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 92342 METTL18
AsTP2
C1orf156
HPM1
methyltransferase like 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64863 METTL4
HsT661
methyltransferase like 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79828 METTL8
TIP
methyltransferase like 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of METTL8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51320 MEX3C
MEX-3C
RKHD2
RNF194
mex-3 RNA binding family member C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MEX3C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4240 MFGE8
BA46
EDIL1
HMFG
HsT19888
MFG-E8
MFGM
OAcGD3S
SED1
SPAG10
hP47
milk fat globule-EGF factor 8 protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MFGE8 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55669 MFN1
hfzo1
hfzo2
mitofusin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MFN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84709 MGARP
C4orf49
CESP-1
HUMMR
OSAP
mitochondria-localized glutamic acid-rich protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MGARP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4249 MGAT5
GNT-V
GNT-VA
mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase (EC:2.4.1.155) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MGAT5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10724 MGEA5
MEA5
NCOAT
OGA
meningioma expressed antigen 5 (hyaluronidase) (EC:2.3.1.48 3.2.1.169) epigallocatechin gallate results in decreased expression of MGEA5 mRNA decreases expression
mRNA 16084531
C045651 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) epigallocatechin gallate results in decreased methylation of MGMT promoter decreases methylation
promoter 14633667
C045651 4255 MGMT
O-6-methylguanine-DNA methyltransferase (EC:2.1.1.63) epigallocatechin gallate results in increased expression of MGMT mRNA increases expression
mRNA 14633667
15703815
C045651 286097 MICU3
EFHA2
mitochondrial calcium uptake family, member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MICU3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4281 MID1
BBBG1
FXY
GBBB1
MIDIN
OGS1
OS
OSX
RNF59
TRIM18
XPRF
ZNFXY
midline 1 (Opitz/BBB syndrome) epigallocatechin gallate results in increased expression of MID1 mRNA increases expression
mRNA 22079256
C045651 4281 MID1
BBBG1
FXY
GBBB1
MIDIN
OGS1
OS
OSX
RNF59
TRIM18
XPRF
ZNFXY
midline 1 (Opitz/BBB syndrome) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MID1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54471 MIEF1
HSU79252
MID51
SMCR7L
dJ1104E15.3
mitochondrial elongation factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MIEF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57708 MIER1
ER1
MI-ER1
mesoderm induction early response 1, transcriptional regulator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MIER1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84864 MINA
MDIG
MINA53
NO52
ROX
MYC induced nuclear antigen [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MINA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 145282 MIPOL1
mirror-image polydactyly 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MIPOL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54069 MIS18A
B28
C21orf45
C21orf46
FASP1
MIS18alpha
hMis18alpha
MIS18 kinetochore protein A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MIS18A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4286 MITF
CMM8
MI
WS2
WS2A
bHLHe32
microphthalmia-associated transcription factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MITF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57496 MKL2
MRTF-B
NPD001
MKL/myocardin-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MKL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4289 MKLN1
TWA2
muskelin 1, intracellular mediator containing kelch motifs [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MKLN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23608 MKRN1
RNF61
makorin ring finger protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MKRN1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 283078 MKX
C10orf48
IFRX
IRXL1
mohawk homeobox [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MKX mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4292 MLH1
COCA2
FCC2
HNPCC
HNPCC2
hMLH1
mutL homolog 1 epigallocatechin gallate results in decreased methylation of MLH1 promoter decreases methylation
promoter 14633667
C045651 4292 MLH1
COCA2
FCC2
HNPCC
HNPCC2
hMLH1
mutL homolog 1 epigallocatechin gallate results in increased expression of MLH1 mRNA increases expression
mRNA 14633667
C045651 4292 MLH1
COCA2
FCC2
HNPCC
HNPCC2
hMLH1
mutL homolog 1 epigallocatechin gallate results in increased expression of MLH1 protein increases expression
protein 14633667
C045651 4292 MLH1
COCA2
FCC2
HNPCC
HNPCC2
hMLH1
mutL homolog 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MLH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8028 MLLT10
AF10
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MLLT10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25974 MMACHC
RP11-291L19.3
cblC
methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MMACHC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4312 MMP1
CLG
CLGN
matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MMP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4316 MMP7
MMP-7
MPSL1
PUMP-1
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) Acetylcysteine inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein] decreases reaction
/ increases expression
protein 17928719
C045651 4316 MMP7
MMP-7
MPSL1
PUMP-1
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) benzyl isothiocyanate inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein] decreases reaction
/ increases expression
protein 17928719
C045651 4316 MMP7
MMP-7
MPSL1
PUMP-1
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) Curcumin inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein] decreases reaction
/ increases expression
protein 17928719
C045651 4316 MMP7
MMP-7
MPSL1
PUMP-1
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) epigallocatechin gallate results in increased expression of MMP7 protein increases expression
protein 17928719
C045651 4316 MMP7
MMP-7
MPSL1
PUMP-1
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) Gallic Acid inhibits the reaction [epigallocatechin gallate results in increased expression of MMP7 protein] decreases reaction
/ increases expression
protein 17928719
C045651 55329 MNS1
SPATA40
meiosis-specific nuclear structural 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MNS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64112 MOAP1
MAP-1
PNMA4
modulator of apoptosis 1 epigallocatechin gallate results in decreased expression of MOAP1 mRNA decreases expression
mRNA 16084531
C045651 64112 MOAP1
MAP-1
PNMA4
modulator of apoptosis 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MOAP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55034 MOCOS
HMCS
MCS
MOS
molybdenum cofactor sulfurase (EC:2.8.1.9) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MOCOS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23041 MON2
MON2 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MON2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 158747 MOSPD2
motile sperm domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MOSPD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4343 MOV10
fSAP113
gb110
Mov10, Moloney leukemia virus 10, homolog (mouse) (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MOV10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10200 MPHOSPH6
MPP
MPP-6
MPP6
M-phase phosphoprotein 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MPHOSPH6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10198 MPHOSPH9
MPP-9
MPP9
M-phase phosphoprotein 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MPHOSPH9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4351 MPI
CDG1B
PMI
PMI1
mannose phosphate isomerase (EC:5.3.1.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MPI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51678 MPP6
PALS2
VAM-1
VAM1
p55T
membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MPP6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4361 MRE11A
ATLD
HNGS1
MRE11
MRE11B
MRE11 meiotic recombination 11 homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRE11A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54948 MRPL16
L16mt
MRP-L16
mitochondrial ribosomal protein L16 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPL16 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9553 MRPL33
C2orf1
L33mt
MRP-L33
RPL33L
mitochondrial ribosomal protein L33 epigallocatechin gallate results in decreased expression of MRPL33 mRNA decreases expression
mRNA 22079256
C045651 9553 MRPL33
C2orf1
L33mt
MRP-L33
RPL33L
mitochondrial ribosomal protein L33 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPL33 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26589 MRPL46
C15orf4
LIECG2
P2ECSL
mitochondrial ribosomal protein L46 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPL46 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64963 MRPS11
HCC-2
mitochondrial ribosomal protein S11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPS11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55168 MRPS18A
HumanS18b
MRP-S18-3
MRPS18-3
S18bmt
mitochondrial ribosomal protein S18A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MRPS18A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51116 MRPS2
MRP-S2
S2mt
mitochondrial ribosomal protein S2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MRPS2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4436 MSH2
COCA1
FCC1
HNPCC
HNPCC1
LCFS2
mutS homolog 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MSH2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 73390 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MSL3L2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4501 MT1X
MT-1l
MT1
metallothionein 1X epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of MT1X mRNA] decreases reaction
/ increases expression
mRNA 20471814
C045651 4501 MT1X
MT-1l
MT1
metallothionein 1X epigallocatechin gallate inhibits the reaction [zinc chloride results in increased expression of MT1X mRNA] decreases reaction
/ increases expression
mRNA 20471814
C045651 4501 MT1X
MT-1l
MT1
metallothionein 1X epigallocatechin gallate results in decreased expression of MT1X mRNA decreases expression
mRNA 20471814
C045651 4502 MT2A
MT2
metallothionein 2A epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of MT2A mRNA] decreases reaction
/ increases expression
mRNA 20471814
C045651 4502 MT2A
MT2
metallothionein 2A epigallocatechin gallate inhibits the reaction [zinc chloride results in increased expression of MT2A mRNA] decreases reaction
/ increases expression
mRNA 20471814
C045651 4502 MT2A
MT2
metallothionein 2A epigallocatechin gallate results in decreased expression of MT2A mRNA decreases expression
mRNA 20471814
C045651 51001 MTERFD1
mTERF3
MTERF domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTERFD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 123263 MTFMT
COXPD15
FMT1
mitochondrial methionyl-tRNA formyltransferase (EC:2.1.2.9) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTFMT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51537 MTFP1
MTP18
mitochondrial fission process 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTFP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4534 MTM1
CNM
MTMX
XLMTM
myotubularin 1 (EC:3.1.3.64) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54516 MTRF1L
HMRF1L
MRF1L
mtRF1a
mitochondrial translational release factor 1-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MTRF1L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10651 MTX2
metaxin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MTX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 347273 MURC
CAVIN4
cavin-4
muscle-related coiled-coil protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MURC mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9961 MVP
LRP
VAULT1
major vault protein epigallocatechin gallate results in decreased expression of MVP mRNA decreases expression
mRNA 18851785
C045651 4599 MX1
IFI-78K
IFI78
MX
MxA
myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MX1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4600 MX2
MXB
myxovirus (influenza virus) resistance 2 (mouse) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4603 MYBL1
A-MYB
AMYB
v-myb avian myeloblastosis viral oncogene homolog-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYBL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog epigallocatechin gallate results in decreased expression of MYC protein decreases expression
protein 12663506
C045651 23077 MYCBP2
PAM
MYC binding protein 2, E3 ubiquitin protein ligase epigallocatechin gallate results in increased expression of MYCBP2 mRNA increases expression
mRNA 22079256
C045651 23077 MYCBP2
PAM
MYC binding protein 2, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYCBP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50804 MYEF2
HsT18564
MEF-2
MST156
MSTP156
myelin expression factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYEF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4628 MYH10
NMMHC-IIB
NMMHCB
myosin, heavy chain 10, non-muscle [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYH10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29116 MYLIP
IDOL
MIR
myosin regulatory light chain interacting protein (EC:6.3.2.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MYLIP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4651 MYO10
myosin X [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4430 MYO1B
myr1
myosin IB [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4643 MYO1E
FSGS6
HuncM-IC
MYO1C
myosin IE [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO1E mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4646 MYO6
DFNA22
DFNB37
myosin VI [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4649 MYO9A
myosin IXA [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYO9A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84665 MYPN
CMD1DD
CMH22
MYOP
RCM4
myopalladin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MYPN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114803 MYSM1
2A-DUB
2ADUB
RP4-592A1.1
Myb-like, SWIRM and MPN domains 1 (EC:3.1.2.15) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MYSM1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 133686 NADK2
C5orf33
MNADK
NADKD1
NAD kinase 2, mitochondrial (EC:2.7.1.23) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NADK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8883 NAE1
A-116A10.1
APPBP1
ula-1
NEDD8 activating enzyme E1 subunit 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55577 NAGK
GNK
HSA242910
N-acetylglucosamine kinase (EC:2.7.1.59) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAGK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 222236 NAPEPLD
FMP30
NAPE-PLD
N-acyl phosphatidylethanolamine phospholipase D (EC:3.1.4.54) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAPEPLD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8774 NAPG
GAMMASNAP
N-ethylmaleimide-sensitive factor attachment protein, gamma [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAPG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100195127 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NARG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79731 NARS2
SLM5
asnRS
asparaginyl-tRNA synthetase 2, mitochondrial (putative) (EC:6.1.1.22) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NARS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9 NAT1
AAC1
MNAT
NAT-1
NATI
N-acetyltransferase 1 (arylamine N-acetyltransferase) (EC:2.3.1.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55226 NAT10
ALP
NET43
N-acetyltransferase 10 (GCN5-related) (EC:2.3.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAT10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51594 NBAS
NAG
SOPH
neuroblastoma amplified sequence [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NBAS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65065 NBEAL1
A530083I02Rik
ALS2CR16
ALS2CR17
neurobeachin-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NBEAL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4683 NBN
AT-V1
AT-V2
ATV
NBS
NBS1
P95
nibrin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NBN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23310 NCAPD3
CAP-D3
CAPD3
hCAP-D3
hHCP-6
hcp-6
non-SMC condensin II complex, subunit D3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCAPD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23397 NCAPH
BRRN1
CAP-H
non-SMC condensin I complex, subunit H [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCAPH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4690 NCK1
NCK
NCKalpha
nck-1
NCK adaptor protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8648 NCOA1
F-SRC-1
KAT13A
RIP160
SRC1
bHLHe42
bHLHe74
nuclear receptor coactivator 1 (EC:2.3.1.48) epigallocatechin gallate results in increased expression of NCOA1 mRNA increases expression
mRNA 22079256
C045651 8648 NCOA1
F-SRC-1
KAT13A
RIP160
SRC1
bHLHe42
bHLHe74
nuclear receptor coactivator 1 (EC:2.3.1.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCOA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10499 NCOA2
GRIP1
KAT13C
NCoA-2
SRC2
TIF2
bHLHe75
nuclear receptor coactivator 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCOA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 135112 NCOA7
ERAP140
ESNA1
Nbla00052
Nbla10993
TLDC4
dJ187J11.3
nuclear receptor coactivator 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NCOA7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4541 ND6
MTND6
MT-ND6
NADH dehydrogenase, subunit 6 (complex I) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ND6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10403 NDC80
HEC
HEC1
HsHec1
KNTC2
TID3
hsNDC80
NDC80 kinetochore complex component [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDC80 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10397 NDRG1
CAP43
CMT4D
DRG-1
DRG1
GC4
HMSNL
NDR1
NMSL
PROXY1
RIT42
RTP
TARG1
TDD5
N-myc downstream regulated 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NDRG1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8509 NDST2
HSST2
NST2
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 (EC:2.8.2.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDST2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51103 NDUFAF1
CGI65
CIA30
NADH dehydrogenase (ubiquinone) complex I, assembly factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDUFAF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4729 NDUFV2
CI-24k
NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa (EC:1.6.5.3 1.6.99.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NDUFV2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 121441 NEDD1
GCP-WD
TUBGCP7
neural precursor cell expressed, developmentally down-regulated 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEDD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4734 NEDD4
NEDD4-1
RPF1
neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase (EC:6.3.2.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEDD4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23327 NEDD4L
NEDD4-2
NEDD4.2
RSP5
hNEDD4-2
neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase (EC:6.3.2.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEDD4L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4739 NEDD9
CAS-L
CAS2
CASL
CASS2
HEF1
neural precursor cell expressed, developmentally down-regulated 9 epigallocatechin gallate results in decreased expression of NEDD9 mRNA decreases expression
mRNA 16084531
C045651 55247 NEIL3
FGP2
FPG2
NEI3
hFPG2
hNEI3
nei endonuclease VIII-like 3 (E. coli) (EC:4.2.99.18) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEIL3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4750 NEK1
NY-REN-55
SRPS2
SRPS2A
NIMA-related kinase 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4752 NEK3
HSPK36
NIMA-related kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEK3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10783 NEK6
SID6-1512
NIMA-related kinase 6 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NEK6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 374987 NEXN-AS1
C1orf118
NEXN antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NEXN-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4763 NF1
NFNS
VRNF
WSS
neurofibromin 1 epigallocatechin gallate results in increased expression of NF1 mRNA increases expression
mRNA 22079256
C045651 4763 NF1
NFNS
VRNF
WSS
neurofibromin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 epigallocatechin gallate results in increased expression of NFE2L2 protein increases expression
protein 16799064
C045651 4774 NFIA
CTF
NF-I/A
NF1-A
NFI-A
NFI-L
nuclear factor I/A epigallocatechin gallate results in increased expression of NFIA mRNA increases expression
mRNA 22079256
C045651 4774 NFIA
CTF
NF-I/A
NF1-A
NFI-A
NFI-L
nuclear factor I/A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFIA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4783 NFIL3
E4BP4
IL3BP1
NF-IL3A
NFIL3A
nuclear factor, interleukin 3 regulated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NFIL3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFKB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of NFKBIA protein] decreases expression
/ decreases reaction
/ increases degradation
protein 19557821
C045651 4793 NFKBIB
IKBB
TRIP9
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NFKBIB mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9054 NFS1
IscS
NIFS
NFS1 cysteine desulfurase (EC:2.8.1.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4799 NFX1
NFX2
nuclear transcription factor, X-box binding 1 (EC:6.3.2.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFX1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4800 NFYA
CBF-A
CBF-B
HAP2
NF-YA
nuclear transcription factor Y, alpha [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NFYA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4801 NFYB
CBF-A
CBF-B
HAP3
NF-YB
nuclear transcription factor Y, beta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NFYB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55768 NGLY1
CDG1V
PNG1
PNGase
N-glycanase 1 (EC:3.5.1.52) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NGLY1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51335 NGRN
DSC92
neugrin, neurite outgrowth associated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NGRN mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 60491 NIF3L1
ALS2CR1
CALS-7
NIF3 NGG1 interacting factor 3-like 1 (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NIF3L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 307652 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NIP30 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4817 NIT1
nitrilase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NIT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51701 NLK
nemo-like kinase (EC:2.7.11.24) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NLK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29922 NME7
MN23H7
NDK_7
NDK7
nm23-H7
NME/NM23 family member 7 (EC:2.7.4.6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NME7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9111 NMI
N-myc (and STAT) interactor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NMI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4837 NNMT
nicotinamide N-methyltransferase (EC:2.1.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NNMT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28987 NOB1
ART-4
MST158
NOB1P
PSMD8BP1
NIN1/RPN12 binding protein 1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOB1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64318 NOC3L
AD24
C10orf117
FAD24
nucleolar complex associated 3 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NOC3L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9221 NOLC1
NOPP130
NOPP140
NS5ATP13
P130
nucleolar and coiled-body phosphoprotein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NOLC1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) epigallocatechin gallate promotes the reaction [Hydrogen Peroxide results in increased expression of NOS3 mRNA] increases expression
/ increases reaction
mRNA 20021702
C045651 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) epigallocatechin gallate results in increased expression of NOS3 mRNA increases expression
mRNA 20021702
20706672
C045651 9520 NPEPPS
AAP-S
MP100
PSA
aminopeptidase puromycin sensitive (EC:3.4.11.14) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NPEPPS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8431 NR0B2
SHP
SHP1
nuclear receptor subfamily 0, group B, member 2 epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 8431 NR0B2
SHP
SHP1
nuclear receptor subfamily 0, group B, member 2 epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of NR0B2 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 8431 NR0B2
SHP
SHP1
nuclear receptor subfamily 0, group B, member 2 epigallocatechin gallate results in increased expression of NR0B2 mRNA increases expression
mRNA 22178739
C045651 9971 NR1H4
BAR
FXR
HRR-1
HRR1
RIP14
nuclear receptor subfamily 1, group H, member 4 [epigallocatechin gallate co-treated with gallocatechol] results in increased activity of NR1H4 protein affects cotreatment
/ increases activity
protein 22178739
C045651 9971 NR1H4
BAR
FXR
HRR-1
HRR1
RIP14
nuclear receptor subfamily 1, group H, member 4 epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] decreases reaction
/ increases activity
protein 22178739
C045651 9971 NR1H4
BAR
FXR
HRR-1
HRR1
RIP14
nuclear receptor subfamily 1, group H, member 4 epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 9971 NR1H4
BAR
FXR
HRR-1
HRR1
RIP14
nuclear receptor subfamily 1, group H, member 4 epigallocatechin gallate inhibits the reaction [GW 4064 results in increased activity of NR1H4 protein] decreases reaction
/ increases activity
protein 22178739
C045651 9971 NR1H4
BAR
FXR
HRR-1
HRR1
RIP14
nuclear receptor subfamily 1, group H, member 4 epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of NR1H4 mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 9971 NR1H4
BAR
FXR
HRR-1
HRR1
RIP14
nuclear receptor subfamily 1, group H, member 4 epigallocatechin gallate results in increased activity of NR1H4 protein increases activity
protein 22178739
C045651 126382 NR2C2AP
TRA16
nuclear receptor 2C2-associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NR2C2AP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 2908 NR3C1
GCCR
GCR
GR
GRL
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) epigallocatechin gallate results in decreased expression of NR3C1 mRNA decreases expression
mRNA 16084531
C045651 2908 NR3C1
GCCR
GCR
GR
GRL
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NR3C1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3164 NR4A1
GFRP1
HMR
N10
NAK-1
NGFIB
NP10
NUR77
TR3
nuclear receptor subfamily 4, group A, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4929 NR4A2
HZF-3
NOT
NURR1
RNR1
TINUR
nuclear receptor subfamily 4, group A, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8013 NR4A3
CHN
CSMF
MINOR
NOR1
TEC
nuclear receptor subfamily 4, group A, member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NR4A3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9315 NREP
C5orf13
D4S114
P311
PRO1873
PTZ17
SEZ17
neuronal regeneration related protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NREP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 3084 NRG1
ARIA
GGF
GGF2
HGL
HRG
HRG1
HRGA
MST131
NDF
SMDF
neuregulin 1 epigallocatechin gallate results in decreased expression of NRG1 mRNA decreases expression
mRNA 20346928
C045651 3084 NRG1
ARIA
GGF
GGF2
HGL
HRG
HRG1
HRGA
MST131
NDF
SMDF
neuregulin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NRG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8204 NRIP1
RIP140
nuclear receptor interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NRIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4905 NSF
SKD2
N-ethylmaleimide-sensitive factor (EC:3.6.4.6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25936 NSL1
C1orf48
MIS14
NSL1, MIS12 kinetochore complex component [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 286053 NSMCE2
C8orf36
MMS21
NSE2
ZMIZ7
non-SMC element 2, MMS21 homolog (S. cerevisiae) epigallocatechin gallate results in decreased expression of NSMCE2 mRNA decreases expression
mRNA 22079256
C045651 286053 NSMCE2
C8orf36
MMS21
NSE2
ZMIZ7
non-SMC element 2, MMS21 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSMCE2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54780 NSMCE4A
C10orf86
NS4EA
NSE4A
non-SMC element 4 homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSMCE4A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 221078 NSUN6
4933414E04Rik
NOPD1
NOP2/Sun domain family, member 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NSUN6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9891 NUAK1
ARK5
NUAK family, SNF1-like kinase, 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUAK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4682 NUBP1
NBP
NBP1
nucleotide binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUBP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84955 NUDCD1
CML66
OVA66
NudC domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUDCD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83594 NUDT12
nudix (nucleoside diphosphate linked moiety X)-type motif 12 (EC:3.6.1.22) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUDT12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11163 NUDT4
DIPP2
DIPP2alpha
DIPP2beta
nudix (nucleoside diphosphate linked moiety X)-type motif 4 (EC:3.6.1.52) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NUDT4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 83540 NUF2
CDCA1
CT106
NUF2R
NUF2, NDC80 kinetochore complex component [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8650 NUMB
C14orf41
S171
c14_5527
numb homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUMB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57122 NUP107
NUP84
nucleoporin 107kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP107 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55746 NUP133
hNUP133
nucleoporin 133kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP133 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23279 NUP160
nucleoporin 160kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP160 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79023 NUP37
p37
nucleoporin 37kDa epigallocatechin gallate results in decreased expression of NUP37 mRNA decreases expression
mRNA 22079256
C045651 79023 NUP37
p37
nucleoporin 37kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP37 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79902 NUP85
Nup75
nucleoporin 85kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP85 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4928 NUP98
ADIR2
NUP196
NUP96
nucleoporin 98kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NUP98 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10482 NXF1
MEX67
TAP
nuclear RNA export factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NXF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11247 NXPH4
NPH4
neurexophilin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of NXPH4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4938 OAS1
IFI-4
OIAS
OIASI
2'-5'-oligoadenylate synthetase 1, 40/46kDa (EC:2.7.7.84) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OAS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4953 ODC1
ODC
ornithine decarboxylase 1 (EC:4.1.1.17) epigallocatechin gallate results in decreased expression of and results in decreased activity of ODC1 protein decreases activity
/ decreases expression
protein 12663506
C045651 57489 ODF2L
RP5-977L11.1
dJ977L11.1
outer dense fiber of sperm tails 2-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ODF2L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4967 OGDH
AKGDH
E1k
OGDC
oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) (EC:1.2.4.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OGDH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8473 OGT
HRNT1
O-GLCNAC
O-linked N-acetylglucosamine (GlcNAc) transferase (EC:2.4.1.255) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OGT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11339 OIP5
5730547N13Rik
CT86
LINT-25
MIS18B
MIS18beta
hMIS18beta
Opa interacting protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OIP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25903 OLFML2B
RP11-227F8.1
olfactomedin-like 2B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OLFML2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4973 OLR1
CLEC8A
LOX1
LOXIN
SCARE1
SLOX1
oxidized low density lipoprotein (lectin-like) receptor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OLR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9480 ONECUT2
OC-2
OC2
one cut homeobox 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ONECUT2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4983 OPHN1
ARHGAP41
MRX60
OPN1
oligophrenin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OPHN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80228 ORAI2
C7orf19
CBCIP2
MEM142B
TMEM142B
ORAI calcium release-activated calcium modulator 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ORAI2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29095 ORMDL2
MST095
MSTP095
adoplin-2
ORM1-like 2 (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ORMDL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26031 OSBPL3
ORP-3
ORP3
OSBP3
oxysterol binding protein-like 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OSBPL3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51526 OSER1
C20orf111
HSPC207
Osr1
Perit1
dJ1183I21.1
oxidative stress responsive serine-rich 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of OSER1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55644 OSGEP
GCPL1
KAE1
OSGEP1
PRSMG1
O-sialoglycoprotein endopeptidase (EC:3.4.24.57) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OSGEP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64172 OSGEPL1
Qri7
O-sialoglycoprotein endopeptidase-like 1 (EC:3.4.24.57) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OSGEPL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5016 OVGP1
CHIT5
EGP
MUC9
OGP
oviductal glycoprotein 1, 120kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of OVGP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54995 OXSM
FASN2D
KASI
KS
3-oxoacyl-ACP synthase, mitochondrial (EC:2.3.1.41) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of OXSM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 655678 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of P76 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 80227 PAAF1
PAAF
Rpn14
WDR71
proteasomal ATPase-associated factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PAAF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26986 PABPC1
PAB1
PABP
PABP1
PABPC2
PABPL1
poly(A) binding protein, cytoplasmic 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PABPC1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5042 PABPC3
PABP3
PABPL3
tPABP
poly(A) binding protein, cytoplasmic 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PABPC3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8761 PABPC4
APP-1
APP1
PABP4
iPABP
poly(A) binding protein, cytoplasmic 4 (inducible form) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PABPC4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79447 PAGR1
C16orf53
GAS
PA1
PAXIP1 associated glutamate-rich protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PAGR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8505 PARG
PARG99
poly (ADP-ribose) glycohydrolase (EC:3.2.1.143) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased cleavage of and results in increased activity of PARP1 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 22079256
C045651 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) epigallocatechin gallate results in increased activity of PARP1 protein increases activity
protein 15657356
C045651 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) epigallocatechin gallate results in increased cleavage of PARP1 protein increases cleavage
protein 15705601
15764647
C045651 64761 PARP12
ARTD12
MST109
MSTP109
ZC3H1
ZC3HDC1
poly (ADP-ribose) polymerase family, member 12 (EC:2.4.2.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 143 PARP4
ADPRTL1
ARTD4
PARP-4
PARPL
PH5P
VAULT3
VPARP
VWA5C
p193
poly (ADP-ribose) polymerase family, member 4 (EC:2.4.2.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56965 PARP6
ARTD17
PARP-6-B1
PARP-6-C
pART17
poly (ADP-ribose) polymerase family, member 6 (EC:2.4.2.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PARP6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79668 PARP8
ARTD16
pART16
poly (ADP-ribose) polymerase family, member 8 (EC:2.4.2.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83666 PARP9
ARTD9
BAL
BAL1
MGC:7868
poly (ADP-ribose) polymerase family, member 9 (EC:2.4.2.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARP9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64098 PARVG
parvin, gamma [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PARVG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55193 PBRM1
BAF180
PB1
polybromo 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PBRM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5089 PBX2
G17
HOX12
PBX2MHC
pre-B-cell leukemia homeobox 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PBX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 301164 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCAF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5095 PCCA
propionyl CoA carboxylase, alpha polypeptide (EC:6.4.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCCA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57575 PCDH10
OL-PCDH
PCDH19
protocadherin 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PCDH10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54510 PCDH18
PCDH68L
protocadherin 18 epigallocatechin gallate results in increased expression of PCDH18 mRNA increases expression
mRNA 22079256
C045651 54510 PCDH18
PCDH68L
protocadherin 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCDH18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51585 PCF11
PCF11 cleavage and polyadenylation factor subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PCF11 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7703 PCGF2
MEL-18
RNF110
ZNF144
polycomb group ring finger 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PCGF2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55795 PCID2
F10
PCI domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCID2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100380451 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PCTK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11235 PDCD10
CCM3
TFAR15
programmed cell death 10 epigallocatechin gallate results in decreased expression of PDCD10 mRNA decreases expression
mRNA 22079256
C045651 11235 PDCD10
CCM3
TFAR15
programmed cell death 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDCD10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9141 PDCD5
TFAR19
programmed cell death 5 epigallocatechin gallate results in decreased expression of PDCD5 mRNA decreases expression
mRNA 22079256
C045651 9141 PDCD5
TFAR19
programmed cell death 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDCD5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27115 PDE7B
bA472E5.1
phosphodiesterase 7B (EC:3.1.4.17) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDE7B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56034 PDGFC
FALLOTEIN
SCDGF
platelet derived growth factor C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDGFC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5159 PDGFRB
CD140B
IBGC4
IMF1
JTK12
PDGFR
PDGFR-1
PDGFR1
platelet-derived growth factor receptor, beta polypeptide (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDGFRB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5162 PDHB
PDHBD
PDHE1-B
PHE1B
pyruvate dehydrogenase (lipoamide) beta (EC:1.2.4.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDHB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5163 PDK1
pyruvate dehydrogenase kinase, isozyme 1 (EC:2.7.11.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PDK1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10611 PDLIM5
ENH
ENH1
LIM
PDZ and LIM domain 5 epigallocatechin gallate results in decreased expression of PDLIM5 mRNA decreases expression
mRNA 16084531
C045651 10611 PDLIM5
ENH
ENH1
LIM
PDZ and LIM domain 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDLIM5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81572 PDRG1
C20orf126
PDRG
p53 and DNA-damage regulated 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PDRG1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23047 PDS5B
APRIN
AS3
CG008
PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PDS5B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57026 PDXP
CIN
PLP
dJ37E16.5
pyridoxal (pyridoxine, vitamin B6) phosphatase (EC:3.1.3.3 3.1.3.74) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PDXP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 100196721 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PECI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57162 PELI1
pellino E3 ubiquitin protein ligase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PELI1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8864 PER2
FASPS
FASPS1
period circadian clock 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PER2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5188 PET112
PET112L
PET112 homolog (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PET112 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8799 PEX11B
PEX11-BETA
PEX14B
peroxisomal biogenesis factor 11 beta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PEX11B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5828 PEX2
PAF1
PBD5A
PBD5B
PMP3
PMP35
PXMP3
RNF72
ZWS3
peroxisomal biogenesis factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PEX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8504 PEX3
PBD10A
TRG18
peroxisomal biogenesis factor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PEX3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5209 PFKFB3
IPFK2
PFK2
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (EC:2.7.1.105 3.1.3.46) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PFKFB3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5241 PGR
NR3C3
PR
progesterone receptor epigallocatechin gallate results in decreased expression of PGR mRNA decreases expression
mRNA 20706672
C045651 9749 PHACTR2
C6orf56
phosphatase and actin regulator 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHACTR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65979 PHACTR4
phosphatase and actin regulator 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHACTR4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51131 PHF11
APY
BCAP
IGEL
IGER
IGHER
NY-REN-34
NYREN34
PHD finger protein 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHF11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26147 PHF19
MTF2L1
PCL3
TDRD19B
PHD finger protein 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHF19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55023 PHIP
BRWD2
DCAF14
WDR11
ndrp
pleckstrin homology domain interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHIP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5260 PHKG1
PHKG
phosphorylase kinase, gamma 1 (muscle) (EC:2.7.11.1 2.7.11.19 2.7.11.26) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PHKG1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7262 PHLDA2
BRW1C
BWR1C
HLDA2
IPL
TSSC3
pleckstrin homology-like domain, family A, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PHLDA2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23187 PHLDB1
LL5A
pleckstrin homology-like domain, family B, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PHLDB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8554 PIAS1
DDXBP1
GBP
GU/RH-II
ZMIZ3
protein inhibitor of activated STAT, 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIAS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10464 PIBF1
C13orf24
CEP90
PIBF
RP11-505F3.1
progesterone immunomodulatory binding factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIBF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8301 PICALM
CALM
CLTH
LAP
phosphatidylinositol binding clathrin assembly protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PICALM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9463 PICK1
PICK
PRKCABP
protein interacting with PRKCA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PICK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55022 PID1
NYGGF4
P-CLI1
PCLI1
phosphotyrosine interaction domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PID1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5277 PIGA
GPI3
MCAHS2
PIG-A
phosphatidylinositol glycan anchor biosynthesis, class A (EC:2.4.1.198) epigallocatechin gallate results in increased expression of PIGA mRNA increases expression
mRNA 16084531
C045651 5277 PIGA
GPI3
MCAHS2
PIG-A
phosphatidylinositol glycan anchor biosynthesis, class A (EC:2.4.1.198) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PIGA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5281 PIGF
phosphatidylinositol glycan anchor biosynthesis, class F (EC:2.7.8.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIGF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51227 PIGP
DCRC
DCRC-S
DSCR5
DSRC
phosphatidylinositol glycan anchor biosynthesis, class P (EC:2.4.1.198) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIGP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55650 PIGV
GPI-MT-II
HPMRS1
PIG-V
phosphatidylinositol glycan anchor biosynthesis, class V [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIGV mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5291 PIK3CB
P110BETA
PI3K
PI3KBETA
PIK3C1
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta (EC:2.7.1.153) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIK3CB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5293 PIK3CD
P110DELTA
PI3K
p110D
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (EC:2.7.1.153) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIK3CD mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11040 PIM2
pim-2 oncogene (EC:2.7.11.1) epigallocatechin gallate results in increased expression of PIM2 mRNA increases expression
mRNA 16084531
C045651 5305 PIP4K2A
PI5P4KA
PIP5K2A
PIP5KII-alpha
PIP5KIIA
PIPK
phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (EC:2.7.1.149) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIP4K2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5311 PKD2
APKD2
PC2
PKD4
Pc-2
TRPP2
polycystic kidney disease 2 (autosomal dominant) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PKD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5586 PKN2
PAK2
PRK2
PRKCL2
PRO2042
Pak-2
protein kinase N2 (EC:2.7.11.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PKN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5318 PKP2
ARVD9
plakophilin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PKP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5325 PLAGL1
LOT1
ZAC
ZAC1
pleiomorphic adenoma gene-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PLAGL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5327 PLAT
T-PA
TPA
plasminogen activator, tissue (EC:3.4.21.68) [Sulindac co-treated with epigallocatechin gallate] results in decreased expression of PLAT mRNA affects cotreatment
/ decreases expression
mRNA 12628509
C045651 5328 PLAU
ATF
BDPLT5
QPD
UPA
URK
u-PA
plasminogen activator, urokinase (EC:3.4.21.73) epigallocatechin gallate results in decreased expression of PLAU mRNA decreases expression
mRNA 16084531
C045651 51196 PLCE1
NPHS3
PLCE
PPLC
phospholipase C, epsilon 1 (EC:3.1.4.11) epigallocatechin gallate results in increased expression of PLCE1 mRNA increases expression
mRNA 22079256
C045651 51196 PLCE1
NPHS3
PLCE
PPLC
phospholipase C, epsilon 1 (EC:3.1.4.11) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLCE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5337 PLD1
phospholipase D1, phosphatidylcholine-specific (EC:3.1.4.4) epigallocatechin gallate results in increased expression of PLD1 mRNA increases expression
mRNA 22079256
C045651 5337 PLD1
phospholipase D1, phosphatidylcholine-specific (EC:3.1.4.4) PLD1 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] increases expression
/ increases reaction
protein 15210717
C045651 5337 PLD1
phospholipase D1, phosphatidylcholine-specific (EC:3.1.4.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5338 PLD2
phospholipase D2 (EC:3.1.4.4) Go 6976 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 15210717
C045651 5338 PLD2
phospholipase D2 (EC:3.1.4.4) PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] increases expression
/ increases reaction
protein 15210717
C045651 5338 PLD2
phospholipase D2 (EC:3.1.4.4) SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 15210717
C045651 26499 PLEK2
pleckstrin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLEK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54477 PLEKHA5
PEPP-2
PEPP2
pleckstrin homology domain containing, family A member 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLEKHA5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144100 PLEKHA7
pleckstrin homology domain containing, family A member 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLEKHA7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55848 PLGRKT
C9orf46
MDS030
PLG-RKT
Plg-R(KT)
plasminogen receptor, C-terminal lysine transmembrane protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLGRKT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10769 PLK2
SNK
hPlk2
hSNK
polo-like kinase 2 (EC:2.7.11.21) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8985 PLOD3
LH3
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (EC:1.14.11.4) epigallocatechin gallate results in increased expression of PLOD3 mRNA increases expression
mRNA 20706672
C045651 8985 PLOD3
LH3
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (EC:1.14.11.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PLOD3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5357 PLS1
plastin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5362 PLXNA2
OCT
PLXN2
plexin A2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PLXNA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5366 PMAIP1
APR
NOXA
phorbol-12-myristate-13-acetate-induced protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PMAIP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5376 PMP22
CMT1A
CMT1E
DSS
GAS-3
HMSNIA
HNPP
Sp110
peripheral myelin protein 22 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PMP22 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5378 PMS1
HNPCC3
PMSL1
hPMS1
PMS1 postmeiotic segregation increased 1 (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PMS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 741857 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PMS2L3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5411 PNN
DRS
DRSP
SDK3
memA
pinin, desmosome associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PNN mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 4860 PNP
NP
PRO1837
PUNP
purine nucleoside phosphorylase (EC:2.4.2.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PNP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57104 PNPLA2
1110001C14Rik
ATGL
PEDF-R
TTS-2.2
TTS2
iPLA2zeta
patatin-like phospholipase domain containing 2 (EC:3.1.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PNPLA2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 87178 PNPT1
COXPD13
DFNB70
OLD35
PNPASE
old-35
polyribonucleotide nucleotidyltransferase 1 (EC:2.7.7.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PNPT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25886 POC1A
PIX2
SOFT
WDR51A
POC1 centriolar protein A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POC1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 134359 POC5
C5orf37
POC5 centriolar protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23649 POLA2
polymerase (DNA directed), alpha 2, accessory subunit [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5427 POLE2
DPE2
polymerase (DNA directed), epsilon 2, accessory subunit (EC:2.7.7.7) epigallocatechin gallate results in decreased expression of POLE2 mRNA decreases expression
mRNA 22079256
C045651 5427 POLE2
DPE2
polymerase (DNA directed), epsilon 2, accessory subunit (EC:2.7.7.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLE2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54107 POLE3
CHARAC17
CHRAC17
YBL1
p17
polymerase (DNA directed), epsilon 3, accessory subunit (EC:2.7.7.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of POLE3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11201 POLI
RAD30B
RAD3OB
polymerase (DNA directed) iota (EC:2.7.7.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51082 POLR1D
AC19
POLR1C
RPA16
RPA9
RPAC2
RPC16
RPO1-3
TCS2
polymerase (RNA) I polypeptide D, 16kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of POLR1D mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55703 POLR3B
C128
HLD8
RPC2
polymerase (RNA) III (DNA directed) polypeptide B (EC:2.7.7.6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLR3B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 171568 POLR3H
RPC22.9
RPC8
polymerase (RNA) III (DNA directed) polypeptide H (22.9kD) (EC:2.7.7.6) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POLR3H mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5443 POMC
ACTH
CLIP
LPH
MSH
NPP
POC
proopiomelanocortin epigallocatechin gallate results in decreased expression of POMC mRNA decreases expression
mRNA 20706672
C045651 10940 POP1
processing of precursor 1, ribonuclease P/MRP subunit (S. cerevisiae) (EC:3.1.26.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51367 POP5
HSPC004
RPP2
RPP20
hPop5
processing of precursor 5, ribonuclease P/MRP subunit (S. cerevisiae) (EC:3.1.26.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5447 POR
CPR
CYPOR
P450R
P450 (cytochrome) oxidoreductase (EC:1.6.2.4) epigallocatechin gallate results in increased activity of POR protein increases activity
protein 15998352
C045651 25913 POT1
HPOT1
protection of telomeres 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of POT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5462 POU5F1B
OCT4-PG1
OTF3C
OTF3P1
POU5F1P1
POU5F1P4
POU5FLC20
POU5FLC8
POU class 5 homeobox 1B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of POU5F1B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8611 PPAP2A
LLP1a
LPP1
PAP-2a
PAP2
phosphatidic acid phosphatase type 2A (EC:3.1.3.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPAP2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8613 PPAP2B
Dri42
LPP3
PAP2B
VCIP
phosphatidic acid phosphatase type 2B (EC:3.1.3.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPAP2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma epigallocatechin gallate results in decreased expression of PPARG mRNA decreases expression
mRNA 20706672
C045651 79144 PPDPF
C20orf149
dJ697K14.9
exdpf
pancreatic progenitor cell differentiation and proliferation factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPDPF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8496 PPFIBP1
L2
SGT2
hSGT2
hSgt2p
PTPRF interacting protein, binding protein 1 (liprin beta 1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPFIBP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23759 PPIL2
CYC4
CYP60
Cyp-60
UBOX7
hCyP-60
peptidylprolyl isomerase (cyclophilin)-like 2 (EC:5.2.1.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPIL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23262 PPIP5K2
HISPPD1
IP7K2
VIP2
diphosphoinositol pentakisphosphate kinase 2 (EC:2.7.4.21 2.7.4.24) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPIP5K2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51400 PPME1
PME-1
protein phosphatase methylesterase 1 (EC:3.1.1.89) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPME1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5499 PPP1CA
PP-1A
PP1A
PP1alpha
PPP1A
protein phosphatase 1, catalytic subunit, alpha isozyme (EC:3.1.3.16) [Ibuprofen co-treated with epigallocatechin gallate] results in increased expression of PPP1CA protein affects cotreatment
/ increases expression
protein 18348186
C045651 4659 PPP1R12A
M130
MBS
MYPT1
protein phosphatase 1, regulatory subunit 12A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP1R12A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23645 PPP1R15A
GADD34
protein phosphatase 1, regulatory subunit 15A epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in increased expression of PPP1R15A mRNA] decreases reaction
/ increases expression
mRNA 22079256
C045651 23645 PPP1R15A
GADD34
protein phosphatase 1, regulatory subunit 15A epigallocatechin gallate results in increased expression of PPP1R15A mRNA increases expression
mRNA 18851785
C045651 23645 PPP1R15A
GADD34
protein phosphatase 1, regulatory subunit 15A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPP1R15A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 170954 PPP1R18
HKMT1098
KIAA1949
protein phosphatase 1, regulatory subunit 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPP1R18 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5523 PPP2R3A
PPP2R3
PR130
PR72
protein phosphatase 2, regulatory subunit B'', alpha (EC:3.1.3.16) epigallocatechin gallate results in increased expression of PPP2R3A mRNA increases expression
mRNA 22079256
C045651 5523 PPP2R3A
PPP2R3
PR130
PR72
protein phosphatase 2, regulatory subunit B'', alpha (EC:3.1.3.16) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP2R3A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55012 PPP2R3C
C14orf10
G4-1
G5pr
protein phosphatase 2, regulatory subunit B'', gamma [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP2R3C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5533 PPP3CC
CALNA3
CNA3
PP2Bgamma
protein phosphatase 3, catalytic subunit, gamma isozyme (EC:3.1.3.16) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP3CC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57718 PPP4R4
KIAA1622
PP4R4
protein phosphatase 4, regulatory subunit 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP4R4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55291 PPP6R3
C11orf23
PP6R3
SAP190
SAPL
SAPLa
SAPS3
protein phosphatase 6, regulatory subunit 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPP6R3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23082 PPRC1
PRC
RP11-302K17.6
peroxisome proliferator-activated receptor gamma, coactivator-related 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PPRC1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23398 PPWD1
peptidylprolyl isomerase domain and WD repeat containing 1 (EC:5.2.1.8) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PPWD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10113 PREB
SEC12
prolactin regulatory element binding [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PREB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 153768 PRELID2
PRELI domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRELID2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 166336 PRICKLE2
EPM5
prickle homolog 2 (Drosophila) epigallocatechin gallate results in increased expression of PRICKLE2 mRNA increases expression
mRNA 22079256
C045651 166336 PRICKLE2
EPM5
prickle homolog 2 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRICKLE2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5557 PRIM1
p49
primase, DNA, polypeptide 1 (49kDa) (EC:2.7.7.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRIM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5558 PRIM2
PRIM2A
p58
primase, DNA, polypeptide 2 (58kDa) (EC:2.7.7.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRIM2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 201973 PRIMPOL
CCDC111
MYP22
primase and polymerase (DNA-directed) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRIMPOL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5583 PRKCH
PKC-L
PKCL
PRKCL
nPKC-eta
protein kinase C, eta (EC:2.7.11.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRKCH mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5589 PRKCSH
AGE-R2
G19P1
PCLD
PKCSH
PLD1
protein kinase C substrate 80K-H (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PRKCSH mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5587 PRKD1
PKC-MU
PKCM
PKD
PRKCM
protein kinase D1 (EC:2.7.11.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRKD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5618 PRLR
hPRLrI
prolactin receptor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRLR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10196 PRMT3
HRMT1L3
protein arginine methyltransferase 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRMT3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29053 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PRO0628 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55478 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRO2012 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55390 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PRO2268 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55119 PRPF38B
NET1
RP11-293A10.1
pre-mRNA processing factor 38B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PRPF38B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5636 PRPSAP2
PAP41
phosphoribosyl pyrophosphate synthetase-associated protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRPSAP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11098 PRSS23
SIG13
SPUVE
ZSIG13
protease, serine, 23 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRSS23 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 58497 PRUNE
DRES-17
DRES17
HTCD37
prune exopolyphosphatase (EC:3.6.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PRUNE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5671 PSG3
pregnancy specific beta-1-glycoprotein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PSG3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11168 PSIP1
DFS70
LEDGF
PAIP
PSIP2
p52
p75
PC4 and SFRS1 interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PSIP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84722 PSRC1
DDA3
FP3214
proline/serine-rich coiled-coil 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PSRC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5724 PTAFR
PAFR
platelet-activating factor receptor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PTAFR mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9317 PTER
HPHRP
RPR-1
phosphotriesterase related [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTER mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5730 PTGDS
L-PGDS
LPGDS
PDS
PGD2
PGDS
PGDS2
prostaglandin D2 synthase 21kDa (brain) (EC:5.3.99.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PTGDS mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5731 PTGER1
EP1
prostaglandin E receptor 1 (subtype EP1), 42kDa epigallocatechin gallate results in decreased expression of PTGER1 mRNA decreases expression
mRNA 20706672
C045651 5742 PTGS1
COX1
COX3
PCOX1
PES-1
PGG/HS
PGHS-1
PGHS1
PHS1
PTGHS
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) epigallocatechin gallate results in decreased expression of PTGS1 mRNA decreases expression
mRNA 20816778
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) 1-Butanol inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA] decreases reaction
/ increases expression
mRNA 19557821
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 19557821
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) epigallocatechin gallate results in decreased expression of PTGS2 mRNA decreases expression
mRNA 16084531
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) epigallocatechin gallate results in increased expression of PTGS2 protein increases expression
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Go 6976 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Go 6976 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) PLD1 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] increases expression
/ increases reaction
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] increases expression
/ increases reaction
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Propranolol promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] increases expression
/ increases reaction
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) SB 203580 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 15210717
C045651 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]] decreases reaction
/ increases expression
/ increases reaction
protein 15210717
C045651 5747 PTK2
FADK
FAK
FAK1
FRNK
PPP1R71
p125FAK
pp125FAK
protein tyrosine kinase 2 (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7803 PTP4A1
HH72
PRL-1
PRL1
PTP(CAAX1)
PTPCAAX1
protein tyrosine phosphatase type IVA, member 1 (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PTP4A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 401494 PTPLAD2
HACD4
protein tyrosine phosphatase-like A domain containing 2 (EC:4.2.1.134) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPLAD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5782 PTPN12
PTP-PEST
PTPG1
protein tyrosine phosphatase, non-receptor type 12 (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5783 PTPN13
FAP-1
PNP1
PTP-BAS
PTP-BL
PTP1E
PTPL1
PTPLE
hPTP1E
protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5774 PTPN3
PTP-H1
PTPH1
protein tyrosine phosphatase, non-receptor type 3 (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5775 PTPN4
MEG
PTPMEG
PTPMEG1
protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPN4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5791 PTPRE
HPTPE
PTPE
R-PTP-EPSILON
protein tyrosine phosphatase, receptor type, E (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPRE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5795 PTPRJ
CD148
DEP1
HPTPeta
R-PTP-ETA
SCC1
protein tyrosine phosphatase, receptor type, J (EC:3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTPRJ mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 138428 PTRH1
C9orf115
PTH1
peptidyl-tRNA hydrolase 1 homolog (S. cerevisiae) (EC:3.1.1.29) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTRH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5806 PTX3
TNFAIP5
TSG-14
pentraxin 3, long [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PTX3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 150962 PUS10
CCDC139
DOBI
pseudouridylate synthase 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PUS10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54517 PUS7
pseudouridylate synthase 7 homolog (S. cerevisiae) (EC:4.2.1.70) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PUS7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83448 PUS7L
pseudouridylate synthase 7 homolog (S. cerevisiae)-like (EC:5.4.99.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PUS7L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11137 PWP1
IEF-SSP-9502
PWP1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PWP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11264 PXMP4
PMP24
peroxisomal membrane protein 4, 24kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PXMP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5837 PYGM
phosphorylase, glycogen, muscle (EC:2.4.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of PYGM mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9230 RAB11B
H-YPT3
RAB11B, member RAS oncogene family epigallocatechin gallate results in decreased expression of RAB11B mRNA decreases expression
mRNA 18851785
C045651 26056 RAB11FIP5
GAF1
RIP11
pp75
RAB11 family interacting protein 5 (class I) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAB11FIP5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 201475 RAB12
RAB12, member RAS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAB12 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5861 RAB1A
RAB1
YPT1
RAB1A, member RAS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 441400 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAB1C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5874 RAB27B
C25KG
RAB27B, member RAS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB27B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9364 RAB28
CORD18
RAB28, member RAS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB28 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11031 RAB31
Rab22B
RAB31, member RAS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB31 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83452 RAB33B
SMC2
RAB33B, member RAS oncogene family [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAB33B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25782 RAB3GAP2
RAB3-GAP150
RAB3GAP150
WARBM2
p150
RAB3 GTPase activating protein subunit 2 (non-catalytic) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB3GAP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 117177 RAB3IP
RABIN3
RAB3A interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAB3IP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10244 RABEPK
RAB9P40
bA65N13.1
p40
Rab9 effector protein with kelch motifs epigallocatechin gallate results in decreased expression of RABEPK mRNA decreases expression
mRNA 18851785
C045651 23637 RABGAP1
GAPCENA
RP11-123N4.2
TBC1D11
RAB GTPase activating protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RABGAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9910 RABGAP1L
HHL
TBC1D18
RAB GTPase activating protein 1-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RABGAP1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAC1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5886 RAD23A
HHR23A
HR23A
RAD23 homolog A (S. cerevisiae) epigallocatechin gallate results in decreased expression of RAD23A mRNA decreases expression
mRNA 20706672
C045651 10111 RAD50
NBSLD
RAD502
hRad50
RAD50 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD50 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5888 RAD51
BRCC5
HRAD51
HsRad51
HsT16930
MRMV2
RAD51A
RECA
RAD51 recombinase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5890 RAD51B
R51H2
RAD51L1
REC2
RAD51 paralog B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5889 RAD51C
BROVCA3
FANCO
R51H3
RAD51L2
RAD51 paralog C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAD51C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 353091 RAET1G
ULBP5
retinoic acid early transcript 1G [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RAET1G mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 100313526 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAG1AP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57186 RALGAPA2
AS250
C20orf74
bA287B20.1
dJ1049G11
dJ1049G11.4
p220
Ral GTPase activating protein, alpha subunit 2 (catalytic) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RALGAPA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55103 RALGPS2
dJ595C2.1
Ral GEF with PH domain and SH3 binding motif 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RALGPS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9693 RAPGEF2
CNrasGEF
NRAPGEP
PDZ-GEF1
PDZGEF1
RA-GEF
RA-GEF-1
Rap-GEP
nRap_GEP
Rap guanine nucleotide exchange factor (GEF) 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAPGEF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51735 RAPGEF6
KIA001LB
PDZ-GEF2
PDZGEF2
RA-GEF-2
RAGEF2
Rap guanine nucleotide exchange factor (GEF) 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RAPGEF6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5914 RARA
NR1B1
RAR
retinoic acid receptor, alpha epigallocatechin gallate results in increased expression of RARA mRNA increases expression
mRNA 12628509
20706672
C045651 5915 RARB
HAP
NR1B2
RRB2
retinoic acid receptor, beta epigallocatechin gallate results in decreased metabolism of RARB promoter decreases metabolic processing
promoter 16037419
C045651 5915 RARB
HAP
NR1B2
RRB2
retinoic acid receptor, beta epigallocatechin gallate results in decreased methylation of RARB promoter decreases methylation
promoter 14633667
C045651 5915 RARB
HAP
NR1B2
RRB2
retinoic acid receptor, beta epigallocatechin gallate results in increased expression of RARB mRNA increases expression
mRNA 14633667
C045651 5915 RARB
HAP
NR1B2
RRB2
retinoic acid receptor, beta epigallocatechin gallate results in increased expression of RARB protein increases expression
protein 14633667
C045651 5918 RARRES1
LXNL
TIG1
retinoic acid receptor responder (tazarotene induced) 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RARRES1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5917 RARS
ArgRS
DALRD1
arginyl-tRNA synthetase (EC:6.1.1.19) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RARS mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9462 RASAL2
NGAP
RAS protein activator like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RASAL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25780 RASGRP3
GRP3
RAS guanyl releasing protein 3 (calcium and DAG-regulated) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RASGRP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 387496 RASL11A
RAS-like, family 11, member A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RASL11A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11228 RASSF8
C12orf2
HOJ1
Ras association (RalGDS/AF-6) domain family (N-terminal) member 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RASSF8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 epigallocatechin gallate results in decreased expression of and results in decreased phosphorylation of RB1 protein decreases expression
/ decreases phosphorylation
protein 15142168
C045651 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 epigallocatechin gallate results in increased expression of RB1 mRNA increases expression
mRNA 18851785
C045651 5928 RBBP4
NURF55
RBAP48
retinoblastoma binding protein 4 epigallocatechin gallate results in increased expression of RBBP4 mRNA increases expression
mRNA 18851785
C045651 23543 RBFOX2
FOX2
Fox-2
HNRBP2
HRNBP2
RBM9
RTA
dJ106I20.3
fxh
RNA binding protein, fox-1 homolog (C. elegans) 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBFOX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29890 RBM15B
HUMAGCGB
OTT3
RNA binding motif protein 15B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RBM15B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55147 RBM23
CAPERbeta
RNPC4
RNA binding motif protein 23 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBM23 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 129831 RBM45
DRB1
RNA binding motif protein 45 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBM45 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5937 RBMS1
C2orf12
HCC-4
MSSP
MSSP-1
MSSP-2
MSSP-3
SCR2
YC1
RNA binding motif, single stranded interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBMS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9978 RBX1
BA554C12.1
RNF75
ROC1
ring-box 1, E3 ubiquitin protein ligase epigallocatechin gallate results in decreased expression of RBX1 mRNA decreases expression
mRNA 22079256
C045651 9978 RBX1
BA554C12.1
RNF75
ROC1
ring-box 1, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RBX1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11123 RCAN3
DSCR1L2
MCIP3
RCN3
hRCN3
RCAN family member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RCAN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10171 RCL1
RNAC
RPCL1
RNA terminal phosphate cyclase-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RCL1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8434 RECK
ST15
reversion-inducing-cysteine-rich protein with kazal motifs [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RECK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A epigallocatechin gallate inhibits the reaction [Glucose affects the localization of RELA protein] affects localization
/ decreases reaction
protein 19557821
C045651 5980 REV3L
POLZ
REV3
REV3-like, polymerase (DNA directed), zeta, catalytic subunit (EC:2.7.7.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of REV3L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91869 RFT1
CDG1N
RFT1 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RFT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64326 RFWD2
COP1
RNF200
ring finger and WD repeat domain 2, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RFWD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5991 RFX3
regulatory factor X, 3 (influences HLA class II expression) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RFX3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8625 RFXANK
ANKRA1
BLS
F14150_1
RFX-B
regulatory factor X-associated ankyrin-containing protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RFXANK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28984 RGCC
C13orf15
RGC-32
RGC32
bA157L14.2
regulator of cell cycle [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RGCC mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23179 RGL1
RGL
ral guanine nucleotide dissociation stimulator-like 1 epigallocatechin gallate results in increased expression of RGL1 mRNA increases expression
mRNA 22079256
C045651 23179 RGL1
RGL
ral guanine nucleotide dissociation stimulator-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RGL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5997 RGS2
G0S8
regulator of G-protein signaling 2, 24kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RGS2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 5999 RGS4
RGP4
SCZD9
regulator of G-protein signaling 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RGS4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57414 RHBDD2
NPD007
RHBDL7
rhomboid domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RHBDD2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54933 RHBDL2
RRP2
rhomboid, veinlet-like 2 (Drosophila) (EC:3.4.21.105) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RHBDL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9886 RHOBTB1
Rho-related BTB domain containing 1 epigallocatechin gallate results in decreased expression of RHOBTB1 mRNA decreases expression
mRNA 16084531
C045651 9886 RHOBTB1
Rho-related BTB domain containing 1 epigallocatechin gallate results in increased expression of RHOBTB1 mRNA increases expression
mRNA 22079256
C045651 9886 RHOBTB1
Rho-related BTB domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RHOBTB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29984 RHOD
ARHD
RHOHP1
RHOM
Rho
ras homolog family member D epigallocatechin gallate results in decreased expression of RHOD mRNA decreases expression
mRNA 18851785
C045651 8780 RIOK3
SUDD
RIO kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RIOK3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6018 RLF
ZN-15L
ZNF292L
rearranged L-myc fusion [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RLF mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51115 RMDN1
FAM82B
RMD-1
RMD1
regulator of microtubule dynamics 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RMDN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64795 RMND5A
CTLH
GID2
GID2A
RMD5
p44CTLH
required for meiotic nuclear division 5 homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RMND5A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64777 RMND5B
GID2
GID2B
required for meiotic nuclear division 5 homolog B (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RMND5B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10535 RNASEH2A
AGS4
JUNB
RNASEHI
RNHIA
RNHL
ribonuclease H2, subunit A (EC:3.1.26.4) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNASEH2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 567505 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNASEN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27289 RND1
ARHS
RHO6
RHOS
Rho family GTPase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RND1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27246 RNF115
BCA2
ZNF364
ring finger protein 115 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF115 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11342 RNF13
RZF
ring finger protein 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 255488 RNF144B
IBRDC2
PIR2
bA528A10.3
p53RFP
ring finger protein 144B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF144B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81790 RNF170
SNAX1
ring finger protein 170 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF170 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285671 RNF180
ring finger protein 180 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF180 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 221687 RNF182
ring finger protein 182 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF182 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25897 RNF19A
RNF19
ring finger protein 19A, RBR E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF19A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57674 RNF213
ALO17
C17orf27
KIAA1618
MYMY2
MYSTR
NET57
ring finger protein 213 epigallocatechin gallate results in increased expression of RNF213 mRNA increases expression
mRNA 22079256
C045651 57674 RNF213
ALO17
C17orf27
KIAA1618
MYMY2
MYSTR
NET57
ring finger protein 213 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF213 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54476 RNF216
CAHH
TRIAD3
U7I1
UBCE7IP1
ZIN
ring finger protein 216 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF216 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 154214 RNF217
C6orf172
IBRDC1
dJ84N20.1
ring finger protein 217 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF217 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79102 RNF26
ring finger protein 26 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF26 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6049 RNF6
ring finger protein (C3H2C3 type) 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RNF6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51136 RNFT1
ring finger protein, transmembrane 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNFT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8732 RNGTT
CAP1A
HCE
HCE1
hCAP
RNA guanylyltransferase and 5'-phosphatase (EC:2.7.7.50 3.1.3.33) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNGTT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9475 ROCK2
ROCK-II
Rho-associated, coiled-coil containing protein kinase 2 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ROCK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4920 ROR2
BDB
BDB1
NTRKR2
receptor tyrosine kinase-like orphan receptor 2 (EC:2.7.10.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ROR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6100 RP9
PAP-1
retinitis pigmentosa 9 (autosomal dominant) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RP9 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23322 RPGRIP1L
CORS3
FTM
JBTS7
MKS5
NPHP8
RPGRIP1-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPGRIP1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6134 RPL10
AUTSX5
DXS648
DXS648E
L10
NOV
QM
ribosomal protein L10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL10 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6137 RPL13
BBC1
D16S444E
D16S44E
L13
ribosomal protein L13 (EC:3.6.5.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL13 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9045 RPL14
CAG-ISL-7
CTG-B33
L14
RL14
hRL14
ribosomal protein L14 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL14 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6142 RPL18A
L18A
ribosomal protein L18a [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL18A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6157 RPL27A
L27A
ribosomal protein L27a [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL27A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 389435 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL27AP6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6158 RPL28
L28
ribosomal protein L28 (EC:3.6.5.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL28 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6164 RPL34
L34
ribosomal protein L34 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL34 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6167 RPL37
L37
ribosomal protein L37 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL37 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6168 RPL37A
L37A
ribosomal protein L37a epigallocatechin gallate results in decreased expression of RPL37A mRNA decreases expression
mRNA 22079256
C045651 6168 RPL37A
L37A
ribosomal protein L37a [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL37A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 116832 RPL39L
RPL39L1
ribosomal protein L39-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPL39L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6125 RPL5
DBA6
L5
ribosomal protein L5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPL5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54913 RPP25
ribonuclease P/MRP 25kDa subunit (EC:3.1.26.5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPP25 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6189 RPS3A
FTE1
MFTL
S3A
ribosomal protein S3A epigallocatechin gallate results in decreased expression of RPS3A mRNA decreases expression
mRNA 22079256
C045651 6189 RPS3A
FTE1
MFTL
S3A
ribosomal protein S3A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPS3A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6197 RPS6KA3
CLS
HU-3
ISPK-1
MAPKAPK1B
MRX19
RSK
RSK2
S6K-alpha3
p90-RSK2
pp90RSK2
ribosomal protein S6 kinase, 90kDa, polypeptide 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9252 RPS6KA5
MSK1
MSPK1
RLPK
ribosomal protein S6 kinase, 90kDa, polypeptide 5 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26750 RPS6KC1
RPK118
humS6PKh1
ribosomal protein S6 kinase, 52kDa, polypeptide 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 220885 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPSAP15 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 epigallocatechin gallate results in increased expression of RPTOR mRNA increases expression
mRNA 22079256
C045651 57521 RPTOR
KOG1
Mip1
regulatory associated protein of MTOR, complex 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPTOR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285367 RPUSD3
RNA pseudouridylate synthase domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPUSD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84881 RPUSD4
RNA pseudouridylate synthase domain containing 4 (EC:5.4.99.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RPUSD4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10692 RRH
retinal pigment epithelium-derived rhodopsin homolog [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RRH mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23378 RRP8
KIAA0409
ribosomal RNA processing 8, methyltransferase, homolog (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RRP8 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 65117 RSRC2
arginine/serine-rich coiled-coil 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of RSRC2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 219790 RTKN2
PLEKHK1
bA531F24.1
rhotekin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RTKN2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84816 RTN4IP1
NIMP
reticulon 4 interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RTN4IP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25914 RTTN
rotatin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RTTN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80230 RUFY1
RABIP4
ZFYVE12
RUN and FYVE domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RUFY1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 860 RUNX2
AML3
CBF-alpha-1
CBFA1
CCD
CCD1
CLCD
OSF-2
OSF2
PEA2aA
PEBP2aA
runt-related transcription factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RUNX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 112611 RWDD2A
RWDD2
dJ747H23.2
RWD domain containing 2A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RWDD2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6256 RXRA
NR2B1
retinoid X receptor, alpha epigallocatechin gallate results in decreased expression of RXRA mRNA decreases expression
mRNA 20706672
C045651 6274 S100A3
S100E
S100 calcium binding protein A3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of S100A3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64766 S100PBP
S100PBPR
S100P binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of S100PBP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 22908 SACM1L
SAC1
SAC1 suppressor of actin mutations 1-like (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SACM1L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9667 SAFB2
scaffold attachment factor B2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAFB2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54809 SAMD9
C7orf5
DRIF1
NFTC
OEF1
OEF2
sterile alpha motif domain containing 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SAMD9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 219285 SAMD9L
C7orf6
DRIF2
UEF1
sterile alpha motif domain containing 9-like epigallocatechin gallate results in increased expression of SAMD9L mRNA increases expression
mRNA 22079256
C045651 219285 SAMD9L
C7orf6
DRIF2
UEF1
sterile alpha motif domain containing 9-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SAMD9L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10284 SAP18
2HOR0202
SAP18P
Sin3A-associated protein, 18kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAP18 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23328 SASH1
SH3D6A
dJ323M4
dJ323M4.1
SAM and SH3 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SASH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 163786 SASS6
SAS-6
SAS6
spindle assembly 6 homolog (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SASS6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6303 SAT1
DC21
KFSD
KFSDX
SAT
SSAT
SSAT-1
spermidine/spermine N1-acetyltransferase 1 (EC:2.3.1.57) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAT1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 112483 SAT2
SSAT2
spermidine/spermine N1-acetyltransferase family member 2 (EC:2.3.1.57) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SAT2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55776 SAYSD1
C6orf64
SAYSVFN motif domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SAYSD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 66234 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SC4MOL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 286205 SCAI
C9orf126
NET40
suppressor of cancer cell invasion [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCAI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114821 SCAND3
Buster4
ZBED9
ZFP38-L
ZNF305P2
ZNF452
dJ1186N24.3
SCAN domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SCAND3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 49855 SCAPER
ZNF291
Zfp291
S-phase cyclin A-associated protein in the ER [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCAPER mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6319 SCD
FADS5
MSTP008
SCD1
SCDOS
stearoyl-CoA desaturase (delta-9-desaturase) (EC:1.14.19.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SCD mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51540 SCLY
SCL
hSCL
selenocysteine lyase (EC:4.4.1.16) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCLY mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6322 SCML1
sex comb on midleg-like 1 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SCML1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79634 SCRN3
SES3
secernin 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCRN3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83482 SCRT1
SCRT
ZNF898
scratch family zinc finger 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SCRT1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57147 SCYL3
PACE-1
PACE1
SCY1-like 3 (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SCYL3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54949 SDHAF2
C11orf79
PGL2
SDH5
succinate dehydrogenase complex assembly factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SDHAF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8436 SDPR
CAVIN2
PS-p68
SDR
cavin-2
serum deprivation response [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SDPR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6397 SEC14L1
PRELID4A
SEC14L
SEC14-like 1 (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SEC14L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26984 SEC22A
SEC22L2
SEC22 vesicle trafficking protein homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SEC22A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6401 SELE
CD62E
ELAM
ELAM1
ESEL
LECAM2
selectin E epigallocatechin gallate results in decreased expression of SELE mRNA decreases expression
mRNA 16084531
C045651 6404 SELPLG
CD162
CLA
PSGL-1
PSGL1
selectin P ligand [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SELPLG mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 80031 SEMA6D
sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SEMA6D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57337 SENP7
SUMO1/sentrin specific peptidase 7 (EC:3.4.22.68) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SENP7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57190 SEPN1
CFTD
MDRS1
RSMD1
RSS
SELN
selenoprotein N, 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SEPN1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84947 SERAC1
serine active site containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERAC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1992 SERPINB1
EI
ELANH2
LEI
M/NEI
MNEI
PI-2
PI2
serpin peptidase inhibitor, clade B (ovalbumin), member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERPINB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 5272 SERPINB9
CAP-3
CAP3
PI-9
PI9
serpin peptidase inhibitor, clade B (ovalbumin), member 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERPINB9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29950 SERTAD1
SEI1
TRIP-Br1
SERTA domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SERTAD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9792 SERTAD2
Sei-2
TRIP-Br2
SERTA domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SERTAD2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 29946 SERTAD3
RBT1
SERTA domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SERTAD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91404 SESTD1
SOLO
SEC14 and spectrin domains 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SESTD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7536 SF1
BBP
D11S636
MBBP
ZCCHC25
ZFM1
ZNF162
splicing factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10262 SF3B4
AFD1
Hsh49
SAP49
SF3b49
splicing factor 3b, subunit 4, 49kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SF3B4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51460 SFMBT1
RU1
SFMBT
hSFMBT
Scm-like with four mbt domains 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SFMBT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 100169978 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SFRS16 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 733142 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SFRS6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6446 SGK1
SGK
serum/glucocorticoid regulated kinase 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SGK1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 100174271 epigallocatechin gallate results in increased expression of SGK269 mRNA increases expression
mRNA 22079256
C045651 100174271 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGK269 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 259230 SGMS1
MOB
MOB1
SMS1
TMEM23
hmob33
sphingomyelin synthase 1 (EC:2.7.8.27) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGMS1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 151246 SGOL2
SGO2
TRIPIN
shugoshin-like 2 (S. pombe) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGOL2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 63898 SH2D4A
PPP1R38
SH2A
SH2 domain containing 4A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SH2D4A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 285590 SH3PXD2B
FAD49
FTHS
HOFI
KIAA1295
TKS4
TSK4
SH3 and PX domains 2B epigallocatechin gallate results in increased expression of SH3PXD2B mRNA increases expression
mRNA 22079256
C045651 285590 SH3PXD2B
FAD49
FTHS
HOFI
KIAA1295
TKS4
TSK4
SH3 and PX domains 2B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SH3PXD2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6470 SHMT1
CSHMT
SHMT
serine hydroxymethyltransferase 1 (soluble) (EC:2.1.2.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SHMT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8036 SHOC2
SIAA0862
SOC2
SUR8
soc-2 suppressor of clear homolog (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SHOC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51092 SIDT2
SID1 transmembrane family, member 2 epigallocatechin gallate results in increased expression of SIDT2 mRNA increases expression
mRNA 22079256
C045651 51092 SIDT2
SID1 transmembrane family, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SIDT2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 59307 SIGIRR
TIR8
single immunoglobulin and toll-interleukin 1 receptor (TIR) domain [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIGIRR mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 150094 SIK1
MSK
SIK
SNF1LK
salt-inducible kinase 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SIK1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6492 SIM1
bHLHe14
single-minded family bHLH transcription factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26037 SIPA1L1
E6TP1
signal-induced proliferation-associated 1 like 1 epigallocatechin gallate results in increased expression of SIPA1L1 mRNA increases expression
mRNA 22079256
C045651 26037 SIPA1L1
E6TP1
signal-induced proliferation-associated 1 like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIPA1L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57568 SIPA1L2
SPAL2
signal-induced proliferation-associated 1 like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SIPA1L2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51804 SIX4
AREC3
SIX homeobox 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SIX4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6502 SKP2
FBL1
FBXL1
FLB1
p45
S-phase kinase-associated protein 2, E3 ubiquitin protein ligase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SKP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84068 SLC10A7
C4orf13
P7
solute carrier family 10, member 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC10A7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 201232 SLC16A13
MCT13
solute carrier family 16, member 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC16A13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9123 SLC16A3
MCT_3
MCT_4
MCT-3
MCT-4
MCT3
MCT4
solute carrier family 16 (monocarboxylate transporter), member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC16A3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26503 SLC17A5
AST
ISSD
NSD
SD
SIALIN
SIASD
SLD
solute carrier family 17 (acidic sugar transporter), member 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC17A5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8604 SLC25A12
AGC1
ARALAR
solute carrier family 25 (aspartate/glutamate carrier), member 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10165 SLC25A13
ARALAR2
CITRIN
CTLN2
solute carrier family 25 (aspartate/glutamate carrier), member 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83884 SLC25A2
ORC2
ORNT2
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 2 epigallocatechin gallate results in increased expression of SLC25A2 mRNA increases expression
mRNA 22079256
C045651 83884 SLC25A2
ORC2
ORNT2
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC25A2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 788 SLC25A20
CAC
CACT
solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A20 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55186 SLC25A36
PNC2
solute carrier family 25 (pyrimidine nucleotide carrier ), member 36 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC25A36 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 91137 SLC25A46
solute carrier family 25, member 46 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC25A46 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1836 SLC26A2
D5S1708
DTD
DTDST
EDM4
MST153
MSTP157
solute carrier family 26 (anion exchanger), member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC26A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11001 SLC27A2
ACSVL1
FACVL1
FATP2
HsT17226
VLACS
VLCS
hFACVL1
solute carrier family 27 (fatty acid transporter), member 2 (EC:6.2.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC27A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10999 SLC27A4
ACSVL4
FATP4
IPS
solute carrier family 27 (fatty acid transporter), member 4 (EC:6.2.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC27A4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6513 SLC2A1
DYT17
DYT18
DYT9
EIG12
GLUT
GLUT1
GLUT1DS
HTLVR
PED
solute carrier family 2 (facilitated glucose transporter), member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC2A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6515 SLC2A3
GLUT3
solute carrier family 2 (facilitated glucose transporter), member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC2A3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7779 SLC30A1
ZNT1
ZRC1
solute carrier family 30 (zinc transporter), member 1 epigallocatechin gallate inhibits the reaction [zinc chloride results in increased expression of SLC30A1 mRNA] decreases reaction
/ increases expression
mRNA 20471814
C045651 7779 SLC30A1
ZNT1
ZRC1
solute carrier family 30 (zinc transporter), member 1 epigallocatechin gallate results in decreased expression of SLC30A1 mRNA decreases expression
mRNA 20471814
C045651 7779 SLC30A1
ZNT1
ZRC1
solute carrier family 30 (zinc transporter), member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC30A1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7782 SLC30A4
ZNT4
solute carrier family 30 (zinc transporter), member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC30A4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9197 SLC33A1
ACATN
AT-1
AT1
CCHLND
SPG42
solute carrier family 33 (acetyl-CoA transporter), member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC33A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10559 SLC35A1
CDG2F
CMPST
CST
hCST
solute carrier family 35 (CMP-sialic acid transporter), member A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55032 SLC35A5
solute carrier family 35, member A5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35A5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 347734 SLC35B2
PAPST1
SLL
UGTrel4
solute carrier family 35 (adenosine 3'-phospho 5'-phosphosulfate transporter), member B2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35B2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11046 SLC35D2
HFRC1
SQV7L
UGTrel8
hfrc
solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), member D2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35D2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55508 SLC35E3
BLOV1
solute carrier family 35, member E3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35E3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80255 SLC35F5
solute carrier family 35, member F5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35F5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 159371 SLC35G1
C10orf60
TMEM20
solute carrier family 35, member G1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35G1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55089 SLC38A4
ATA3
NAT3
PAAT
solute carrier family 38, member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC38A4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 145389 SLC38A6
NAT-1
solute carrier family 38, member 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC38A6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 153129 SLC38A9
solute carrier family 38, member 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC38A9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27173 SLC39A1
ZIP1
ZIRTL
solute carrier family 39 (zinc transporter), member 1 epigallocatechin gallate results in increased expression of SLC39A1 mRNA increases expression
mRNA 20471814
C045651 57181 SLC39A10
LZT-Hs2
solute carrier family 39 (zinc transporter), member 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC39A10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23516 SLC39A14
LZT-Hs4
NET34
ZIP14
cig19
solute carrier family 39 (zinc transporter), member 14 epigallocatechin gallate inhibits the reaction [IL6 protein results in increased expression of SLC39A14 mRNA] decreases reaction
/ increases expression
mRNA 20471814
C045651 23516 SLC39A14
LZT-Hs4
NET34
ZIP14
cig19
solute carrier family 39 (zinc transporter), member 14 epigallocatechin gallate results in increased expression of SLC39A14 mRNA increases expression
mRNA 16084531
C045651 55630 SLC39A4
AEZ
AWMS2
ZIP4
solute carrier family 39 (zinc transporter), member 4 epigallocatechin gallate results in increased expression of SLC39A4 mRNA increases expression
mRNA 20471814
C045651 30061 SLC40A1
FPN1
HFE4
IREG1
MST079
MTP1
SLC11A3
solute carrier family 40 (iron-regulated transporter), member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC40A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84102 SLC41A2
SLC41A1-L1
solute carrier family 41 (magnesium transporter), member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC41A2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29015 SLC43A3
EEG1
FOAP-13
PRO1659
SEEEG-1
solute carrier family 43, member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC43A3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 283537 SLC46A3
FKSG16
solute carrier family 46, member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC46A3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9497 SLC4A7
NBC2
NBC3
NBCN1
SBC2
SLC4A6
solute carrier family 4, sodium bicarbonate cotransporter, member 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC4A7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 200931 SLC51A
OSTA
OSTalpha
solute carrier family 51, alpha subunit epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 200931 SLC51A
OSTA
OSTalpha
solute carrier family 51, alpha subunit epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of SLC51A mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 123264 SLC51B
OSTB
OSTBETA
solute carrier family 51, beta subunit epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 123264 SLC51B
OSTB
OSTBETA
solute carrier family 51, beta subunit epigallocatechin gallate inhibits the reaction [GW 4064 results in increased expression of SLC51B mRNA] decreases reaction
/ increases expression
mRNA 22178739
C045651 6526 SLC5A3
SMIT
SMIT1
SMIT2
solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC5A3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8884 SLC5A6
SMVT
solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC5A6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6540 SLC6A13
GAT-2
GAT2
GAT3
solute carrier family 6 (neurotransmitter transporter), member 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC6A13 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6533 SLC6A6
TAUT
solute carrier family 6 (neurotransmitter transporter), member 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC6A6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6535 SLC6A8
CCDS1
CRT
CRTR
CT1
solute carrier family 6 (neurotransmitter transporter), member 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC6A8 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84138 SLC7A6OS
solute carrier family 7, member 6 opposite strand [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SLC7A6OS mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 28232 SLCO3A1
OATP-D
OATP3A1
OATPD
SLC21A11
solute carrier organic anion transporter family, member 3A1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLCO3A1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7871 SLMAP
SLAP
sarcolemma associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLMAP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 128710 SLX4IP
C20orf94
bA204H22.1
bA254M13.1
dJ1099D15.3
SLX4 interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLX4IP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4086 SMAD1
BSP-1
BSP1
JV4-1
JV41
MADH1
MADR1
SMAD family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMAD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4088 SMAD3
HSPC193
HsT17436
JV15-2
LDS1C
LDS3
MADH3
SMAD family member 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMAD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4091 SMAD6
AOVD2
HsT17432
MADH6
MADH7
SMAD family member 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMAD6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6594 SMARCA1
ISWI
NURF140
SNF2L
SNF2L1
SNF2LB
SNF2LT
SWI
SWI2
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6595 SMARCA2
BAF190
BRM
NCBRS
SNF2
SNF2L2
SNF2LA
SWI2
Sth1p
hBRM
hSNF2a
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCA2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56916 SMARCAD1
ADERM
ETL1
HEL1
SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1 (EC:3.6.4.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCAD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50485 SMARCAL1
HARP
HHARP
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCAL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6598 SMARCB1
BAF47
INI1
MRD15
RDT
RTPS1
SNF5
SNF5L1
Sfh1p
Snr1
hSNFS
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMARCB1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10592 SMC2
CAP-E
CAPE
SMC-2
SMC2L1
structural maintenance of chromosomes 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79677 SMC6
SMC-6
SMC6L1
hSMC6
structural maintenance of chromosomes 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMC6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56935 SMCO4
C11orf75
FN5
single-pass membrane protein with coiled-coil domains 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMCO4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57150 SMIM8
C6orf162
dJ102H19.2
small integral membrane protein 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMIM8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6607 SMN2
BCD541
C-BCD541
GEMIN1
SMNC
TDRD16B
survival of motor neuron 2, centromeric epigallocatechin gallate affects the splicing of and results in increased expression of SMN2 mRNA alternative form affects splicing
/ increases expression
mRNA 17962980
C045651 6607 SMN2
BCD541
C-BCD541
GEMIN1
SMNC
TDRD16B
survival of motor neuron 2, centromeric epigallocatechin gallate results in increased expression of SMN2 protein increases expression
protein 17962980
C045651 54498 SMOX
C20orf16
PAO
PAO-1
PAOH1
SMO
spermine oxidase (EC:1.5.3.16) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SMOX mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23583 SMUG1
FDG
HMUDG
UNG3
single-strand-selective monofunctional uracil-DNA glycosylase 1 epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of SMUG1 mRNA] decreases expression
/ decreases reaction
mRNA 22079256
C045651 23583 SMUG1
FDG
HMUDG
UNG3
single-strand-selective monofunctional uracil-DNA glycosylase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SMUG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6615 SNAI1
SLUGH2
SNA
SNAH
SNAIL
SNAIL1
dJ710H13.1
snail family zinc finger 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNAI1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23557 SNAPIN
BLOC1S7
BLOS7
SNAPAP
SNAP-associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNAPIN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85028 SNHG12
C1orf79
LINC00100
NCRNA00100
RP4-669K10.5
small nucleolar RNA host gene 12 (non-protein coding) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNHG12 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79753 SNIP1
PMRED
Smad nuclear interacting protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNIP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677792 SNORA1
ACA1
small nucleolar RNA, H/ACA box 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677802 SNORA14B
ACA14b
small nucleolar RNA, H/ACA box 14B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA14B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677811 SNORA28
ACA28
small nucleolar RNA, H/ACA box 28 epigallocatechin gallate results in decreased expression of SNORA28 mRNA decreases expression
mRNA 22079256
C045651 677811 SNORA28
ACA28
small nucleolar RNA, H/ACA box 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA28 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677812 SNORA29
ACA29
small nucleolar RNA, H/ACA box 29 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA29 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677793 SNORA2A
ACA2A
small nucleolar RNA, H/ACA box 2A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA2A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 594839 SNORA33
ACA33
small nucleolar RNA, H/ACA box 33 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA33 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 619569 SNORA41
ACA41
small nucleolar RNA, H/ACA box 41 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA41 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677826 SNORA45
ACA3-2
small nucleolar RNA, H/ACA box 45 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA45 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677833 SNORA54
ACA54
small nucleolar RNA, H/ACA box 54 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA54 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677834 SNORA55
ACA55
small nucleolar RNA, H/ACA box 55 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA55 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 654319 SNORA5A
ACA5
ACA5A/B/C
small nucleolar RNA, H/ACA box 5A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA5A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677796 SNORA5C
ACA5c
small nucleolar RNA, H/ACA box 5C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA5C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 574040 SNORA6
ACA6
small nucleolar RNA, H/ACA box 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677837 SNORA60
ACA60
small nucleolar RNA, H/ACA box 60 epigallocatechin gallate results in decreased expression of SNORA60 mRNA decreases expression
mRNA 22079256
C045651 677837 SNORA60
ACA60
small nucleolar RNA, H/ACA box 60 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA60 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26779 SNORA69
RNU69
U69
U69A
small nucleolar RNA, H/ACA box 69 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA69 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26821 SNORA74A
RNU19
U19
small nucleolar RNA, H/ACA box 74A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA74A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 654321 SNORA75
U23
small nucleolar RNA, H/ACA box 75 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORA75 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26765 SNORD12C
E2
E2-1
E3
RNU106
SNORD106
U106
small nucleolar RNA, C/D box 12C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD12C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6077 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD13P2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6079 SNORD15A
RNU15A
SNORNA
U15A
small nucleolar RNA, C/D box 15A epigallocatechin gallate results in decreased expression of SNORD15A mRNA decreases expression
mRNA 22079256
C045651 6079 SNORD15A
RNU15A
SNORNA
U15A
small nucleolar RNA, C/D box 15A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD15A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 677848 SNORD1A
R38A
snR38A
small nucleolar RNA, C/D box 1A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD1A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6082 SNORD20
RNU20
U20
small nucleolar RNA, C/D box 20 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD20 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6083 SNORD21
RNU21
U21
small nucleolar RNA, C/D box 21 epigallocatechin gallate results in decreased expression of SNORD21 mRNA decreases expression
mRNA 22079256
C045651 6083 SNORD21
RNU21
U21
small nucleolar RNA, C/D box 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD21 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9300 SNORD28
RNU28
U28
small nucleolar RNA, C/D box 28 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD28 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9299 SNORD30
RNU30
U30
small nucleolar RNA, C/D box 30 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD30 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 94162 SNORD38A
RNU38A
U38A
small nucleolar RNA, C/D box 38A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD38A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 94163 SNORD38B
RNU38B
U38B
small nucleolar RNA, C/D box 38B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD38B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26809 SNORD42A
RNU42A
U42
U42A
small nucleolar RNA, C/D box 42A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD42A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26808 SNORD42B
RNU42B
U42B
small nucleolar RNA, C/D box 42B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD42B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26807 SNORD43
RNU43
U43
small nucleolar RNA, C/D box 43 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD43 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26806 SNORD44
RNU44
U44
small nucleolar RNA, C/D box 44 epigallocatechin gallate results in decreased expression of SNORD44 mRNA decreases expression
mRNA 22079256
C045651 26806 SNORD44
RNU44
U44
small nucleolar RNA, C/D box 44 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD44 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 692085 SNORD45C
U45C
small nucleolar RNA, C/D box 45C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD45C mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26800 SNORD49A
RNU49
U49
U49A
small nucleolar RNA, C/D box 49A epigallocatechin gallate results in decreased expression of SNORD49A mRNA decreases expression
mRNA 22079256
C045651 26800 SNORD49A
RNU49
U49
U49A
small nucleolar RNA, C/D box 49A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD49A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 692087 SNORD49B
U49B
small nucleolar RNA, C/D box 49B epigallocatechin gallate results in decreased expression of SNORD49B mRNA decreases expression
mRNA 22079256
C045651 692087 SNORD49B
U49B
small nucleolar RNA, C/D box 49B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD49B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26773 SNORD4A
RNU101A
Z17A
mgh18S-121
small nucleolar RNA, C/D box 4A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD4A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26772 SNORD4B
RNU101B
Z17B
small nucleolar RNA, C/D box 4B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD4B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26799 SNORD50A
RNU50
U50
small nucleolar RNA, C/D box 50A epigallocatechin gallate results in decreased expression of SNORD50A mRNA decreases expression
mRNA 22079256
C045651 26799 SNORD50A
RNU50
U50
small nucleolar RNA, C/D box 50A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD50A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 692088 SNORD50B
U50'
U50B
small nucleolar RNA, C/D box 50B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD50B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26798 SNORD51
RNU51
U51
small nucleolar RNA, C/D box 51 epigallocatechin gallate results in decreased expression of SNORD51 mRNA decreases expression
mRNA 22079256
C045651 26798 SNORD51
RNU51
U51
small nucleolar RNA, C/D box 51 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD51 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26796 SNORD53
RNU53
U53
small nucleolar RNA, C/D box 53 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD53 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26795 SNORD54
RNU54
U54
small nucleolar RNA, C/D box 54 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD54 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26811 SNORD55
RNU39
RNU55
SNORD39
U39
U55
small nucleolar RNA, C/D box 55 epigallocatechin gallate results in decreased expression of SNORD55 mRNA decreases expression
mRNA 22079256
C045651 26811 SNORD55
RNU39
RNU55
SNORD39
U39
U55
small nucleolar RNA, C/D box 55 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD55 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26791 SNORD58A
RNU58A
U58a
small nucleolar RNA, C/D box 58A epigallocatechin gallate results in decreased expression of SNORD58A mRNA decreases expression
mRNA 22079256
C045651 26791 SNORD58A
RNU58A
U58a
small nucleolar RNA, C/D box 58A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD58A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 692075 SNORD6
mgh28S-2412
small nucleolar RNA, C/D box 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD6 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26785 SNORD63
RNU63
U63
small nucleolar RNA, C/D box 63 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD63 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8944 SNORD73A
RNU73
RNU73A
U73
U73a
small nucleolar RNA, C/D box 73A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD73A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 619498 SNORD74
U74
Z18
small nucleolar RNA, C/D box 74 epigallocatechin gallate results in decreased expression of SNORD74 mRNA decreases expression
mRNA 22079256
C045651 619498 SNORD74
U74
Z18
small nucleolar RNA, C/D box 74 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD74 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 692195 SNORD75
U75
small nucleolar RNA, C/D box 75 epigallocatechin gallate results in decreased expression of SNORD75 mRNA decreases expression
mRNA 22079256
C045651 692195 SNORD75
U75
small nucleolar RNA, C/D box 75 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD75 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 692197 SNORD77
U77
small nucleolar RNA, C/D box 77 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD77 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 692198 SNORD78
U78
small nucleolar RNA, C/D box 78 epigallocatechin gallate results in decreased expression of SNORD78 mRNA decreases expression
mRNA 22079256
C045651 692198 SNORD78
U78
small nucleolar RNA, C/D box 78 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD78 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 26770 SNORD79
RNU103
U79
Z22
small nucleolar RNA, C/D box 79 epigallocatechin gallate results in decreased expression of SNORD79 mRNA decreases expression
mRNA 22079256
C045651 26770 SNORD79
RNU103
U79
Z22
small nucleolar RNA, C/D box 79 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD79 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25826 SNORD82
RNU82
U82
Z25
small nucleolar RNA, C/D box 82 epigallocatechin gallate results in decreased expression of SNORD82 mRNA decreases expression
mRNA 22079256
C045651 25826 SNORD82
RNU82
U82
Z25
small nucleolar RNA, C/D box 82 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD82 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 116938 SNORD83B
RNU83B
U83B
small nucleolar RNA, C/D box 83B epigallocatechin gallate results in decreased expression of SNORD83B mRNA decreases expression
mRNA 22079256
C045651 116938 SNORD83B
RNU83B
U83B
small nucleolar RNA, C/D box 83B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD83B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 619570 SNORD95
U95
small nucleolar RNA, C/D box 95 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD95 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 619571 SNORD96A
U96A
small nucleolar RNA, C/D box 96A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SNORD96A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9410 SNRNP40
40K
HPRP8BP
PRP8BP
PRPF8BP
RP11-490K7.3
SPF38
WDR57
small nuclear ribonucleoprotein 40kDa (U5) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNRNP40 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10073 SNUPN
KPNBL
RNUT1
Snurportin1
snurportin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNUPN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23161 SNX13
RGS-PX1
sorting nexin 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28966 SNX24
PRO1284
sorting nexin 24 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX24 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83891 SNX25
SBBI31
sorting nexin 25 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX25 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 92017 SNX29
A-388D4.1
RUNDC2A
sorting nexin 29 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX29 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8723 SNX4
ATG24B
sorting nexin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29886 SNX8
Mvp1
sorting nexin 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51429 SNX9
SDP1
SH3PX1
SH3PXD3A
WISP
sorting nexin 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) SOD2 protein inhibits the reaction [epigallocatechin gallate analog results in increased abundance of Reactive Oxygen Species] decreases reaction
/ increases abundance
protein 16115949
C045651 6649 SOD3
EC-SOD
superoxide dismutase 3, extracellular (EC:1.15.1.1) epigallocatechin gallate results in decreased expression of SOD3 mRNA decreases expression
mRNA 20706672
C045651 6655 SOS2
son of sevenless homolog 2 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SOS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65124 SOWAHC
ANKRD57
C2orf26
sosondowah ankyrin repeat domain family member C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SOWAHC mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6672 SP100
lysp100b
SP100 nuclear antigen [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SP100 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79582 SPAG16
PF20
WDR29
sperm associated antigen 16 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPAG16 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 619455 SPANXA2-OT1
CXorf18
SPANXA2 overlapping transcript 1 (non-protein coding) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPANXA2-OT1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6683 SPAST
ADPSP
FSP2
SPG4
spastin (EC:3.6.4.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPAST mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 147841 SPC24
SPBC24
SPC24, NDC80 kinetochore complex component [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPC24 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60559 SPCS3
PRO3567
SPC22/23
SPC3
YLR066W
signal peptidase complex subunit 3 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPCS3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80208 SPG11
KIAA1840
spastic paraplegia 11 (autosomal recessive) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPG11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56907 SPIRE1
Spir-1
spire-type actin nucleation factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPIRE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 200734 SPRED2
Spred-2
sprouty-related, EVH1 domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPRED2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81848 SPRY4
HH17
sprouty homolog 4 (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPRY4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84926 SPRYD3
SPRY domain containing 3 (EC:2.7.1.112) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPRYD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9517 SPTLC2
HSN1C
LCB2
LCB2A
NSAN1C
SPT2
hLCB2a
serine palmitoyltransferase, long chain base subunit 2 (EC:2.3.1.50) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SPTLC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144108 SPTY2D1
SPT2, Suppressor of Ty, domain containing 1 (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SPTY2D1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6713 SQLE
squalene epoxidase (EC:1.14.13.132) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SQLE mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 58472 SQRDL
PRO1975
sulfide quinone reductase-like (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SQRDL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8878 SQSTM1
A170
OSIL
PDB3
ZIP3
p60
p62
p62B
sequestosome 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SQSTM1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55133 SRBD1
S1 RNA binding domain 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRBD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6716 SRD5A2
steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) (EC:1.3.1.22) epigallocatechin gallate results in decreased expression of SRD5A2 mRNA decreases expression
mRNA 20706672
C045651 6720 SREBF1
SREBP-1c
SREBP1
bHLHd1
sterol regulatory element binding transcription factor 1 epigallocatechin gallate results in decreased expression of SREBF1 mRNA decreases expression
mRNA 20816778
C045651 57522 SRGAP1
ARHGAP13
SLIT-ROBO Rho GTPase activating protein 1 epigallocatechin gallate results in increased expression of SRGAP1 mRNA increases expression
mRNA 22079256
C045651 57522 SRGAP1
ARHGAP13
SLIT-ROBO Rho GTPase activating protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRGAP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23380 SRGAP2
ARHGAP34
FNBP2
SRGAP2A
SRGAP3
SLIT-ROBO Rho GTPase activating protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRGAP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6717 SRI
CP-22
CP22
SCN
V19
sorcin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRI mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6733 SRPK2
SFRSK2
SRSF protein kinase 2 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SRPK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10250 SRRM1
160-KD
POP101
SRM160
serine/arginine repetitive matrix 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SRRM1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23635 SSBP2
HSPC116
SOSS-B2
single-stranded DNA binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSBP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23648 SSBP3
CSDP
SSDP
SSDP1
single stranded DNA binding protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSBP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 619518 SSBP3-AS1
C1orf191
MST128
SSBP3 antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SSBP3-AS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54434 SSH1
SSH1L
slingshot protein phosphatase 1 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSH1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85464 SSH2
SSH-2
SSH-2L
slingshot protein phosphatase 2 (EC:3.1.3.16 3.1.3.48) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SSH2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6749 SSRP1
FACT
FACT80
T160
structure specific recognition protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SSRP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6764 ST5
DENND2B
HTS1
p126
suppression of tumorigenicity 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ST5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10610 ST6GALNAC2
SAITL1
SIAT7
SIAT7B
SIATL1
ST6GalNAII
STHM
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 (EC:2.4.99.7) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ST6GALNAC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81849 ST6GALNAC5
SIAT7E
ST6GalNAcV
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ST6GALNAC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10274 STAG1
SA1
SCC3A
stromal antigen 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10735 STAG2
SA-2
SA2
SCC3B
bA517O1.1
stromal antigen 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAG2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10254 STAM2
Hbp
STAM2A
STAM2B
signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAM2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57559 STAMBPL1
ALMalpha
AMSH-FP
AMSH-LP
bA399O19.2
STAM binding protein-like 1 (EC:3.1.2.15) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAMBPL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90627 STARD13
ARHGAP37
DLC2
GT650
LINC00464
StAR-related lipid transfer (START) domain containing 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STARD13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6772 STAT1
CANDF7
ISGF-3
STAT91
signal transducer and activator of transcription 1, 91kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6773 STAT2
ISGF-3
P113
STAT113
signal transducer and activator of transcription 2, 113kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6774 STAT3
APRF
HIES
signal transducer and activator of transcription 3 (acute-phase response factor) epigallocatechin gallate results in decreased expression of STAT3 mRNA decreases expression
mRNA 20816778
C045651 27067 STAU2
39K2
39K3
staufen double-stranded RNA binding protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STAU2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8614 STC2
STC-2
STCRP
stanniocalcin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of STC2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6793 STK10
LOK
PRO2729
serine/threonine kinase 10 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9263 STK17A
DRAK1
serine/threonine kinase 17a (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK17A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6788 STK3
KRS1
MST2
serine/threonine kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 27148 STK36
FU
serine/threonine kinase 36 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK36 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11329 STK38
NDR
NDR1
serine/threonine kinase 38 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK38 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23012 STK38L
NDR2
serine/threonine kinase 38 like (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK38L mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6789 STK4
KRS2
MST1
TIIAC
YSK3
serine/threonine kinase 4 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83931 STK40
SHIK
SgK495
serine/threonine kinase 40 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STK40 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90529 STPG1
C1orf201
MAPO2
sperm-tail PG-rich repeat containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STPG1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 92335 STRADA
LYK5
NY-BR-96
PMSE
STRAD
Stlk
STE20-related kinase adaptor alpha [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STRADA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55437 STRADB
ALS2CR2
CALS-21
ILPIP
ILPIPA
PAPK
STE20-related kinase adaptor beta [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STRADB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6801 STRN
SG2NA
striatin, calmodulin binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STRN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8676 STX11
FHL4
HLH4
HPLH4
syntaxin 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55014 STX17
syntaxin 17 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX17 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6810 STX4
STX4A
p35-2
syntaxin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8417 STX7
syntaxin 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STX7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6814 STXBP3
MUNC18-3
MUNC18C
PSP
UNC-18C
syntaxin binding protein 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STXBP3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 134957 STXBP5
LGL3
LLGL3
Nbla04300
syntaxin binding protein 5 (tomosyn) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STXBP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29091 STXBP6
amisyn
syntaxin binding protein 6 (amisyn) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of STXBP6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 387082 SUMO4
IDDM5
SMT3H4
SUMO-4
dJ281H8.4
small ubiquitin-like modifier 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SUMO4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6821 SUOX
sulfite oxidase (EC:1.8.3.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SUOX mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8464 SUPT3H
SPT3
SPT3L
suppressor of Ty 3 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SUPT3H mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 440423 SUZ12P1
SUZ12P
suppressor of zeste 12 homolog pseudogene 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SUZ12P1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54823 SWT1
C1orf26
HsSwt1
SWT1 RNA endoribonuclease homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SWT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 256126 SYCE2
CESC1
synaptonemal complex central element protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SYCE2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25949 SYF2
CBPIN
NTC31
P29
fSAP29
SYF2 pre-mRNA-splicing factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of SYF2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 81493 SYNC
SYNC1
SYNCOILIN
syncoilin, intermediate filament protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYNC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23224 SYNE2
EDMD5
NUA
NUANCE
Nesp2
Nesprin-2
SYNE-2
TROPH
spectrin repeat containing, nuclear envelope 2 epigallocatechin gallate results in increased expression of SYNE2 mRNA increases expression
mRNA 22079256
C045651 23224 SYNE2
EDMD5
NUA
NUANCE
Nesp2
Nesprin-2
SYNE-2
TROPH
spectrin repeat containing, nuclear envelope 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYNE2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8871 SYNJ2
INPP5H
synaptojanin 2 (EC:3.1.3.36) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYNJ2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 255928 SYT14
SCAR11
sytXIV
synaptotagmin XIV [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYT14 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 94121 SYTL4
SLP4
synaptotagmin-like 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SYTL4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51204 TACO1
CCDC44
translational activator of mitochondrially encoded cytochrome c oxidase I [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TACO1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4070 TACSTD2
EGP-1
EGP1
GA733-1
GA7331
GP50
M1S1
TROP2
tumor-associated calcium signal transducer 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TACSTD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6871 TADA2A
ADA2
ADA2A
TADA2L
hADA2
transcriptional adaptor 2A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TADA2A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9014 TAF1B
MGC:9349
RAF1B
RAFI63
SL1
TAFI63
TATA box binding protein (TBP)-associated factor, RNA polymerase I, B, 63kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TAF1B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79101 TAF1D
JOSD3
RAFI41
TAF(I)41
TAFI41
TATA box binding protein (TBP)-associated factor, RNA polymerase I, D, 41kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TAF1D mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 85461 TANC1
ROLSB
TANC
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TANC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26115 TANC2
ROLSA
rols
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 epigallocatechin gallate results in increased expression of TANC2 mRNA increases expression
mRNA 22079256
C045651 26115 TANC2
ROLSA
rols
tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TANC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79613 TANGO6
TMCO7
transport and golgi organization 6 homolog (Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TANGO6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10010 TANK
I-TRAF
ITRAF
TRAF2
TRAF family member-associated NFKB activator epigallocatechin gallate results in decreased expression of TANK mRNA decreases expression
mRNA 16084531
C045651 51347 TAOK3
DPK
JIK
MAP3K18
TAO kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TAOK3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80222 TARS2
TARSL1
thrRS
threonyl-tRNA synthetase 2, mitochondrial (putative) (EC:6.1.1.3) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TARS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 50832 TAS2R4
T2R4
taste receptor, type 2, member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TAS2R4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55617 TASP1
C20orf13
dJ585I14.2
taspase, threonine aspartase, 1 (EC:3.4.25.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TASP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83874 TBC1D10A
EPI64
TBC1D10
dJ130H16.1
dJ130H16.2
TBC1 domain family, member 10A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D10A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23232 TBC1D12
TBC1 domain family, member 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55296 TBC1D19
TBC1 domain family, member 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55357 TBC1D2
PARIS-1
PARIS1
TBC1D2A
TBC1 domain family, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 221322 TBC1D32
BROMI
C6orf170
C6orf171
bA301B7.2
bA57L9.1
dJ310J6.1
TBC1 domain family, member 32 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBC1D32 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79718 TBL1XR1
C21
DC42
IRA1
TBLR1
transducin (beta)-like 1 X-linked receptor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBL1XR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10716 TBR1
TBR-1
TES-56
T-box, brain, 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TBR1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9096 TBX18
T-box 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TBX18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6926 TBX3
TBX3-ISO
UMS
XHL
T-box 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TBX3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 90843 TCEAL8
transcription elongation factor A (SII)-like 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCEAL8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 127428 TCEANC2
C1orf83
RP4-758J24.3
transcription elongation factor A (SII) N-terminal and central domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCEANC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6925 TCF4
E2-2
ITF-2
ITF2
PTHS
SEF-2
SEF2
SEF2-1
SEF2-1A
SEF2-1B
TCF-4
bHLHb19
transcription factor 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCF4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55346 TCP11L1
dJ85M6.3
t-complex 11, testis-specific-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TCP11L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55775 TDP1
tyrosyl-DNA phosphodiesterase 1 (EC:3.1.4.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TDP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81550 TDRD3
tudor domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TDRD3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23424 TDRD7
CATC4
CTRCT36
PCTAIRE2BP
RP11-508D10.1
TRAP
tudor domain containing 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TDRD7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7004 TEAD4
EFTR-2
RTEF1
TCF13L1
TEF-3
TEF3
TEFR-1
hRTEF-1B
TEA domain family member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEAD4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7006 TEC
PSCTK4
tec protein tyrosine kinase (EC:2.7.10.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEC mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79736 TEFM
C17orf42
transcription elongation factor, mitochondrial epigallocatechin gallate results in decreased expression of TEFM mRNA decreases expression
mRNA 22079256
C045651 79736 TEFM
C17orf42
transcription elongation factor, mitochondrial [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEFM mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54386 TERF2IP
DRIP5
RAP1
telomeric repeat binding factor 2, interacting protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TERF2IP mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7015 TERT
CMM9
DKCA2
DKCB4
EST2
PFBMFT1
TCS1
TP2
TRT
hEST2
hTRT
telomerase reverse transcriptase (EC:2.7.7.49) epigallocatechin gallate results in decreased expression of TERT mRNA decreases expression
mRNA 18581255
20706672
C045651 7015 TERT
CMM9
DKCA2
DKCB4
EST2
PFBMFT1
TCS1
TP2
TRT
hEST2
hTRT
telomerase reverse transcriptase (EC:2.7.7.49) epigallocatechin gallate results in decreased expression of TERT protein decreases expression
protein 18581255
C045651 54790 TET2
KIAA1546
MDS
tet methylcytosine dioxygenase 2 (EC:1.14.11.n2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TET2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55852 TEX2
HT008
TMEM96
testis expressed 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEX2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 93081 TEX30
C13orf27
testis expressed 30 epigallocatechin gallate results in decreased expression of TEX30 mRNA decreases expression
mRNA 22079256
C045651 93081 TEX30
C13orf27
testis expressed 30 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TEX30 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7019 TFAM
MTTF1
MTTFA
TCF6
TCF6L1
TCF6L2
TCF6L3
transcription factor A, mitochondrial [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TFAM mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51106 TFB1M
CGI75
mtTFB
mtTFB1
transcription factor B1, mitochondrial (EC:2.1.1.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TFB1M mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7024 TFCP2
LBP1C
LSF
LSF1D
SEF
TFCP2C
transcription factor CP2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TFCP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7029 TFDP2
DP2
transcription factor Dp-2 (E2F dimerization partner 2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TFDP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7045 TGFBI
BIGH3
CDB1
CDG2
CDGG1
CSD
CSD1
CSD2
CSD3
EBMD
LCD1
transforming growth factor, beta-induced, 68kDa [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TGFBI mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7046 TGFBR1
AAT5
ACVRLK4
ALK-5
ALK5
LDS1A
LDS2A
MSSE
SKR4
TGFR-1
transforming growth factor, beta receptor 1 (EC:2.7.11.30) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TGFBR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7049 TGFBR3
BGCAN
betaglycan
transforming growth factor, beta receptor III [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TGFBR3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7050 TGIF1
HPE4
TGIF
TGFB-induced factor homeobox 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TGIF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 168451 THAP5
THAP domain containing 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of THAP5 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 100286461 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of THEM2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9984 THOC1
HPR1
P84
P84N5
THO complex 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of THOC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57187 THOC2
CXorf3
THO2
dJ506G2.1
hTREX120
THO complex 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of THOC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 374500 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of THSD1P1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 29087 THYN1
MDS012
MY105
THY28
THY28KD
thymocyte nuclear protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of THYN1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7072 TIA1
TIA-1
WDM
TIA1 cytotoxic granule-associated RNA binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TIA1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7074 TIAM1
T-cell lymphoma invasion and metastasis 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TIAM1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 166815 TIGD2
tigger transposable element derived 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TIGD2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7078 TIMP3
HSMRK222
K222
K222TA2
SFD
TIMP metallopeptidase inhibitor 3 [Sulindac co-treated with epigallocatechin gallate] results in decreased expression of TIMP3 mRNA affects cotreatment
/ decreases expression
mRNA 12628509
C045651 26277 TINF2
DKCA3
TIN2
TERF1 (TRF1)-interacting nuclear factor 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TINF2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9414 TJP2
C9DUPq21.11
DFNA51
DUP9q21.11
X104
ZO2
tight junction protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TJP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7084 TK2
MTDPS2
MTTK
thymidine kinase 2, mitochondrial (EC:2.7.1.21) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TK2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 116238 TLCD1
TLC domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLCD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7088 TLE1
ESG
ESG1
GRG1
transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLE1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7091 TLE4
BCE-1
BCE1
E(spI)
ESG
ESG4
GRG4
transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLE4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7098 TLR3
CD283
IIAE2
toll-like receptor 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TLR3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4071 TM4SF1
H-L6
L6
M3S1
TAAL6
transmembrane 4 L six family member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TM4SF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23023 TMCC1
transmembrane and coiled-coil domain family 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMCC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8834 TMEM11
C17orf35
PM1
PMI
transmembrane protein 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TMEM11 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84216 TMEM117
transmembrane protein 117 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM117 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 144404 TMEM120B
transmembrane protein 120B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM120B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83935 TMEM133
transmembrane protein 133 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM133 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65084 TMEM135
PMP52
transmembrane protein 135 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM135 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51524 TMEM138
transmembrane protein 138 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM138 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 28978 TMEM14A
C6orf73
transmembrane protein 14A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM14A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 201799 TMEM154
transmembrane protein 154 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM154 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84187 TMEM164
bB360B22.3
transmembrane protein 164 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM164 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55858 TMEM165
CDG2K
FT27
GDT1
TMPT27
TPARL
transmembrane protein 165 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM165 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 66074 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM167 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 134285 TMEM171
PRP2
transmembrane protein 171 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM171 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80775 TMEM177
transmembrane protein 177 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM177 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55266 TMEM19
transmembrane protein 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 147007 TMEM199
C17orf32
transmembrane protein 199 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM199 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23670 TMEM2
transmembrane protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85019 TMEM241
C18orf45
hVVT
transmembrane protein 241 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM241 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 140738 TMEM37
PR
PR1
transmembrane protein 37 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM37 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 148534 TMEM56
transmembrane protein 56 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM56 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85025 TMEM60
C7orf35
transmembrane protein 60 epigallocatechin gallate results in decreased expression of TMEM60 mRNA decreases expression
mRNA 22079256
C045651 85025 TMEM60
C7orf35
transmembrane protein 60 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM60 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80021 TMEM62
transmembrane protein 62 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM62 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91147 TMEM67
JBTS6
MECKELIN
MKS3
NPHP11
TNEM67
transmembrane protein 67 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMEM67 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 83857 TMTC1
OLF
TMTC1A
transmembrane and tetratricopeptide repeat containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TMTC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56255 TMX4
DJ971N18.2
PDIA14
TXNDC13
thioredoxin-related transmembrane protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TMX4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of TNF mRNA] decreases reaction
/ increases expression
mRNA 19557821
C045651 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor epigallocatechin gallate inhibits the reaction [Glucose results in increased expression of TNF protein] decreases reaction
/ increases expression
protein 19557821
C045651 7127 TNFAIP2
B94
EXOC3L3
tumor necrosis factor, alpha-induced protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFAIP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25816 TNFAIP8
GG2-1
MDC-3.13
NDED
SCC-S2
SCCS2
tumor necrosis factor, alpha-induced protein 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFAIP8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8793 TNFRSF10D
CD264
DCR2
TRAIL-R4
TRAILR4
TRUNDD
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TNFRSF10D mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51330 TNFRSF12A
CD266
FN14
TWEAKR
tumor necrosis factor receptor superfamily, member 12A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFRSF12A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55504 TNFRSF19
TAJ
TAJ-alpha
TRADE
TROY
tumor necrosis factor receptor superfamily, member 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFRSF19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7132 TNFRSF1A
CD120a
FPF
MS5
TBP1
TNF-R
TNF-R-I
TNF-R55
TNFAR
TNFR1
TNFR1-d2
TNFR55
TNFR60
p55
p55-R
p60
tumor necrosis factor receptor superfamily, member 1A epigallocatechin gallate results in decreased expression of TNFRSF1A mRNA decreases expression
mRNA 20816778
C045651 3604 TNFRSF9
4-1BB
CD137
CDw137
ILA
tumor necrosis factor receptor superfamily, member 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFRSF9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 epigallocatechin gallate results in decreased expression of TNFSF10 mRNA decreases expression
mRNA 16084531
C045651 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNFSF10 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23043 TNIK
TRAF2 and NCK interacting kinase (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNIK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23112 TNRC6B
trinucleotide repeat containing 6B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNRC6B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64759 TNS3
TEM6
TENS1
tensin 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TNS3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10140 TOB1
APRO6
PIG49
TOB
TROB
TROB1
transducer of ERBB2, 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TOB1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9804 TOMM20
MAS20
MOM19
TOM20
translocase of outer mitochondrial membrane 20 homolog (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TOMM20 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7153 TOP2A
TOP2
TP2A
topoisomerase (DNA) II alpha 170kDa (EC:5.99.1.3) epigallocatechin gallate results in increased expression of TOP2A mRNA increases expression
mRNA 18851785
C045651 7155 TOP2B
TOPIIB
top2beta
topoisomerase (DNA) II beta 180kDa (EC:5.99.1.3) epigallocatechin gallate results in increased expression of TOP2B mRNA increases expression
mRNA 18851785
C045651 9760 TOX
TOX1
thymocyte selection-associated high mobility group box [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TOX mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 15795422
C045651 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 epigallocatechin gallate results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein increases activity
/ increases expression
/ increases phosphorylation
protein 15764647
C045651 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 epigallocatechin gallate results in increased expression of and results in increased phosphorylation of TP53 protein increases expression
/ increases phosphorylation
protein 15657356
19406223
C045651 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 mRNA affects the susceptibility to epigallocatechin gallate affects response to substance
mRNA 19406223
C045651 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 protein results in increased susceptibility to epigallocatechin gallate increases response to substance
protein 15764647
23285096
C045651 7158 TP53BP1
53BP1
p202
tumor protein p53 binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TP53BP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7164 TPD52L1
D53
hD53
tumor protein D52-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TPD52L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1200 TPP1
CLN2
LPIC
TPP-1
tripeptidyl peptidase I (EC:3.4.14.9) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TPP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8460 TPST1
TANGO13A
tyrosylprotein sulfotransferase 1 (EC:2.8.2.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TPST1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8459 TPST2
TANGO13B
tyrosylprotein sulfotransferase 2 (EC:2.8.2.20) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TPST2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 387590 TPTEP1
psiTPTE22
transmembrane phosphatase with tensin homology pseudogene 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TPTEP1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10758 TRAF3IP2
ACT1
C6orf2
C6orf4
C6orf5
C6orf6
CIKS
PSORS13
TRAF3 interacting protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAF3IP2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7188 TRAF5
MGC:39780
RNF84
TNF receptor-associated factor 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAF5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9697 TRAM2
translocation associated membrane protein 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAM2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9881 TRANK1
LBA1
tetratricopeptide repeat and ankyrin repeat containing 1 epigallocatechin gallate results in increased expression of TRANK1 mRNA increases expression
mRNA 22079256
C045651 9881 TRANK1
LBA1
tetratricopeptide repeat and ankyrin repeat containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRANK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 60684 TRAPPC11
C4orf41
FOIGR
GRY
LGMD2S
trafficking protein particle complex 11 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAPPC11 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51112 TRAPPC12
TTC-15
TTC15
trafficking protein particle complex 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAPPC12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51693 TRAPPC2L
HSPC176
trafficking protein particle complex 2-like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRAPPC2L mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 27095 TRAPPC3
BET3
trafficking protein particle complex 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAPPC3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 1787 TRDMT1
DMNT2
DNMT2
MHSAIIP
PUMET
RNMT1
tRNA aspartic acid methyltransferase 1 (EC:2.1.1.204) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRDMT1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55809 TRERF1
BCAR2
HSA277276
RAPA
RP1-139D8.5
TREP132
TReP-132
dJ139D8.5
transcriptional regulating factor 1 epigallocatechin gallate results in increased expression of TRERF1 mRNA increases expression
mRNA 22079256
C045651 55809 TRERF1
BCAR2
HSA277276
RAPA
RP1-139D8.5
TREP132
TReP-132
dJ139D8.5
transcriptional regulating factor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRERF1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10221 TRIB1
C8FW
GIG-2
GIG2
SKIP1
TRB-1
TRB1
tribbles pseudokinase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRIB1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 6737 TRIM21
RNF81
RO52
SSA
SSA1
tripartite motif containing 21 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM21 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10346 TRIM22
GPSTAF50
RNF94
STAF50
tripartite motif containing 22 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM22 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8805 TRIM24
PTC6
RNF82
TF1A
TIF1
TIF1A
TIF1ALPHA
hTIF1
tripartite motif containing 24 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM24 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 4591 TRIM37
MUL
POB1
TEF3
tripartite motif containing 37 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM37 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54765 TRIM44
DIPB
HSA249128
MC7
tripartite motif containing 44 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM44 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80128 TRIM46
GENEY
TRIFIC
tripartite motif containing 46 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRIM46 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 85363 TRIM5
RNF88
TRIM5alpha
tripartite motif containing 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 286827 TRIM59
MRF1
RNF104
TRIM57
TSBF1
tripartite motif containing 59 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIM59 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11078 TRIOBP
DFNB28
TARA
dJ37E16.4
TRIO and F-actin binding protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIOBP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9319 TRIP13
16E1BP
thyroid hormone receptor interactor 13 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRIP13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 93587 TRMT10A
RG9MTD2
TRM10
tRNA methyltransferase 10 homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRMT10A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79979 TRMT2B
CXorf34
dJ341D10.3
tRNA methyltransferase 2 homolog B (S. cerevisiae) (EC:2.1.1.35) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRMT2B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26133 TRPC4AP
C20orf188
TRRP4AP
TRUSS
transient receptor potential cation channel, subfamily C, member 4 associated protein [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRPC4AP mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7442 TRPV1
VR1
transient receptor potential cation channel, subfamily V, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TRPV1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9819 TSC22D2
TILZ4a
TILZ4b
TILZ4c
TSC22 domain family, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TSC22D2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 23555 TSPAN15
2700063A19Rik
NET-7
NET7
TM4SF15
tetraspanin 15 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TSPAN15 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90139 TSPAN18
TSPAN
tetraspanin 18 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TSPAN18 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10098 TSPAN5
NET-4
NET4
TM4SF9
TSPAN-5
tetraspanin 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TSPAN5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7105 TSPAN6
T245
TM4SF6
TSPAN-6
tetraspanin 6 epigallocatechin gallate results in decreased expression of TSPAN6 mRNA decreases expression
mRNA 16084531
C045651 55720 TSR1
TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TSR1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 90121 TSR2
DT1P1A10
WGG1
TSR2, 20S rRNA accumulation, homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TSR2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7260 TSSC1
tumor suppressing subtransferable candidate 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TSSC1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55622 TTC27
tetratricopeptide repeat domain 27 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTC27 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 150737 TTC30B
IFT70
fleer
tetratricopeptide repeat domain 30B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTC30B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 123016 TTC8
BBS8
RP51
tetratricopeptide repeat domain 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTC8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7272 TTK
CT96
ESK
MPH1
MPS1
MPS1L1
PYT
TTK protein kinase (EC:2.7.12.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTK mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25809 TTLL1
C22orf7
HS323M22B
tubulin tyrosine ligase-like family, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TTLL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51174 TUBD1
TUBD
tubulin, delta 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TUBD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 114791 TUBGCP5
GCP5
tubulin, gamma complex associated protein 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TUBGCP5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7284 TUFM
COXPD4
EF-TuMT
EFTU
P43
Tu translation elongation factor, mitochondrial [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TUFM mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56995 TULP4
TUSP
tubby like protein 4 epigallocatechin gallate results in increased expression of TULP4 mRNA increases expression
mRNA 22079256
C045651 56995 TULP4
TUSP
tubby like protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TULP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 221830 TWISTNB
TWIST neighbor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TWISTNB mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7295 TXN
TRDX
TRX
TRX1
thioredoxin epigallocatechin gallate results in increased expression of TXN mRNA increases expression
mRNA 20706672
C045651 9352 TXNL1
TRP32
TXL-1
TXNL
Txl
thioredoxin-like 1 epigallocatechin gallate results in decreased expression of TXNL1 mRNA decreases expression
mRNA 16084531
C045651 54957 TXNL4B
DLP
Dim2
thioredoxin-like 4B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of TXNL4B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7301 TYRO3
BYK
Dtk
RSE
Sky
Tif
TYRO3 protein tyrosine kinase (EC:2.7.10.1) epigallocatechin gallate results in decreased expression of TYRO3 mRNA decreases expression
mRNA 12628509
C045651 7306 TYRP1
CAS2
CATB
GP75
OCA3
TRP
TRP1
TYRP
b-PROTEIN
tyrosinase-related protein 1 (EC:1.14.18.-) epigallocatechin gallate results in decreased expression of TYRP1 mRNA decreases expression
mRNA 20706672
C045651 55075 UACA
NUCLING
uveal autoantigen with coiled-coil domains and ankyrin repeats [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UACA mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9039 UBA3
NAE2
UBE1C
hUBA3
ubiquitin-like modifier activating enzyme 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBA3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7318 UBA7
D8
UBA1B
UBE1L
UBE2
ubiquitin-like modifier activating enzyme 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBA7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 283991 UBALD2
FAM100B
UBA-like domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBALD2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 51619 UBE2D4
HBUCE1
ubiquitin-conjugating enzyme E2D 4 (putative) (EC:6.3.2.19) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBE2D4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 92912 UBE2Q2
ubiquitin-conjugating enzyme E2Q family member 2 (EC:6.3.2.19) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBE2Q2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65264 UBE2Z
USE1
ubiquitin-conjugating enzyme E2Z (EC:6.3.2.19) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBE2Z mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 56061 UBFD1
UBPH
ubiquitin family domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBFD1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 29978 UBQLN2
ALS15
CHAP1
DSK2
N4BP4
PLIC2
ubiquilin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBQLN2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 56893 UBQLN4
A1U
A1Up
C1orf6
CIP75
UBIN
ubiquilin 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UBQLN4 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 197131 UBR1
JBS
ubiquitin protein ligase E3 component n-recognin 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23304 UBR2
C6orf133
RP3-392M17.3
bA49A4.1
dJ242G1.1
dJ392M17.3
ubiquitin protein ligase E3 component n-recognin 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBR2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 130507 UBR3
ZNF650
ubiquitin protein ligase E3 component n-recognin 3 (putative) (EC:6.3.2.-) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBR3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7343 UBTF
NOR-90
UBF
UBF-1
UBF1
upstream binding transcription factor, RNA polymerase I [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UBTF mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23376 UFL1
KIAA0776
Maxer
NLBP
RCAD
RP3-393D12.1
UFM1-specific ligase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UFL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7357 UGCG
GCS
GLCT1
UDP-glucose ceramide glucosyltransferase (EC:2.4.1.80) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UGCG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7358 UGDH
GDH
UDP-GlcDH
UDPGDH
UGD
UDP-glucose 6-dehydrogenase (EC:1.1.1.22) epigallocatechin gallate results in increased expression of UGDH mRNA increases expression
mRNA 16084531
C045651 25989 ULK3
unc-51 like kinase 3 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ULK3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 25972 UNC50
GMH1
UNCL
URP
unc-50 homolog (C. elegans) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UNC50 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 65109 UPF3B
HUPF3B
MRXS14
RENT3B
UPF3X
UPF3 regulator of nonsense transcripts homolog B (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UPF3B mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 139596 UPRT
FUR1
UPP
uracil phosphoribosyltransferase (FUR1) homolog (S. cerevisiae) (EC:2.4.2.9) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UPRT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7381 UQCRB
MC3DN3
QCR7
QP-C
QPC
UQBC
UQBP
UQCR6
UQPC
ubiquinol-cytochrome c reductase binding protein (EC:1.10.2.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UQCRB mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8975 USP13
ISOT3
IsoT-3
ubiquitin specific peptidase 13 (isopeptidase T-3) (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23358 USP24
ubiquitin specific peptidase 24 (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP24 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 29761 USP25
USP21
ubiquitin specific peptidase 25 (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP25 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84669 USP32
NY-REN-60
USP10
ubiquitin specific peptidase 32 (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP32 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9736 USP34
ubiquitin specific peptidase 34 (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP34 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57602 USP36
DUB1
ubiquitin specific peptidase 36 (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of USP36 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8078 USP5
ISOT
ubiquitin specific peptidase 5 (isopeptidase T) (EC:3.4.19.12) epigallocatechin gallate results in decreased expression of USP5 mRNA decreases expression
mRNA 18851785
C045651 9712 USP6NL
RNTRE
TRE2NL
USP6NL-IT1
USP6 N-terminal like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP6NL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8239 USP9X
DFFRX
FAF
FAM
ubiquitin specific peptidase 9, X-linked (EC:3.4.19.12) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of USP9X mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10813 UTP14A
NYCO16
SDCCAG16
dJ537K23.3
UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UTP14A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57050 UTP3
CRL1
CRLZ1
SAS10
UTP3, small subunit (SSU) processome component, homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of UTP3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55813 UTP6
C17orf40
HCA66
UTP6, small subunit (SSU) processome component, homolog (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UTP6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7402 UTRN
DMDL
DRP
DRP1
utrophin epigallocatechin gallate results in increased expression of UTRN mRNA increases expression
mRNA 22079256
C045651 7402 UTRN
DMDL
DRP
DRP1
utrophin [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UTRN mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7405 UVRAG
DHTX
VPS38
p63
UV radiation resistance associated [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of UVRAG mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8673 VAMP8
EDB
VAMP-8
vesicle-associated membrane protein 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VAMP8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 81839 VANGL1
KITENIN
LPP2
STB2
STBM2
VANGL planar cell polarity protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VANGL1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7410 VAV2
VAV-2
vav 2 guanine nucleotide exchange factor [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VAV2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79609 VCPKMT
C14orf138
METTL21D
VCP-KMT
valosin containing protein lysine (K) methyltransferase [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of VCPKMT mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7417 VDAC2
POR
voltage-dependent anion channel 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of VDAC2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A epigallocatechin gallate results in decreased expression of VEGFA mRNA decreases expression
mRNA 20346928
C045651 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A epigallocatechin gallate results in decreased secretion of VEGFA protein decreases secretion
protein 17992120
C045651 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of VEGFA mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 154807 VKORC1L1
vitamin K epoxide reductase complex, subunit 1-like 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VKORC1L1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23230 VPS13A
CHAC
CHOREIN
vacuolar protein sorting 13 homolog A (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 157680 VPS13B
CHS1
COH1
vacuolar protein sorting 13 homolog B (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54832 VPS13C
vacuolar protein sorting 13 homolog C (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55187 VPS13D
vacuolar protein sorting 13 homolog D (S. cerevisiae) epigallocatechin gallate results in increased expression of VPS13D mRNA increases expression
mRNA 22079256
C045651 55187 VPS13D
vacuolar protein sorting 13 homolog D (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS13D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84313 VPS25
DERP9
EAP20
FAP20
vacuolar protein sorting 25 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS25 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 26276 VPS33B
vacuolar protein sorting 33 homolog B (yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS33B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51542 VPS54
HCC8
SLP-8p
VPS54L
WR
hVps54L
vacuolar protein sorting 54 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS54 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23355 VPS8
KIAA0804
vacuolar protein sorting 8 homolog (S. cerevisiae) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VPS8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7443 VRK1
PCH1
PCH1A
vaccinia related kinase 1 (EC:2.7.11.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of VRK1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7453 WARS
GAMMA-2
IFI53
IFP53
tryptophanyl-tRNA synthetase (EC:6.1.1.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of WARS mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 10352 WARS2
TrpRS
tryptophanyl tRNA synthetase 2, mitochondrial (EC:6.1.1.2) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WARS2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10163 WASF2
IMD2
SCAR2
WASF4
WAVE2
dJ393P12.2
WAS protein family, member 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of WASF2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 11193 WBP4
FBP21
WW domain binding protein 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WBP4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 115825 WDFY2
PROF
RP11-147H23.1
WDF2
ZFYVE22
WD repeat and FYVE domain containing 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDFY2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23001 WDFY3
ALFY
ZFYVE25
WD repeat and FYVE domain containing 3 epigallocatechin gallate results in increased expression of WDFY3 mRNA increases expression
mRNA 22079256
C045651 23001 WDFY3
ALFY
ZFYVE25
WD repeat and FYVE domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDFY3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11169 WDHD1
AND-1
CHTF4
CTF4
WD repeat and HMG-box DNA binding protein 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDHD1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55759 WDR12
YTM1
WD repeat domain 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR12 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57728 WDR19
ATD5
CED4
DYF-2
IFT144
NPHP13
ORF26
Oseg6
PWDMP
WD repeat domain 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79446 WDR25
C14orf67
WD repeat domain 25 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR25 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 10785 WDR4
TRM82
TRMT82
WD repeat domain 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54521 WDR44
RAB11BP
RPH11
WD repeat domain 44 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR44 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55112 WDR60
FAP163
SRPS6
WD repeat domain 60 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR60 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 80349 WDR61
REC14
SKI8
WD repeat domain 61 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR61 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23335 WDR7
TRAG
WD repeat domain 7 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR7 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55100 WDR70
WD repeat domain 70 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WDR70 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7474 WNT5A
hWNT5A
wingless-type MMTV integration site family, member 5A epigallocatechin gallate results in increased expression of WNT5A mRNA increases expression
mRNA 22079256
C045651 7474 WNT5A
hWNT5A
wingless-type MMTV integration site family, member 5A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WNT5A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 11059 WWP1
AIP5
Tiul1
hSDRP1
WW domain containing E3 ubiquitin protein ligase 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of WWP1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis epigallocatechin gallate results in decreased expression of XIAP decreases expression
15705601
C045651 7514 XPO1
CRM1
emb
exp1
exportin 1 (CRM1 homolog, yeast) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XPO1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23214 XPO6
EXP6
RANBP20
exportin 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XPO6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9213 XPR1
SYG1
X3
xenotropic and polytropic retrovirus receptor 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XPR1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7518 XRCC4
X-ray repair complementing defective repair in Chinese hamster cells 4 epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of XRCC4 mRNA] decreases expression
/ decreases reaction
mRNA 22079256
C045651 7518 XRCC4
X-ray repair complementing defective repair in Chinese hamster cells 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XRCC4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9942 XYLB
xylulokinase homolog (H. influenzae) (EC:2.7.1.17) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XYLB mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 64132 XYLT2
PXYLT2
XT-II
XT2
xylT-II
xylosyltransferase II (EC:2.4.2.26) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of XYLT2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57002 YAE1D1
C7orf36
Yae1 domain containing 1 epigallocatechin gallate results in decreased expression of YAE1D1 mRNA decreases expression
mRNA 22079256
C045651 57002 YAE1D1
C7orf36
Yae1 domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YAE1D1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 8565 YARS
CMTDIC
TYRRS
YRS
YTS
tyrosyl-tRNA synthetase (EC:6.1.1.1) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YARS mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 646531 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YBX1P2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 8089 YEATS4
4930573H17Rik
B230215M10Rik
GAS41
NUBI-1
YAF9
YEATS domain containing 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YEATS4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84272 YIPF4
FinGER4
Yip1 domain family, member 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YIPF4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79693 YRDC
DRIP3
IRIP
RP11-109P14.4
SUA5
yrdC N(6)-threonylcarbamoyltransferase domain containing [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YRDC mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 91746 YTHDC1
YT521
YT521-B
YTH domain containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YTHDC1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64848 YTHDC2
CAHL
YTH domain containing 2 (EC:3.6.4.13) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of YTHDC2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54915 YTHDF1
C20orf21
YTH domain family, member 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YTHDF1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7532 YWHAG
14-3-3GAMMA
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of YWHAG mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 113763 ZBED6CL
C7orf29
ZBED6 C-terminal like [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZBED6CL mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 253461 ZBTB38
CIBZ
ZNF921
zinc finger and BTB domain containing 38 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZBTB38 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51101 ZC2HC1A
C8orf70
FAM164A
zinc finger, C2HC-type containing 1A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZC2HC1A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 85364 ZCCHC3
C20orf99
zinc finger, CCHC domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZCCHC3 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 203430 ZCCHC5
Mar3
Mart3
ZHC5
zinc finger, CCHC domain containing 5 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZCCHC5 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84240 ZCCHC9
PPP1R41
zinc finger, CCHC domain containing 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZCCHC9 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54503 ZDHHC13
HIP14L
HIP3RP
zinc finger, DHHC-type containing 13 (EC:2.3.1.225) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZDHHC13 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84287 ZDHHC16
APH2
zinc finger, DHHC-type containing 16 (EC:2.3.1.225) [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZDHHC16 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90637 ZFAND2A
AIRAP
zinc finger, AN1-type domain 2A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFAND2A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 54469 ZFAND6
AWP1
ZA20D3
ZFAND5B
zinc finger, AN1-type domain 6 epigallocatechin gallate results in decreased expression of ZFAND6 mRNA decreases expression
mRNA 22079256
C045651 54469 ZFAND6
AWP1
ZA20D3
ZFAND5B
zinc finger, AN1-type domain 6 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFAND6 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 441951 ZFAS1
C20orf199
HSUP1
HSUP2
NCRNA00275
ZNFX1-AS1
ZNFX1 antisense RNA 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFAS1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57623 ZFAT
AITD3
ZFAT1
ZNF406
zinc finger and AT hook domain containing [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFAT mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 678 ZFP36L2
BRF2
ERF-2
ERF2
RNF162C
TIS11D
ZFP36 ring finger protein-like 2 epigallocatechin gallate results in increased expression of ZFP36L2 mRNA increases expression
mRNA 16084531
C045651 678 ZFP36L2
BRF2
ERF-2
ERF2
RNF162C
TIS11D
ZFP36 ring finger protein-like 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFP36L2 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9765 ZFYVE16
PPP1R69
zinc finger, FYVE domain containing 16 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFYVE16 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84936 ZFYVE19
MPFYVE
zinc finger, FYVE domain containing 19 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZFYVE19 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23051 ZHX3
TIX1
zinc fingers and homeoboxes 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZHX3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7586 ZKSCAN1
9130423L19Rik
KOX18
PHZ-37
ZNF139
ZNF36
ZSCAN33
zinc finger with KRAB and SCAN domains 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZKSCAN1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 57178 ZMIZ1
MIZ
RAI17
TRAFIP10
ZIMP10
hZIMP10
zinc finger, MIZ-type containing 1 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMIZ1 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7750 ZMYM2
FIM
MYM
RAMP
SCLL
ZNF198
zinc finger, MYM-type 2 epigallocatechin gallate results in decreased expression of ZMYM2 mRNA decreases expression
mRNA 16084531
C045651 7750 ZMYM2
FIM
MYM
RAMP
SCLL
ZNF198
zinc finger, MYM-type 2 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMYM2 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9202 ZMYM4
CDIR
MYM
ZNF198L3
ZNF262
zinc finger, MYM-type 4 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMYM4 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23613 ZMYND8
PRKCBP1
PRO2893
RACK7
zinc finger, MYND-type containing 8 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZMYND8 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7559 ZNF12
GIOT-3
HZF11
KOX3
ZNF325
zinc finger protein 12 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF12 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7561 ZNF14
GIOT-4
KOX6
zinc finger protein 14 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF14 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 90338 ZNF160
F11
HKr18
HZF5
KR18
zinc finger protein 160 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF160 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7764 ZNF217
ZABC1
zinc finger protein 217 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF217 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 286101 ZNF252P
ZNF252
zinc finger protein 252, pseudogene [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF252P mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 55609 ZNF280C
SUHW3
ZNF633
zinc finger protein 280C [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF280C mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 54816 ZNF280D
SUHW4
ZNF634
zinc finger protein 280D [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF280D mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57336 ZNF287
ZKSCAN13
ZSCAN45
zinc finger protein 287 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF287 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 162979 ZNF296
ZFP296
ZNF342
zinc finger protein 296 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF296 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 55900 ZNF302
HSD16
MST154
MSTP154
ZNF135L
ZNF140L
ZNF327
zinc finger protein 302 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF302 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7580 ZNF32
KOX30
zinc finger protein 32 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF32 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 6940 ZNF354A
EZNF
HKL1
KID-1
KID1
TCF17
zinc finger protein 354A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF354A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 195828 ZNF367
AFF29
CDC14B
ZFF29
zinc finger protein 367 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF367 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7587 ZNF37A
KOX21
ZNF37
zinc finger protein 37A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF37A mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 84911 ZNF382
KS1
zinc finger protein 382 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF382 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79797 ZNF408
zinc finger protein 408 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF408 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 353088 ZNF429
zinc finger protein 429 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF429 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 220929 ZNF438
bA330O11.1
zinc finger protein 438 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF438 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 79973 ZNF442
zinc finger protein 442 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF442 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 25888 ZNF473
HZFP100
ZN473
zinc finger protein 473 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF473 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 220992 ZNF485
zinc finger protein 485 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF485 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57473 ZNF512B
GM632
zinc finger protein 512B [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF512B mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 9849 ZNF518A
ZNF518
zinc finger protein 518A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF518A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90233 ZNF551
zinc finger protein 551 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF551 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 126295 ZNF57
ZNF424
zinc finger protein 57 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF57 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 64763 ZNF574
FP972
zinc finger protein 574 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF574 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 147949 ZNF583
zinc finger protein 583 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF583 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 23060 ZNF609
zinc finger protein 609 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF609 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 90441 ZNF622
ZPR9
zinc finger protein 622 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF622 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 9831 ZNF623
zinc finger protein 623 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF623 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 57547 ZNF624
zinc finger protein 624 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF624 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 121274 ZNF641
zinc finger protein 641 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF641 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 339500 ZNF678
zinc finger protein 678 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF678 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 148213 ZNF681
zinc finger protein 681 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF681 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 51058 ZNF691
Zfp691
zinc finger protein 691 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF691 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 58492 ZNF77
pT1
zinc finger protein 77 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF77 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 163049 ZNF791
zinc finger protein 791 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF791 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 91752 ZNF804A
C2orf10
zinc finger protein 804A epigallocatechin gallate results in increased expression of ZNF804A mRNA increases expression
mRNA 22079256
C045651 91752 ZNF804A
C2orf10
zinc finger protein 804A [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF804A mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 152485 ZNF827
zinc finger protein 827 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF827 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 91603 ZNF830
CCDC16
OMCG1
zinc finger protein 830 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZNF830 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7639 ZNF85
HPF4
HTF1
zinc finger protein 85 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZNF85 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 84083 ZRANB3
4933425L19Rik
AH2
zinc finger, RAN-binding domain containing 3 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZRANB3 mRNA affects cotreatment
/ decreases expression
mRNA 22079256
C045651 7310 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZRSR1 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 7746 ZSCAN9
PRD51
ZNF193
zinc finger and SCAN domain containing 9 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZSCAN9 mRNA affects cotreatment
/ increases expression
mRNA 22079256
C045651 79699 ZYG11B
ZYG11
zyg-11 family member B, cell cycle regulator [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ZYG11B mRNA affects cotreatment
/ decreases expression
mRNA 22079256

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (48)

OMIM preferred title UniProt
#300438 17-beta-hydroxysteroid dehydrogenase x deficiency Q99714
#609135 Aplastic anemia O14746
#210900 Bloom syndrome; blm P54132
%606641 Body mass index; bmi P37231
#609338 Carotid intimal medial thickness 1 P37231
#604121 Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant; adcadn P26358
#605479 Cholestasis, benign recurrent intrahepatic, 2; bric2 O95342
#601847 Cholestasis, progressive familial intrahepatic, 2; pfic2 O95342
#162800 Cyclic neutropenia P08246
#119900 Digital clubbing, isolated congenital P15428
#613989 Dyskeratosis congenita, autosomal dominant, 2; dkca2 O14746
#600274 Frontotemporal dementia; ftd P10636
#230200 Galactokinase deficiency P51570
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#137800 Glioma susceptibility 1; glm1 P04626
P37231
#232300 Glycogen storage disease ii P10253
#605130 Hairy elbows, short stature, facial dysmorphism, and developmental delay Q03164
#114550 Hepatocellular carcinoma P08581
#145000 Hyperparathyroidism 1; hrpt1 O00255
#259100 Hypertrophic osteoarthropathy, primary, autosomal recessive, 1; phoar1 P15428
#604367 Lipodystrophy, familial partial, type 3; fpld3 P37231
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P04626
#613839 Megaloblastic anemia due to dihydrofolate reductase deficiency P00374
#615134 Melanoma, cutaneous malignant, susceptibility to, 9; cmm9 O14746
#614104 Mental retardation, autosomal dominant 7; mrd7 Q13627
#300705 Mental retardation, x-linked 17; mrx17 Q99714
#300220 Mental retardation, x-linked, syndromic 10; mrxs10 Q99714
#259600 Multicentric osteolysis, nodulosis, and arthropathy; mona P08253
#131100 Multiple endocrine neoplasia, type i; men1 O00255
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#614116 Neuropathy, hereditary sensory, type ie; hsn1e P26358
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P37231
#167000 Ovarian cancer P04626
#260540 Parkinson-dementia syndrome P10636
#172700 Pick disease of brain P10636
#614742 Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1; pfbmft1 O14746
#178500 Pulmonary fibrosis, idiopathic; ipf O14746
#605074 Renal cell carcinoma, papillary, 1; rccp1 P08581
#609620 Short qt syndrome 1; sqt1 Q12809
#607250 Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 Q9NUW8
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#188570 Thyroid hormone resistance, generalized, autosomal dominant; grth P10828
#274300 Thyroid hormone resistance, generalized, autosomal recessive; grth P10828
#145650 Thyroid hormone resistance, selective pituitary; prth P10828
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473

KEGG DISEASE (54)

KEGG disease name UniProt
H00033 Adrenal carcinoma O00255 (related)
H00034 Carcinoid O00255 (related)
H00045 Malignant islet cell carcinoma O00255 (related)
H00246 Primary hyperparathyroidism O00255 (related)
H01102 Pituitary adenomas O00255 (related)
H00764 Cri du chat syndrome O14746 (related)
H01132 Aplastic anemia (AA) O14746 (related)
H01299 Idiopathic pulmonary fibrosis O14746 (related)
H00022 Bladder cancer O14746 (marker)
P04626 (related)
H00024 Prostate cancer O14746 (marker)
H00624 Familial cholestasis O95342 (related)
H01197 Dihydrofolate reductase (DHFR) deficiency P00374 (related)
H00018 Gastric cancer P04626 (related)
P08581 (related)
P10415 (related)
H00019 Pancreatic cancer P04626 (related)
H00026 Endometrial Cancer P04626 (related)
H00027 Ovarian cancer P04626 (related)
H00028 Choriocarcinoma P04626 (related)
P08253 (related)
P10415 (related)
H00030 Cervical cancer P04626 (related)
P10415 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
H00046 Cholangiocarcinoma P04626 (related)
P08581 (related)
P35354 (related)
H00100 Neutropenic disorders P08246 (related)
H00025 Penile cancer P08253 (related)
P35354 (related)
H00472 Torg-Winchester syndrome P08253 (related)
H00021 Renal cell carcinoma P08581 (related)
H00036 Osteosarcoma P08684 (marker)
H00069 Glycogen storage diseases (GSD) P10253 (related)
H00005 Chronic lymphocytic leukemia (CLL) P10415 (related)
H00013 Small cell lung cancer P10415 (related)
H00041 Kaposi's sarcoma P10415 (related)
H00054 Nasopharyngeal cancer P10415 (related)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00249 Thyroid hormone resistance syndrome P10828 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H00457 Primary hypertrophic osteoarthropathy (PHO) P15428 (related)
H01246 Isolated congenital nail clubbing (ICNC) P15428 (related)
H00017 Esophageal cancer P35354 (related)
H00032 Thyroid cancer P37231 (related)
H00409 Type II diabetes mellitus P37231 (related)
H00420 Familial partial lipodystrophy (FPL) P37231 (related)
H00070 Galactosemia P51570 (related)
H00094 DNA repair defects P54132 (related)
H00296 Defects in RecQ helicases P54132 (related)
H00001 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Q03164 (related)
Q03164 (marker)
H00002 Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) Q03164 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00480 Non-syndromic X-linked mental retardation Q99714 (related)
H00658 Syndromic X-linked mental retardation Q99714 (related)
H00925 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency Q99714 (related)
H00063 Spinocerebellar ataxia (SCA) Q9NUW8 (related)

Diseases related to CTD interactions

30 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D000236 C045651 Adenoma therapeutic
16039397
D001008 C045651 Anxiety Disorders therapeutic
20599478
D001249 C045651 Asthma therapeutic
16516891
D050197 C045651 Atherosclerosis therapeutic
19782057
22521609
D001327 C045651 Autoimmune Diseases therapeutic
19761891
D001943 C045651 Breast Neoplasms marker/mechanism
therapeutic
10518005
22307971
D002294 C045651 Carcinoma, Squamous Cell therapeutic
12205293
D002312 C045651 Cardiomyopathy, Hypertrophic therapeutic
22000973
D019970 C045651 Cocaine-Related Disorders therapeutic
11790403
D003110 C045651 Colonic Neoplasms therapeutic
11809530
D015179 C045651 Colorectal Neoplasms therapeutic
20346928
D003924 C045651 Diabetes Mellitus, Type 2 therapeutic
16988119
D018450 C045651 Disease Progression marker/mechanism
22307971
D056486 C045651 Drug-Induced Liver Injury marker/mechanism
therapeutic
19646978
20438794
22178739
D006331 C045651 Heart Diseases therapeutic
18528854
D006948 C045651 Hyperkinesis therapeutic
20700049
D007249 C045651 Inflammation therapeutic
19782057
22101032
22521609
D008106 C045651 Liver Cirrhosis, Experimental therapeutic
17481882
19646978
D008175 C045651 Lung Neoplasms therapeutic
16039397
19239017
D008545 C045651 Melanoma therapeutic
11746506
17992120
D009134 C045651 Muscular Atrophy, Spinal therapeutic
17962980
D009203 C045651 Myocardial Infarction therapeutic
18294627
D009336 C045651 Necrosis marker/mechanism
therapeutic
18528854
21645609
D056627 C045651 Peritoneal Fibrosis therapeutic
22101032
D011041 C045651 Poisoning therapeutic
22079256
D011230 C045651 Precancerous Conditions therapeutic
11809530
D011472 C045651 Prostatitis therapeutic
21427997
D011658 C045651 Pulmonary Fibrosis therapeutic
19497426
D012878 C045651 Skin Neoplasms therapeutic
12205293
16039397
D013375 C045651 Substance Withdrawal Syndrome therapeutic
17958328